WO2014097140A1 - Indole carboxamide derivatives as p2x7 receptor antagonists - Google Patents

Indole carboxamide derivatives as p2x7 receptor antagonists Download PDF

Info

Publication number
WO2014097140A1
WO2014097140A1 PCT/IB2013/061029 IB2013061029W WO2014097140A1 WO 2014097140 A1 WO2014097140 A1 WO 2014097140A1 IB 2013061029 W IB2013061029 W IB 2013061029W WO 2014097140 A1 WO2014097140 A1 WO 2014097140A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
indole
methyl
hydroxy
carboxylic acid
Prior art date
Application number
PCT/IB2013/061029
Other languages
French (fr)
Inventor
Kurt Hilpert
Francis Hubler
Dorte Renneberg
Simon STAMM
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to EP13826623.4A priority Critical patent/EP2935211B1/en
Priority to JP2015548833A priority patent/JP6295270B2/en
Priority to CN201380065566.6A priority patent/CN104854087B/en
Priority to ES13826623.4T priority patent/ES2614495T3/en
Priority to KR1020157019206A priority patent/KR102232744B1/en
Priority to CA2891499A priority patent/CA2891499C/en
Priority to US14/653,363 priority patent/US9556117B2/en
Publication of WO2014097140A1 publication Critical patent/WO2014097140A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to indole carboxamide derivatives of formula (I) and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as P2X 7 receptor antagonists.
  • P2X 7 receptors belong to the family of P2X ionotropic receptors that are activated by extracellular nucleotides, in particular adenosine triphosphate (ATP).
  • P2RX7 is distinguished from other P2X family members by the high concentrations (mM range) of ATP required to activate it and its ability to form a large pore upon prolonged or repeated stimulation (North, R. A., Physiol. Rev. 2002, 82(4), 1013-67; Surprenant, A., Rassendren, F. et al., Science 1996, 272(5262), 735-8; Virginio, C, MacKenzie, A. et al., J.
  • P2RX7 is present on many cell types, especially ones known to be involved in inflammatory and immune processes. This is reflected within both the periphery and the CNS as Lipopolysaccharide S (LPS) priming of monocytes and microglia followed by ATP stimulation has been shown to lead to the local release and processing of I L1 ⁇ and other family members including IL18 through a P2RX7 mediated mechanism. Indeed mice lacking the P2X7 receptor are unable to release I L1 ⁇ following LPS priming and ATP stimulation providing further evidence of its role in this pathway (Solle, M., Labasi, J. et al., J. Biol.
  • LPS Lipopolysaccharide S
  • P2RX7 is also expressed on epithelial and endothelial cells (Ferrari, D., Chiozzi, P. et al., Neuropharmacology 1997, 36(9), 1295-301 ; Wiley, J. S., Chen, J. R. et al., Ciba Found Symp. 1996, 198, 149-60 and 160-5; North, R. A., Physiol. Rev. 2002, 82(4), 1013-67).
  • diseases associated with the central nervous system such as stroke or injury and diseases associated with neuro-degeneration and neuroinflammation such as Alzheimer's disease, Huntington's disease, epilepsy, Amyotrophic lateral sclerosis, acute spinal cord injury additionally to meningitis, sleep disorders, mood and anxiety disorders as well as chronic and neuropathic and inflammatory pain.
  • peripheral inflammatory disorders and autoimmune diseases including but not limited to rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease, airways hyper-responsiveness, septic shock, bronchitis, glomerulonephritis, irritable bowel disease, skin injury, lung emphysema, Limb girdle dystrophy type 2B, fibrosis, Syndrome of synovitis Acne Pustulosis, atherosclerosis, burn injury, spinal cord injury, Hyperostosis Osteitis, Crohn's disease, ulcerative colitis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, trauma, meningitis, osteoporosis, burn injury, ischemic heart disease, and varicose veins and trauma, are all examples where the involvement of P2X7 channels has been implicated.
  • P2X7 antagonists that can be efficiently used in treating neuropathic pain, chronic inflammatory pain, inflammation, and neurodegenerative conditions.
  • the present invention relates to indole carboxamide derivatives of formula (I),
  • n 1 , 2, 3 or 4;
  • R 1 represents hydrogen and R 2 represents hydroxy; hydroxy-(Ci-C 3 )alkyl; (Ci-C 3 )alkoxy; -NHR ; -N(CH 3 ) 2 ; -CN; -CONH 2 ; (d-C 4 )alkoxy-carbonyl; (Ci-C 4 )alkylamino-carbonyl; aryl which is unsubstituted or mono- or di-substituted with (CrC 3 )fluoroalkyl or halogen; or heteroaryl which is unsubstituted or mono- or di-substituted with (Ci-C 4 )alkyl, (C C 3 )fluoroalkyl or halogen; or
  • R 1 represents (Ci-C 3 )alkyl or hydroxy-(Ci-C 3 )alkyl and R 2 represents hydrogen;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen, (Ci-C 4 )alkyl or halogen
  • R 6 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )alkyl-carbonyl, hydroxy-(Ci- C 4 )alkyl, hydroxy-(C 2 -C 4 )alkoxy, (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl, (d-C 4 )alkoxy-(C 2 - C 4 )alkoxy, hydroxy, amino, nitro or halogen;
  • R 7 represents hydrogen or (Ci-C 3 )alkyl
  • R 8 represents hydrogen, (Ci-C 4 )alkyl or hydroxy
  • R 9 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkylthio, formyl or halogen;
  • R 10 represents fluoro, chloro, methyl, ethyl, (Ci-C 2 )fluoroalkyl or methoxy;
  • R 11 represents hydrogen, benzyl, (Ci-C 4 )alkyl-carbonyl, (Ci-C 4 )alkoxy-carbonyl or (Ci- C 4 )alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci- C 4 )alkoxy-carbonyl;
  • the compounds of formula (I) according to embodiment 1) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the (Z)- or (/ ⁇ -configuration unless indicated otherwise.
  • the compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • alkyl refers to a straight or branched chain alkyl group containing one to four carbon atoms.
  • (C x -C y )alkyl refers to an alkyl group as defined before containing x to y carbon atoms.
  • a (C C 4 )alkyl group contains from one to four carbon atoms.
  • Representative examples of alkyl groups include methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and tert. -butyl.
  • R 1 represents "(CrC 3 )alkyl”
  • the term means (C C 3 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl and / ' so-propyl. Preferred is methyl.
  • R 5 represents "(C C 4 )alkyl”
  • the term means (C C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
  • R 6 represents "(C C 4 )alkyl”
  • the term means (C C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and te/t-butyl and notably methyl, ethyl, n-propyl and / ' so-butyl. Preferred are methyl and / ' so-butyl.
  • R 7 represents "(CrC 3 )alkyl”
  • the term means (C C 3 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl and / ' so-propyl. Preferred is methyl.
  • R 8 represents "(C C 4 )alkyl”
  • the term means (C C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
  • R 9 represents "(C C 4 )alkyl”
  • the term means (C C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
  • (C C 4 )alkyl group is a substituent to a heteroaryl group
  • the term "(C C 4 )alkyl” means (C C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl,7-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
  • alkoxy refers to an alkyl-O- group wherein the alkyl group is as defined above.
  • (C x -C y )alkoxy refers to an alkoxy group as defined before containing x to y carbon atoms.
  • a (C C 4 )alkoxy group contains from one to four carbon atoms.
  • Representative examples of alkoxy groups include methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec.-butoxy and te/t-butoxy.
  • R 2 represents "(CrC 3 )alkoxy"
  • the term means (C C 3 )alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy and / ' so-propoxy. Preferred is methoxy.
  • R 6 represents "(C C 4 )alkoxy"
  • the term means (C C 4 )alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec.-butoxy and te/t-butoxy and notably methoxy and ethoxy. Preferred is methoxy.
  • hydroxy-(C C 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with hydroxy.
  • Examples of said groups are hydroxy-methyl, 1-hydroxy- ethyl, 2-hydroxy-ethyl, 1-hydroxy-prop-1-yl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 1- hydroxy-prop-2-yl, 2-hydroxy-prop-2-yl, 1-hydroxy-but-1-yl, 2-hydroxy-but-1-yl, 3-hydroxy- but-1-yl, 4-hydroxy-but-1-yl, 1-hydroxy-but-2-yl, 2-hydroxy-but-2-yl, 3-hydroxy-but-2-yl, 4- hydroxy-but-2-yl, 1-hydroxy-2-methyl-prop-1-yl, 2-hydroxy-2-methyl-prop-1-yl, 3-hydroxy- 2-methyl-prop-1-yl, and 2-hydroxy-1 , 1-dimethyl-eth-1-yl.
  • hydroxy- (CrC 3 )alkyl refers to an alkyl group as defined before containing one to three carbon atoms in which one hydrogen atom has been replaced with hydroxy.
  • examples of said groups are hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl,
  • R 1 represents "hydroxy-(CrC 3 )alkyl"
  • the term means hydroxy-(C C 3 )alkyl groups as defined above. Representative examples of said groups are hydroxy-methyl, 2- hydroxy-ethyl and 3-hydroxy-prop-1-yl. Preferred is hydroxy-methyl.
  • R 2 represents "hydroxy-(C C 3 )alkyl"
  • the term means hydroxy-(C C 3 )alkyl groups as defined above. Representative examples of said groups are hydroxy-methyl, 2- hydroxy-ethyl and 3-hydroxy-prop-1-yl. Preferred is hydroxy-methyl.
  • R 6 represents "hydroxy-(C C 4 )alkyl"
  • the term means hydroxy-(C C 4 )alkyl groups as defined above. Examples of said groups are hydroxy-methyl, 1-hydroxy-ethyl,
  • 2- hydroxy-ethyl 1-hydroxy-prop-1-yl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 1-hydroxy-prop-2-yl, 2-hydroxy-prop-2-yl, 1-hydroxy-but-1-yl, 2-hydroxy-but-1-yl, 3-hydroxy-but-1-yl, 4-hydroxy-but-1-yl, 1-hydroxy-but-2-yl, 2-hydroxy-but-2-yl, 3-hydroxy-but-2-yl, 4-hydroxy- but-2-yl, 1-hydroxy-2-methyl-prop-1-yl, 2-hydroxy-2-methyl-prop-1-yl, 3-hydroxy-2-methyl- prop-1-yl, and 2-hydroxy-1 ,1-dimethyl-eth-1-yl.
  • hydroxy-(C 2 -C 4 )alkoxy refers to an alkoxy group as defined before containing from two to four carbon atoms in which one hydrogen atom has been replaced with hydroxy.
  • Examples of said groups are 2-hydroxy-ethoxy, 2- hydroxy-prop-1-yloxy, 3-hydroxy-prop-1-yloxy, 1-hydroxy-prop-2-yloxy, 2-hydroxy-but-1- yloxy, 3-hydroxy-but-1-yloxy, 4-hydroxy-but-1-yloxy, 1-hydroxy-but-2-yloxy, 3-hydroxy-but- 2-yloxy, 4-hydroxy-but-2-yloxy, 2-hydroxy-2-methyl-prop-1-yloxy, 3-hydroxy-2-methyl- prop-1-yloxy, and 2-hydroxy-1 , 1-dimethyl-eth-1-yloxy.
  • Preferred is 2-hydroxy-ethoxy.
  • (Ci-C 2 )alkoxy-(CrC 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with (C C 2 )alkoxy as defined before.
  • Examples of said groups are methoxy-methyl, methoxy-ethyl, methoxy-propyl, methoxy-butyl, ethoxy-methyl, ethoxy-ethyl, ethoxy-propyl and ethoxy-butyl.
  • R 6 represents "(CrC 2 )alkoxy-(CrC 4 )alkyl
  • the term means "(C C 2 )alkoxy- (C C 4 )alkyl groups as defined above. Representative examples of said groups are methoxy-methyl, 2-methoxy-ethyl, 3-methoxy-prop-1-yl, 4-methoxy-but-1-yl, ethoxy- methyl, 2-ethoxy-ethyl, 3-ethoxy-prop-1-yl and 4-ethoxy-but-1-yl. Preferred is 3-methoxy- prop-1-yl.
  • preferred (Ci-C 2 )alkoxy-(C C 4 )alkyl groups representing R 6 are 2-ethoxy-ethyl, 2-methoxy-prop-2-yl and 3-methoxy-prop-1-yl.
  • (CrC 4 )alkoxy-(C 2 -C 4 )alkoxy refers to an alkoxy group as defined before containing from two to four carbon atoms in which one hydrogen atom has been replaced with (C C 4 )alkoxy as defined before.
  • a preferred example of said groups is 2-te/f-butoxy-ethoxy.
  • alkylthio used alone or in combination, refers to an alkyl-S- group wherein the alkyl group is as defined above.
  • (C x -C y )alkylthio (x and y each being an integer) refers to an alkylthio group as defined before containing x to y carbon atoms.
  • a (C C 4 )alkylthio group contains from one to four carbon atoms.
  • alkylthio groups include methylthio, ethylthio, n-propylthio, / ' so-propylthio, n-butylthio, iso- butylthio, sec.-butylthio and te/t-butylthio.
  • R 9 represents "(C C 4 )alkylthio"
  • the term means (C C 4 )alkylthio groups as defined above. Examples of said groups are methylthio, ethylthio, n-propylthio, / ' so-propylthio, n-butylthio, / ' so-butylthio, sec.-butylthio and te/t-butylthio. Preferred is methylthio.
  • alkyl-sulfonyl refers to an alkyl-S(0) 2 - group wherein the alkyl group is as defined above, which is attached to the rest of the molecule via the sulfonyl-S-atom.
  • (C x -C y )alkyl-sulfonyl refers to an alkyl-sulfonyl group as defined before containing x to y carbon atoms.
  • a (C C 4 )alkyl-sulfonyl group contains from one to four carbon atoms.
  • alkyl-sulfonyl groups include methyl-sulfonyl, ethyl-sulfonyl, n-propyl-sulfonyl, iso- propyl-sulfonyl, n-butyl-sulfonyl, / ' so-butyl-sulfonyl, sec.-butyl-sulfonyl and te/t-butyl- sulfonyl.
  • R 11 represents "(C C 4 )alkyl-sulfonyl"
  • the term means (C C 4 )alkyl-sulfonyl groups as defined above. Examples of said groups are methyl-sulfonyl, ethyl-sulfonyl, n- propyl-sulfonyl, / ' so-propyl-sulfonyl, n-butyl-sulfonyl, / ' so-butyl-sulfonyl, sec.-butyl-sulfonyl and te/t-butyl-sulfonyl.
  • Preferred are methyl-sulfonyl and ethyl-sulfonyl.
  • alkyl-carbonyl refers to an alkyl-C(O)- group wherein the alkyl group is as defined before, which is attached to the rest of the molecule via the carbonyl-C-atom.
  • (C x -C y )alkyl-carbonyl (x and y each being an integer) refers to an alkyl-carbonyl group as defined before containing in the alkyl radical x to y carbon atoms.
  • a (C C 4 )alkyl-carbonyl group contains in the alkyl radical one to four carbon atoms.
  • alkyl-carbonyl groups include methyl-carbonyl, ethyl- carbonyl, n-propyl-carbonyl, / ' so-propyl-carbonyl, n-butyl-carbonyl, / ' so-butyl-carbonyl, sec- butyl-carbonyl and te/t-butyl-carbonyl.
  • R 6 represents "(C C 4 )alkyl-carbonyl”
  • the term means (C C 4 )alkyl-carbonyl groups as defined above. Examples of said groups are methyl-carbonyl, ethyl-carbonyl, n- propyl-carbonyl, / ' so-propyl-carbonyl, n-butyl-carbonyl, / ' so-butyl-carbonyl, sec.-butyl- carbonyl and te/t-butyl-carbonyl. Preferred is methyl-carbonyl.
  • R 11 represents "(C C 4 )alkyl-carbonyl”
  • the term means (C C 4 )alkyl-carbonyl groups as defined above. Examples of said groups are methyl-carbonyl, ethyl-carbonyl, n- propyl-carbonyl, / ' so-propyl-carbonyl, n-butyl-carbonyl, / ' so-butyl-carbonyl, sec.-butyl- carbonyl and te/t-butyl-carbonyl. Preferred is methyl-carbonyl.
  • alkoxy-carbonyl refers to an alkoxy-C(O)- group wherein the alkoxy group is as defined before, which is attached to the rest of the molecule via the carbonyl-C-atom.
  • (C x -C y )alkoxy-carbonyl (x and y each being an integer) refers to an alkoxy-carbonyl group as defined before containing in the alkoxy radical x to y carbon atoms.
  • a (C C 4 )alkoxy-carbonyl group contains in the alkoxy radical one to four carbon atoms.
  • alkoxy-carbonyl groups include methoxy-carbonyl, ethoxy-carbonyl, n-propoxy-carbonyl, / ' so-propoxy-carbonyl, n-butoxy- carbonyl, / ' so-butoxy-carbonyl, sec.-butoxy-carbonyl and te/t-butoxy-carbonyl.
  • R 2 represents "(CrC 4 )alkoxy-carbonyl”
  • the term means (C C 4 )alkoxy-carbonyl groups as defined above. Examples of said groups are methoxy-carbonyl, ethoxy- carbonyl, n-propoxy-carbonyl, / ' so-propoxy-carbonyl, n-butoxy-carbonyl, / ' so-butoxy- carbonyl, sec.-butoxy-carbonyl and te/t-butoxy-carbonyl. Preferred is methoxy-carbonyl.
  • R 11 represents "(C C 4 )alkoxy-carbonyl”
  • the term means (C C 4 )alkoxy-carbonyl groups as defined above.
  • Examples of said groups are methoxy-carbonyl, ethoxy- carbonyl, 7-propoxy-carbonyl, / ' so-propoxy-carbonyl, n-butoxy-carbonyl, / ' so-butoxy- carbonyl, sec.-butoxy-carbonyl and te/t-butoxy-carbonyl. Preferred is te/t-butoxy- carbonyl.
  • (C C 4 )alkoxy-carbonyl group is a substituent to a (C C 4 )alkyl-sulfonyl group representing R 11
  • the term "(CrC 4 )alkoxy-carbonyl” means (C C 4 )alkoxy-carbonyl groups as defined above. Examples of said groups are methoxy-carbonyl, ethoxy-carbonyl, n- propoxy-carbonyl, / ' so-propoxy-carbonyl, n-butoxy-carbonyl, / ' so-butoxy-carbonyl, sec.- butoxy-carbonyl and te/t-butoxy-carbonyl. Preferred is methoxy-carbonyl.
  • alkylamino-carbonyl refers to an alkyl-NH-C(O)- group wherein the alkyl group is as defined before, which is attached to the rest of the molecule via the -NH-C(O)- group.
  • (C x -C y )alkylamino-carbonyl refers to an alkylamino-carbonyl group as defined before containing in the alkyl radical x to y carbon atoms.
  • a (C C 4 )alkylamino-carbonyl group contains in the alkyl radical one to four carbon atoms.
  • alkylamino-carbonyl groups include methylamino-carbonyl, ethylamino-carbonyl, n-propylamino-carbonyl, iso- propylamino-carbonyl, n-butylamino-carbonyl, / ' so-butylamino-carbonyl, sec.-butylamino- carbonyl and te/t-butylamino-carbonyl.
  • R 2 represents "(CrC 4 )alkylamino-carbonyl"
  • the term means (C C 4 )alkylamino- carbonyl groups as defined above. Examples of said groups are methylamino-carbonyl, ethylamino-carbonyl, n-propylamino-carbonyl, / ' so-propylamino-carbonyl, n-butylamino- carbonyl, / ' so-butylamino-carbonyl, sec.-butylamino-carbonyl and te/t-butylamino- carbonyl. Preferred is methylamino-carbonyl.
  • (C x -C y )fluoroalkyl refers to an alkyl group as defined before containing x to y carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluoro.
  • a (CrC 3 )fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluoro.
  • R 10 represents "(CrC 2 )fluoroalkyl” the term means (C C 2 )fluoroalkyl groups as defined above. Representative examples of said groups are difluoromethyl, trifluoromethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred is trifluoromethyl.
  • (CrC 3 )fluoroalky is a substituent to an aryl or a heteroaryl group
  • the term "(C C 3 )fluoroalkyl” means (CrC 3 )fluoroalkyl groups as defined above. Representative examples of said groups are difluoromethyl, trifluoromethyl, 2,2-difluoroethyl and 2,2,2- trifluoroethyl. Preferred is trifluoromethyl.
  • halogen means fluoro, chloro, bromo or iodo.
  • R 5 represents "halogen" the term means fluoro, chloro, bromo or iodo. Preferred is chloro.
  • R 6 represents "halogen" the term means fluoro, chloro, bromo or iodo. Preferred is iodo. In another embodiment chloro is preferred.
  • R 9 represents "halogen" the term means fluoro, chloro, bromo or iodo. Preferred is fluoro.
  • halogen is a substituent to an aryl or a heteroaryl group
  • halogen means fluoro, chloro, bromo or iodo. Preferred is chloro.
  • aryl used alone or in any combination, means a phenyl or a naphthyl group. Preferred is a phenyl group. The aryl group is unsubstituted or substituted as explicitly defined. Examples are 4-chloro-phenyl and 4-trifluoromethyl-phenyl.
  • heteroaryl used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1 , 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Preferred is a 5- or 6-membered monocyclic heteroaryl group.
  • heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2, 1 ,3]oxadiazolyl, benzo[2,1 ,3]thiadiazolyl, benzo[1 ,2,3]thiadiazolyl, quinolinyl, is
  • pyridyl and pyrimidyl are unsubstituted or substituted as explicitly defined.
  • examples of such unsubstituted or substituted heteroaryl groups are pyridyl (notably pyridin-3-yl), 2-chloro- pyridyl (notably 2-chloro-pyridin-5-yl), 2-trifluoromethyl-pyridyl (notably 2-trifluoromethyl- pyridin-5-yl), 2-methyl-pyrimidyl (notably 2-methyl-pyrimidin-5-yl) and 2-trifluoromethyl- pyrimidyl (notably 2-trifluoromethyl-pyrimidin-5-yl).
  • 5- or 6-membered monocyclic heteroaryl group used alone or in combination, means a 5- or 6-membered monocyclic aromatic ring containing one nitrogen atom and optionally one additional heteroatom selected from oxygen, nitrogen and sulfur. Preferred are 6-membered monocyclic aromatic rings containing one or two nitrogen atoms. Examples of such heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Preferred are pyridyl and pyrimidyl.
  • heteroaryl groups are unsubstituted or substituted as explicitly defined.
  • examples of such unsubstituted or substituted 5- or 6-membered monocyclic heteroaryl groups are pyridyl (notably pyridin-3-yl), 2-chloro-pyridyl (notably 2-chloro- pyridin-5-yl), 2-trifluoromethyl-pyridyl (notably 2-trifluoromethyl-pyridin-5-yl), 2-methyl- pyrimidyl (notably 2-methyl-pyrimidin-5-yl) and 2-trifluoromethyl-pyrimidyl (notably 2- trifluoromethyl-pyrimidin-5-yl).
  • 6-membered monocyclic heteroaryl group used alone or in combination, means a 6-membered monocyclic aromatic ring containing one or two nitrogen atoms.
  • heteroaryl groups are pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Preferred are pyridyl and pyrimidyl.
  • the heteroaryl groups are unsubstituted or substituted as explicitly defined.
  • Examples of such unsubstituted or substituted 6-membered monocyclic heteroaryl groups are pyridyl (notably pyridin-3-yl), 2-chloro-pyridyl (notably 2- chloro-pyridin-5-yl), 2-trifluoromethyl-pyridyl (notably 2-trifluoromethyl-pyridin-5-yl), 2- methyl-pyrimidyl (notably 2-methyl-pyrimidin-5-yl) and 2-trifluoromethyl-pyrimidyl (notably 2-trifluoromethyl-pyrimidin-5-yl).
  • pyridyl notably pyridin-3-yl
  • 2-chloro-pyridyl notably 2- chloro-pyridin-5-yl
  • 2-trifluoromethyl-pyridyl notably 2-trifluoromethyl-pyridin-5-yl
  • 2- methyl-pyrimidyl notably 2-methyl-pyrimidin-5-yl
  • a further embodiment of the invention relates to compounds according to embodiment 1), wherein
  • n 1 , 2, 3 or 4;
  • R 1 represents hydrogen and R 2 represents hydroxy; hydroxy-(d-C 3 )alkyl; (Ci-C 3 )alkoxy;
  • R 1 represents (Ci-C 3 )alkyl or hydroxy-(Ci-C 3 )alkyl and R 2 represents hydrogen;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen, (Ci-C 4 )alkyl or halogen
  • R 6 represents hydrogen, (d-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, amino, nitro or halogen
  • R 7 represents hydrogen or (Ci-C 3 )alkyl
  • R 8 represents hydrogen, (Ci-C 4 )alkyl or hydroxy
  • R 9 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkylthio, formyl or halogen;
  • R 10 represents chloro, methyl or methoxy
  • R 11 represents hydrogen, benzyl, (Ci-C 4 )alkyl-carbonyl, (Ci-C 4 )alkoxy-carbonyl or (Ci- C 4 )alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci- C 4 )alkoxy-carbonyl;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 2, 3 or 4;
  • R 1 represents hydrogen and R 2 represents hydroxy; hydroxy-(d-C 3 )alkyl; -NHR ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono- substituted with (Ci-C 4 )alkyl, (CrC 3 )fluoroalkyl or halogen; or
  • R 1 represents (Ci-C 3 )alkyl or hydroxy-(Ci-C 3 )alkyl and R 2 represents hydrogen;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl or amino;
  • R 7 represents hydrogen
  • R 8 represents hydrogen
  • R 9 represents hydrogen, (Ci-C 4 )alkyl or halogen
  • R 10 represents chloro or methyl
  • R 11 represents (Ci-C 4 )alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci-C 4 )alkoxy-carbonyl;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 2, 3 or 4;
  • R 1 represents hydrogen and R 2 represents hydroxy; hydroxy-methyl; -NHR 11 ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono- substituted with methyl, trifluoromethyl or chloro; or R 1 represents methyl or hydroxy-methyl and R 2 represents hydrogen;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen, methyl, / ' so-butyl, methoxy or 3-methoxy-prop-1-yl
  • R 7 represents hydrogen
  • R 8 represents hydrogen
  • R 9 represents hydrogen, methyl or fluoro
  • R 10 represents chloro or methyl
  • R 11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 1 , 2, 3 or 4;
  • R 1 represents hydrogen
  • R 2 represents hydroxy; hydroxy-(d-C 3 )alkyl; (Ci-C 3 )alkoxy; -NHR ; -N(CH 3 ) 2 ; -CN; -CONH 2 ; (Ci-C 4 )alkoxy-carbonyl; (Ci-C 4 )alkylamino-carbonyl; aryl which is unsubstituted or mono- or di-substituted with (CrC 3 )fluoroalkyl or halogen; or heteroaryl which is unsubstituted or mono- or di-substituted with (Ci-C 4 )alkyl, (CrC 3 )fluoroalkyl or halogen; R 3 represents hydrogen or fluoro;
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen, (Ci-C 4 )alkyl or halogen
  • R 6 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, amino, nitro or halogen;
  • R 7 represents hydrogen or (Ci-C 3 )alkyl
  • R 8 represents hydrogen, (Ci-C 4 )alkyl or hydroxy
  • R 9 represents hydrogen, (Ci-C 4 )alkyl, (d— C 4 )alkylthio, formyl or halogen;
  • R 10 represents chloro, methyl or methoxy
  • R 11 represents hydrogen, benzyl, (Ci-C 4 )alkyl-carbonyl, (Ci-C 4 )alkoxy-carbonyl or (Ci-
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein n represents 2, 3 or 4;
  • R 1 represents hydrogen
  • R 2 represents hydroxy; hydroxy-(Ci-C 3 )alkyl; -NHR ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with (Ci- C 4 )alkyl, (CrC 3 )fluoroalkyl or halogen;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy or (Ci-C 2 )alkoxy-(d-C 4 )alkyl;
  • R 7 represents hydrogen
  • R 8 represents hydrogen
  • R 9 represents hydrogen, (Ci-C 4 )alkyl or halogen
  • R 10 represents chloro or methyl
  • R 11 represents (Ci-C 4 )alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci-C 4 )alkoxy-carbonyl;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 2, 3 or 4;
  • R 1 represents hydrogen
  • R 2 represents hydroxy; hydroxy-methyl; -NHR 11 ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with methyl, trifluoromethyl or chloro;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen, methyl, / ' so-butyl, methoxy or 3-methoxy-prop-1-yl
  • R 7 represents hydrogen
  • R 8 represents hydrogen
  • R 9 represents hydrogen, methyl or fluoro
  • R 10 represents chloro or methyl
  • R 11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 2 or 3;
  • R 1 represents hydrogen
  • R 2 represents hydroxy; or a 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with methyl, trifluoromethyl or chloro;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen, methyl, / ' so-butyl, methoxy or 3-methoxy-prop-1-yl
  • R 7 represents hydrogen
  • R 8 represents hydrogen
  • R 9 represents hydrogen
  • R 10 represents chloro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 2 or 3;
  • R 1 represents (d-C 3 )alkyl or hydroxy-(Ci-C 3 )alkyl
  • R 2 represents hydrogen
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen
  • R 7 represents hydrogen or (Ci-C 3 )alkyl
  • R 8 represents hydrogen
  • R 9 represents hydrogen or formyl
  • R 10 represents chloro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
  • n 2 or 3;
  • R 1 represents methyl or hydroxy-methyl
  • R 2 represents hydrogen
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 5 represents hydrogen
  • R 6 represents hydrogen
  • R 7 represents hydrogen or methyl
  • R 8 represents hydrogen
  • R 9 represents hydrogen
  • R 10 represents chloro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein
  • n 2 or 3;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), 8) or 9), wherein
  • R 1 represents hydroxy-methyl
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5) or 10), wherein
  • R 2 represents hydroxy; hydroxy-(d-C 3 )alkyl; -NHR ; or -CN;
  • R 11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 10), wherein
  • R 2 represents hydroxy
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5) or 10), wherein
  • R 2 represents a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with (d-C 4 )alkyl, (C C 3 )fluoroalkyl or halogen;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 10), wherein R 2 represents a 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with methyl, trifluoromethyl or chloro;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 15), wherein
  • R 3 and R 4 represent hydrogen
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 15), wherein
  • R 3 and R 4 represent fluoro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1), 1 P), 4) or 10) to 17), wherein
  • R 5 represents hydrogen
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 10) to 18), wherein
  • R 6 represents hydrogen
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5) or 10) to 18), wherein
  • R 6 represents (d-C 4 )alkyl, (Ci-C 4 )alkoxy or (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1), 1 P), 4), 8), 9) or 10) to 20), wherein
  • R 7 represents hydrogen
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1), 1 P), 4) or 10) to 21), wherein
  • R 8 represents hydrogen
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8) or 10) to 22), wherein R 9 represents hydrogen;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6) or 10) to 22), wherein
  • R 9 represents methyl or fluoro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 10) to 17), 19) or 20), wherein
  • R 5 , R 7 , R 8 and R 9 represent hydrogen
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6) or 10) to 25), wherein
  • R 10 represents chloro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5), 10) or 16) to 26), wherein
  • R 11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), 8) to 1 1) or 16) to 26), wherein, in case R is different from hydrogen, the stereogenic center is as depicted in formula (l S ti)
  • Preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of:
  • a stereogenic center which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration; for example a compound listed as 4-Chloro-1 H-indole-5-carboxylic acid (1-cycloheptyl-2- hydroxy-ethyl)-amide may be 4-Chloro-1 H-indole-5-carboxylic acid ((S)-1-cycloheptyl-2- hydroxy-ethyl)-amide, 4-Chloro-1 H-indole-5-carboxylic acid ((R)-1-cycloheptyl-2-hydroxy- ethyl)-amide or any mixture thereof.
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), which are also compounds of formula (I H ET)
  • n 2 or 3;
  • X represents CH or N
  • R 2S represents hydrogen, (d-C 4 )alkyl, (CrC 3 )fluoroalkyl or halogen;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 6 represents hydrogen or (Ci-C 4 )alkyl
  • a further embodiment of the invention relates to compounds according to embodiment 30), wherein
  • n 2 or 3;
  • X represents CH or N
  • R 2S represents hydrogen, methyl, trifluoromethyl or chloro
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 6 represents hydrogen or methyl
  • a further embodiment of the invention relates to compounds according to any one of embodiments 30) or 31 ), wherein
  • X represents N
  • a further embodiment of the invention relates to compounds according to any one of embodiments 30) to 32), wherein
  • R 2S represents methyl or trifluoromethyl
  • a further embodiment of the invention relates to compounds according to any one of embodiments 30) to 33), wherein
  • R 6 represents methyl
  • a further embodiment of the invention relates to compounds according to embodiment 1), which are also compounds of formula (I 0 H) wherein
  • n 2 or 3;
  • R 3 represents hydrogen or fluoro
  • R 4 represents hydrogen or fluoro
  • R 6 represents (d-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxy-(Ci-C 4 )alkyl, hydroxy-(C 2 -C 4 )alkoxy, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl or halogen;
  • R 10 represents chloro, methyl or trifluoromethyl
  • a further embodiment of the invention relates to compounds according to embodiment 35), wherein
  • R 3 and R 4 represent fluoro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 35) or 36), wherein
  • R 6 represents methyl, ethyl, n-propyl, / ' so-butyl, methoxy, ethoxy, 1-hydroxy-ethyl, 2- hydroxy-prop-2-yl, 2-hydroxy-ethoxy, 2-ethoxy-ethyl, 2-methoxy-prop-2-yl, 3-methoxy- prop-1-yl or chloro;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 35) to 37), wherein
  • R 10 represents chloro
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1), 10) to 18) or 21) to 28), wherein
  • R 6 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxy-(Ci-C 4 )alkyl, hydroxy-(C 2 - C 4 )alkoxy, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl or halogen;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1), 10) to 18) or 21) to 28), wherein
  • R 6 represents hydrogen, methyl, ethyl, n-propyl, / ' so-butyl, methoxy, ethoxy, 1-hydroxy- ethyl, 2-hydroxy-prop-2-yl, 2-hydroxy-ethoxy, 2-ethoxy-ethyl, 2-methoxy-prop-2-yl, 3- methoxy-prop-1-yl or chloro;
  • a further embodiment of the invention relates to compounds according to any one of embodiments 1), 10) to 25), 27), 28), 39) or 40), wherein
  • R 10 represents chloro, methyl or trifluoromethyl
  • a stereogenic center which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration; for example a compound listed as 4-Chloro-7-(1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-amide may be 4-Chloro-7-((R)-1-hydroxy- ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-amide, 4- Chloro-7-((S)-1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy- cyclohexylmethyl)-amide or any mixture thereof.
  • the invention relates to compounds according to embodiment 1); or according to embodiment 1) limited by the features of an embodiment dependent on embodiment 1; or according to embodiment 1) limited by the features of a cascade of dependent embodiments e.g. in the form of "embodiment 3) depending on embodiment 2) depending on embodiment 1)".
  • each combination is specifically disclosed.
  • one or more of said other embodiments are themselves dependent on one or more further embodiments, it is understood that each combination is specifically disclosed if obtainable with regard to the given dependencies and multiple dependencies.
  • embodiments resulting from cascades of more than three embodiments depending on each other may be construed under observance of the given dependencies and multiple dependencies and are thus intended to be specifically disclosed.
  • Representative examples of embodiments which are possible based on the dependencies of the embodiments 1) to 42) as disclosed hereinabove and which are therefore intended and herewith specifically disclosed in individualized form are:
  • the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • Isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile.
  • the compounds of formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • pharmaceutically acceptable salts refers to non-toxic, inorganic or organic acid and/or base addition salts, Lit. e.g. "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
  • compounds of formula (I) are suitable for use as medicaments.
  • compounds of formula (I) modulate the P2X 7 receptor, i.e. they act as P2X 7 receptor antagonists, and are useful for the prevention or treatment of diseases which are associated with the activation of the P2X 7 receptor such as pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of pain.
  • Pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain.
  • Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • normally non-painful sensations such as "pins and needles” (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.
  • Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome.
  • Neurodegenerative and neuro-inflammatory diseases include Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); Amyotrophic lateral sclerosis, amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease.
  • CJD Creutzfeldt-Jakob disease
  • nvCJD new variant Creutzfeldt-Jakob disease
  • cerebral atherosclerosis and vasculitis cerebral atherosclerosis and vasculitis
  • temporal arteritis myasthenia gravis
  • Huntington's disease Lewy Body dementia
  • Bone and joint diseases include arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis; Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferenti
  • Obstructive diseases of the airways include asthma, including bronchial, allergic, intrinsic, and extrinsic asthma, exercise-induced, drug- induced (including aspirin and NSAID-induced) and dust- induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper- responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including
  • Cardiovascular diseases include atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis; inflammatory and auto- immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; and disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.
  • Eye diseases include blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; and infections of the eyes including viral, fungal, and bacterial infections.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of skin diseases.
  • Skin diseases include psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of abdominal and gastrointestinal tract diseases.
  • Abdominal and gastrointestinal tract diseases include hepatitis, including autoimmune, alcoholic and viral hepatitis; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; non-inflammatory diarrhea; glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; Coeliac disease, irritable bowel disease/syndrome, and food-related allergies which may have effects remote from the gut, for example migraine, rhinitis or eczema; allograft rejection including acute and chronic allograft rejection following, for example, transplantation of kidney, heart, liver
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of genitourinary diseases.
  • Genitourinary diseases include nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, hemorrhagic cystitis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; and erectile dysfunction, both male and female.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of cancer.
  • the treatment of cancer includes the treatment of brain tumors, prostate, lung, breast, ovarian, bowel and colon, stomach, pancreatic, skin and bone marrow (including leukaemias) and lymphoproliferative systems, such as non-Hodgkin's and Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumor recurrences, and paraneoplastic syndromes.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of other auto-immune and allergic disorders.
  • Other auto-immune and allergic disorders include Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-lgE syndrome, and antiphospholipid syndrome.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of other disorders with an inflammatory or immunological component.
  • Other disorders with an inflammatory or immunological component include acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes.
  • AIDS acquired immune deficiency syndrome
  • leprosy leprosy
  • Sezary syndrome Sezary syndrome
  • paraneoplastic syndromes paraneoplastic syndromes.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of mood, depression, sleep and anxiety disorders.
  • the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of injury induced trauma and spinal cord injury.
  • compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
  • Pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
  • Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
  • Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
  • Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
  • Neurodegenerative and neuro-inflammatory diseases such as Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); amyloidosis; Amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease;
  • CJD Creutzfeldt-Jakob disease
  • nvCJD new variant Creutzfeldt-Jakob disease
  • amyloidosis amyloidosis
  • Amyotrophic lateral sclerosis multiple sclerosis and other demyelinating syndromes
  • cerebral atherosclerosis and vasculitis cerebral atherosclerosis and vasculitis
  • temporal arteritis myasthenia gravis
  • Huntington's disease
  • Bone and joint diseases such as arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic
  • Cardiovascular diseases such as inflammatory and auto-immune cardiomyopathies
  • Eye diseases such as degenerative or inflammatory disorders affecting the retina;
  • Skin diseases such as psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses; and discoid lupus erythematosus;
  • Abdominal and gastrointestinal tract diseases such as fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; Crohn's disease; colitis including ulcerative colitis; and irritable bowel disease/syndrome;
  • Genitourinary diseases such as nephritis including interstitial and glomerulonephritis; nephrotic syndrome; and cystitis including acute and chronic (interstitial) cystitis; and
  • compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
  • Pain wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain (preferred); lower back and neck pain; inflammatory pain; neuropathic pain (preferred); visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
  • Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
  • normally non-painful sensations such as "pins and needles” (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
  • Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
  • Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
  • COPD Chronic obstructive pulmonary disease
  • the invention also relates to the use of a compound of formula (I) according to any one of embodiments 1) to 42) for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.
  • the present invention also relates to pharmaceutically acceptable salts and to pharmaceutical compositions and formulations of compounds of formula (I) according to any one of embodiments 1) to 42).
  • a pharmaceutical composition according to the present invention contains at least one compound of formula (I) according to any one of embodiments 1) to 42) (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants.
  • the compounds of formula (I) according to any one of embodiments 1) to 42) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such as especially oral) or parenteral administration (including topical application or inhalation).
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I) according to any one of embodiments 1 ) to 42), or a pharmaceutically acceptable salt thereof.
  • the term “about” (or alternatively “around”) placed before a numerical value "X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X.
  • the term “about” (or alternatively “around”) placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.
  • room temperature RT as used herein refers to a temperature of about 25°C.
  • the compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and n are as defined for formula (I).
  • Other abbreviations used are defined in the experimental section.
  • the generic groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and n might be incompatible with the assembly illustrated in the schemes below and will therefore require the use of protecting groups (PG).
  • protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups are as necessary in place.
  • Compounds of formula (I) can be prepared (Scheme 1) by reaction of carboxylic acids of formula II with amines of formula III using standard amide coupling reagents such as TBTU, EDC.HCI/HOBt, HATU or PyBOP in the presence of a suitable base such as DIPEA or Et 3 N and in a suitable solvent such as DCM, THF or DMF preferably at temperatures between RT and 45°C.
  • a suitable base such as DIPEA or Et 3 N
  • a suitable solvent such as DCM, THF or DMF preferably at temperatures between RT and 45°C.
  • Scheme 1 General synthesis of compounds of formula (I) Compounds of formula la wherein m represents 0, 1 or 2 (Scheme 2) can be prepared as described in Scheme 1.
  • Alcohol derivatives of formula lb wherein m represents 0, 1 or 2 and R 9 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkylthio or halogen can be prepared by reduction of methyl esters of formula la wherein m represents 0, 1 or 2 and R 9 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 4 )alkylthio or halogen using a suitable reducing reagent such as lithium aluminum hydride, lithium borohydride or diisobutylaluminum hydride in a suitable solvent such as THF at temperatures between 0°C and RT.
  • a suitable reducing reagent such as lithium aluminum hydride, lithium borohydride or diisobutylaluminum hydride in a suitable solvent such as THF at temperatures between 0°C and RT.
  • Amides of formula lc wherein R 2 represents hydrogen or (C C 4 )alkyl can be prepared following a two step procedure: (i) hydrolysis of methyl esters of formula la, wherein m represents 0, by treatment with a suitable base such as LiOH, NaOH or KOH in the presence of water and a suitable organic solvent such as MeOH, EtOH or THF at temperatures around RT and (ii) coupling of the obtained acid with amines of formula R 2 NH 2 using amide coupling conditions such as those previously described for the synthesis of compounds of formula (I).
  • a suitable base such as LiOH, NaOH or KOH
  • a suitable organic solvent such as MeOH, EtOH or THF
  • Nitriles of formula Id can be prepared by dehydration of primary amides of formula lc, wherein R 2 represents hydrogen, using a suitable dehydrating reagent such as Burgess reagent in a suitable solvent such as DCM at temperatures between RT and °C.
  • Compounds of formula Ig (or Ii, respectively) (Scheme 3) can be prepared by reductive alkylation of amines of formula If with benzaldehyde (or an excess of formaldehyde, respectively) in the presence of a suitable reducing agent such as NaBH(OAc) 3 , NaBH 3 CN or NaBH 4 and carrying out the reaction in a suitable solvent such as dichloroethane or a mixture of solvents such as DCM/MeOH/AcOH at temperatures around RT.
  • a suitable reducing agent such as NaBH(OAc) 3 , NaBH 3 CN or NaBH 4
  • Indole carboxylic acids of formula I la can be prepared according to the synthetic routes given in scheme 5.
  • compounds of formula IX wherein R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (C C 2 )alkoxy-(Ci-C 4 )alkyl, nitro, chloro or fluoro and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared from iodides of formula VII wherein R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (C C 2 )alkoxy-(Ci-C 4 )alkyl, nitro, chloro or fluoro and Y represents methoxycarbonyl or cyano using Sonogashira cross-coupling conditions such as those described above.
  • compounds of formula VIII wherein R 6 represents (C C 4 )alkyl or (C C 2 )alkoxy-(Ci- C 4 )alkyl and Y represents methoxycarbonyl or cyano can be prepared by Suzuki type cross-coupling of iodides of formula XII wherein Y represents methoxycarbonyl or cyano with boronic acid reagents of type R 6 B(OH) 2 wherein R 6 represents (C C 4 )alkyl or (C C 2 )alkoxy-(Ci-C 4 )alkyl in the presence of a suitable palladium catalyst such as bis(triphenylphosphine)palladium(ll) dichloride and a base such as K 3 P0 4 and heating in a suitable solvent such as a mixture of toluene/water 20/1 at temperatures around 1 10°C.
  • a suitable palladium catalyst such as bis(triphenylphosphine)palladium(ll) dichloride and a base
  • compounds of formula VIII wherein R 6 represents (C C 2 )alkoxy-(C 2 -C 4 )alkyl and Y represents methoxycarbonyl (Scheme 5) can be prepared by a two step procedure: (i) Suzuki type cross-coupling of iodides of formula XII wherein Y represents methoxycarbonyl with (C C 2 )alkoxy-vinyl boronic acid pinacol ester or (Ci-C 2 )alkoxy-(C C 2 )alkyl-vinyl boronic acid pinacol ester reagents in the presence of a suitable palladium catalyst such as Pd(OAc) 2 , a suitable ligand such as 2- dicyclohexylphosphino-2',6'-dimethoxybiphenyl and a base such as KOH and heating in a suitable solvent such as CH 3 CN at temperatures around 70°C and (ii) reduction of the double bond under hydrogenation conditions in the presence
  • compounds of formula VI II wherein R 6 represents (C 3 -C 4 )alkyl or (C C 2 )alkoxy-(C 3 -C 4 )alkyl and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by Sonogashira type cross-coupling of iodides of formula XI I wherein Y represents methoxycarbonyl or cyano with (C C 2 )alkylacetylene or (C C 2 )alkoxy-(Ci- C 2 )alkylacetylene in the presence of a suitable palladium catalyst such as bis(triphenylphosphine)palladium(l l) dichloride, in the presence of a suitable copper catalyst such as copper iodide, in the presence of a suitable base such as Et 3 N and heating in a suitable solvent such as THF at temperatures between RT and 80°C.
  • a suitable palladium catalyst such as bis(triphenylphosphine)
  • the subsequent reduction of the triple bond can be carried out under hydrogenation conditions in the presence of a suitable catalyst such as Pt0 2 and a suitable solvent such as EtOH at temperatures around RT.
  • a suitable catalyst such as Pt0 2 and a suitable solvent such as EtOH at temperatures around RT.
  • the subsequent hydration of the triple bond can be carried out by treatment with an acid such as p-toluenesulfonic acid in the presence of a suitable solvent such as toluene at temperatures around 80°C and leads to compounds of formula VI I I wherein R 6 represents (C 2 -C 4 )alkyl-carbonyl and Y represents methoxycarbonyl or cyano.
  • compounds of formula VII wherein R 6 represents acetyl or ethyl, and Y represents methoxycarbonyl can be regioselectively prepared by Sonogashira type cross-coupling of iodides of formula XL wherein Y represents methoxycarbonyl with trimethylsilylacetylene following standard conditions such as those previously described for the synthesis of compounds of formula VI I I.
  • the subsequent reduction of the triple bond under hydrogenation conditions as those previously described for the synthesis of compounds of formula VI I I delivers compounds of formula VI I wherein R 6 represents ethyl and Y represents methoxycarbonyl.
  • the subsequent hydration of the triple bond can be carried out by treatment with an acid such as p-toluenesulfonic acid in the presence of a suitable solvent such as toluene at temperatures around 80°C and leads to compounds of formula VI I wherein R 6 represents acetyl and Y represents methoxycarbonyl.
  • Compounds of formula XL wherein Y represents methoxycarbonyl or cyano can be prepared by bis-iodination of anilines of formula XIV wherein Y represents methoxycarbonyl or cyano following standard iodination conditions such as those previously described for the synthesis of compounds of formula XI and XI I but using 2.2 equivalents of iodinating reagent.
  • Compounds of formula IV wherein Y represents methoxycarbonyl or cyano can be prepared by rhodium-catalyzed cycloisomerization of anilines of formula V wherein Y represents methoxycarbonyl or cyano in the presence of a rhodium catalyst such as chloro(1 ,5-cyclooctadiene)rhodium(l) dimer and a ligand such as tris(4- fluorophenylphosphine) and heating in a suitable solvent such as DMF at temperatures between 50°C and 90°C.
  • a rhodium catalyst such as chloro(1 ,5-cyclooctadiene)rhodium(l) dimer
  • a ligand such as tris(4- fluorophenylphosphine
  • compounds of formula IV wherein Y represents methoxycarbonyl or cyano can be prepared by copper-catalyzed cycloisomerization of anilines of formula IX wherein Y represents methoxycarbonyl or cyano using a suitable copper catalyst such as copper iodide and heating in a suitable solvent such as DMF at temperatures between 50°C and 100°C.
  • compounds of formula IV wherein R 6 represents hydrogen and Y represents methoxycarbonyl can be prepared by simultaneous deiodination and desulfurization of methylsulfanyl indoles of formula XIII by treatment with a suitable catalyst such as Raney nickel in the presence of a suitable solvent such as EtOH at temperatures around RT.
  • compounds of formula IV wherein R 6 represents (C C 4 )alkyl and Y represents methoxycarbonyl can be prepared by desulfurization of methylsulfanyl indoles of formula VI wherein R 6 represents (C C 4 )alkyl by treatment with a suitable catalyst such as Raney nickel in the presence of a suitable solvent such as EtOH at temperatures around RT.
  • Compounds of formula XIII can be prepared by Gassman indole synthesis by consecutive treatment of anilines of formula XII with (i) a chlorinating reagent such as N-chlorosuccinimide or te/f-butyl hypochlorite, with (ii) a protected aldehyde such as methylthioacetaldehyde dimethylacetal in the presence for both steps of a suitable solvent such as DCM at temperatures between -50°C and -78°C, with (iii) a base such as Et 3 N in the presence of a suitable solvent such as chlorobenzene at temperatures between 80°C and 120°C and finally with (iv) an acid such as HCI in the presence of a solvent such as dioxane or Et 2 0 at temperatures around RT.
  • a chlorinating reagent such as N-chlorosuccinimide or te/f-butyl hypochlorite
  • compounds of formula IV (Scheme 5) wherein R 5 represents hydrogen or (C C 4 )alkyl, R 6 represents hydrogen, (C C 4 )alkyl, (C C 4 )alkoxy or (CrC 2 )alkoxy-(Cr C 4 )alkyl, R 0 represents methyl (or ethyl respectively) and Y represents methoxycarbonyl or cyano
  • R 5 represents hydrogen or (C C 4 )alkyl
  • R 6 represents hydrogen, (C C 4 )alkyl, (C C 4 )alkoxy or (Ci-C 2 )alkoxy-(CrC 4 )alkyl
  • R 0 represents chloro and Y represents methoxycarbonyl or cyano with trimethylboroxine (or vinyl boronic acid pinacol ester respectively) in the presence of a suitable palladium catalyst such as [1 ,3-bis(2,6- diisoprop
  • compounds of formula IV (Scheme 5) wherein R 6 represents -C(OMe)Me 2 and Y represents methoxycarbonyl or cyano can be prepared from ketone of formula IV wherein R 6 represents acetyl and Y represents methoxycarbonyl or cyano by a two step procedure: (i) addition of a methylmagnesium halide solution in the presence of a suitable solvent such as THF at temperatures around RT and (ii) alkylation with Mel in the presence of a suitable base such as a suspension of NaH in mineral oil and a suitable solvent such as THF at temperatures between 0°C and RT.
  • a suitable solvent such as THF at temperatures around RT
  • a suitable base such as a suspension of NaH in mineral oil
  • a suitable solvent such as THF at temperatures between 0°C and RT.
  • Other tertiary ethers may be prepared in analogy.
  • compounds of formula IV (Scheme 5) wherein R 6 represents hydroxy (or hydroxy-(Ci-C 4 )alkyl respectively) and Y represents cyano can be prepared from methyl ether of formula IV wherein R 6 represents methoxy (or methoxy-(C C 4 )alkyl respectively) and Y represents cyano by treatment with BBr 3 in the presence of a suitable solvent such as DCM at temperatures between -78°C and 55°C.
  • a suitable solvent such as DCM
  • Carboxylic acid derivatives of formula I la can be prepared by hydrolysis of methyl esters of formula IV wherein Y represents methoxycarbonyl by standard treatment with a suitable base such as LiOH, NaOH or KOH in the presence of water and a suitable organic solvent such as MeOH, EtOH or THF at temperatures between RT and 60°C.
  • carboxylic acid derivatives of formula I la can be prepared by hydrolysis of nitriles of formula IV wherein Y represents cyano with a suitable base such as KOH or NaOH in the presence of water and optionally a suitable organic solvent such as 2-propanol at temperatures around 150°C.
  • Indole carboxylic acids of formula lib can be prepared according to the synthetic routes given in scheme 6.
  • Hydrazines of formula XVII can be prepared by diazotisation of anilines of formula XII wherein R 0 represents chloro with for instance sodium nitrite in a suitable solvent such as aq. HCI at temperatures around 0°C and subsequent reduction of the diazonium salt with for instance tin(ll) chloride dihydrate in a suitable solvent such as aq. HCI at temperatures between 0°C and RT.
  • Indoles of formula XVIII can be prepared by Fisher indole reaction between hydrazine derivatives of formula XVII and ketones of formula R 8 COCH 2 SMe wherein R 8 represents (C C 4 )alkyl in the presence of a suitable acid such as HCI and a suitable solvent such as EtOH at temperatures between 50°C and 80°C.
  • compounds of formula XVI (Scheme 6) can be prepared from anilines of formula VIII wherein Y represents methoxycarbonyl by a similar two-step sequence (hydrazine formation and Fisher indole synthesis) using similar conditions such as those previously described for the synthesis of compounds of formula XVIII from compounds of formula XII.
  • compounds of formula XV wherein R 6 represents hydrogen can be prepared from compounds of formula XVIII by simultaneous deiodination and desulfurization following conditions such as those previously described for the synthesis of compounds of formula IV from compounds of formula XIII.
  • Carboxylic acid derivatives of formula lib wherein R 8 represents (C C 4 )alkyl can be prepared by hydrolysis of methyl esters of formula XV following conditions such as those previously described for the synthesis of compounds of formula I la.
  • Indole derivatives of formula A wherein R 9 represents formyl can be prepared from indole derivatives of formula IV wherein Y represents methoxycarbonyl by Vilsmeier- Haack reaction with phosphorus oxychloride and DMF at temperatures between 0°C and 40°C.
  • Resulting formylated indole derivatives can be transformed to indole derivatives of formula A wherein R 9 represents methyl (Scheme 7) following a two-step one-pot procedure: (i) formation of tosyl hydrazone by condensation with p-toluenesulfonyl hydrazide in the presence of p-toluene sulfonic acid, sulfolane and a suitable solvent such as DMF at temperatures around 100°C and (ii) consecutive reduction of resulting tosyl hydrazone with for instance sodium borohydride at temperatures around 100°C.
  • Indole derivatives of formula A wherein R 9 represents chloro (or bromo, respectively) can be prepared by chlorination (or bromination, respectively) of indole derivatives of formula IV wherein Y represents methoxycarbonyl with a suitable halogenating reagent such as NCS (or NBS, respectively) in the presence of a suitable solvent such as DMF or CH 2 CI 2 at temperatures between 0°C and RT.
  • a suitable halogenating reagent such as NCS (or NBS, respectively) in the presence of a suitable solvent such as DMF or CH 2 CI 2 at temperatures between 0°C and RT.
  • Indole derivatives of formula A wherein R 9 represents fluoro can be prepared by fluorination of indole derivatives of formula IV wherein Y represents methoxycarbonyl with a suitable fluorinating reagent such as 1-fluoro-2,4,6-trimethylpyridinium triflate in the presence of a suitable solvent such as MeOH at temperatures around 65°C.
  • Carboxylic acid derivatives of formula lie (Scheme 7) can be prepared by hydrolysis of methyl esters of formula A following conditions such as those previously described for the synthesis of compounds of formula I la.
  • Indole derivatives of formula B wherein R 7 represents (C C 3 )alkyl can be prepared by alkylation of indole derivatives of formula IV, XV or A with a suitable alkylating reagent such as R 7 Br or R 7 I wherein R 7 represents (C C 3 )alkyl and a suitable base such as NaH in the presence of a suitable solvent such as DMF at temperatures between 0°C and RT.
  • a suitable alkylating reagent such as R 7 Br or R 7 I wherein R 7 represents (C C 3 )alkyl and a suitable base such as NaH in the presence of a suitable solvent such as DMF at temperatures between 0°C and RT.
  • Carboxylic acid derivatives of formula lid (Scheme 7) can be prepared by hydrolysis of methyl esters of formula B following conditions such as those previously described for the synthesis of compounds of formula I la.
  • aniline intermediates of formula XIV wherein Y represents methoxycarbonyl or cyano can be prepared according to procedures known in the art. Two possible synthetic routes are outlined in Scheme 8 below, which also illustrate alternative synthetic accesses to compounds of formula VIII wherein Y represents methoxycarbonyl or cyano.
  • Carboxylic acid derivatives of formula XX wherein R 5 represents hydrogen or halogen, R 6 represents hydrogen, (C C 4 )alkoxy or halogen and R 0 represents fluoro, chloro, (C C 2 )fluoroalkyl or methoxy (Scheme 8) can be prepared by oxidation of toluene derivatives of formula XIX wherein R 5 represents hydrogen or halogen, R 6 represents hydrogen, (C C 4 )alkoxy or halogen and R 0 represents fluoro, chloro, (C C 2 )fluoroalkyl or methoxy with a suitable oxidizing reagent such as KMn0 4 in the presence of water and a solvent such as pyridine at temperatures around 100°C.
  • a suitable oxidizing reagent such as KMn0 4 in the presence of water and a solvent such as pyridine at temperatures around 100°C.
  • carboxylic acid derivatives of formula XX wherein R 6 represents hydrogen, (Ci-C 4 )alkyl, (C C 4 )alkoxy, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy or halogen can be prepared by hydrolysis of nitriles of formula XXIII wherein R 6 represents hydrogen, (C C 4 )alkyl, (C C 4 )alkoxy, (Ci-C 2 )alkoxy-(C C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy or halogen by treatment with a suitable base such as KOH or NaOH in the presence of water and a suitable organic solvent such as 2-propanol at temperatures around 150°C.
  • a suitable base such as KOH or NaOH
  • Nitriles of formula XXIII wherein R 6 represents hydrogen, (C C 4 )alkyl, (C C 4 )alkoxy, (Ci-C 2 )alkoxy-(C C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy or halogen can be prepared by treatment of anilines of formula XXII with a suitable diazotisation reagent such as te/f-butyl nitrite in the presence of a suitable cyanating reagent such as copper(l) cyanide in a suitable solvent such as CH 3 CN at temperatures between 0°C and 80°C.
  • carboxylic acid derivatives of formula XX wherein R 6 represents (C C 4 )alkoxy (or (C C 4 )alkoxy-(C 2 -C 4 )alkoxy, respectively) can be prepared by nucleophilic aromatic substitution of fluorides of formula XX wherein R 6 represents fluoro with (C C 4 )-alcohol (or (C C 4 )alkoxy-(C 2 -C 4 )alcohol, respectively) in the presence of a base such as Cs 2 C0 3 and a suitable solvent such as DMF at temperatures between RT and 110°C.
  • Methyl esters of formula XXI wherein R N represents nitro can be prepared by treatment of carboxylic acids of formula XX with a suitable base such as Cs 2 C0 3 or K 2 C0 3 and a suitable alkylating reagent such as Mel in the presence of a suitable solvent such as DMF at temperatures around RT.
  • a suitable base such as Cs 2 C0 3 or K 2 C0 3
  • a suitable alkylating reagent such as Mel in the presence of a suitable solvent such as DMF at temperatures around RT.
  • compounds of formula XXI wherein R N represents acetylamino, R 5 represents hydrogen, (C C 4 )alkyl, fluoro or chloro, R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (CrC 2 )alkoxy-(C C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy, fluoro or chloro and R 0 represents methyl or ethyl (Scheme 8) can be prepared from phenols of formula XXI wherein R N represents acetylamino, R 5 represents hydrogen, (C C 4 )alkyl, fluoro or chloro, R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (Ci-C 2 )alkoxy-(CrC 4 )alkyl, (C C 4 )alkoxy-(C 2 - C 4 )alkoxy, fluoro
  • anilines of formula XIV wherein Y represents methoxycarbonyl (or VIII wherein R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (C C 4 )alkyl-carbonyl, (C C 2 )alkoxy- (C C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy or halogen and Y represents methoxycarbonyl, respectively) (Scheme 8) can be prepared by methanolysis of acetylated anilines of formula XXI wherein R N represents acetylamino and R 6 represents hydrogen (or XXI wherein R N represents acetylamino and R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (C C 4 )alkyl-carbonyl, (Ci-C 2 )alkoxy-(C C 4 )alkyl, (C C 4 )alkoxy
  • anilines of formula XIV wherein R 5 represents hydrogen, (C C 4 )alkyl, fluoro or chloro and Y represents cyano (or VIII wherein R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (C C 4 )alkyl-carbonyl, (CrC 2 )alkoxy-(CrC 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy, fluoro or chloro, R 5 represents hydrogen, (C C 4 )alkyl, fluoro or chloro and Y represents cyano, respectively) (Scheme 8) can be prepared by palladium catalysed cyanation of bromides of formula XXXIX wherein R 5 represents hydrogen, (C C 4 )alkyl, fluoro or chloro and R 6 represents hydrogen, (C C 4 )alkyl, (C C 4 )alkoxy, (C C 4 )alkyl
  • anilines of formula XIV wherein Y represents methoxycarbonyl (or VIII wherein R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy, (C C 4 )alkyl-carbonyl, (C C 2 )alkoxy- (C C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy or halogen and Y represents methoxycarbonyl, respectively) (Scheme 8) can be prepared by esterification of anilines of formula XIV wherein Y represents hydroxycarbonyl (or VIII wherein R 6 represents (C C 4 )alkyl, (C C 4 )alkoxy , (C C 4 )alkyl-carbonyl, (CrC 2 )alkoxy-(C C 4 )alkyl, (C C 4 )alkoxy-(C 2 -C 4 )alkoxy or halogen and Y represents hydroxycarbonyl, respectively)
  • Scheme 8 Synthesis of aniline precursors XIV and VIII If not commercially available, amines of formula Ilia, wherein R 4 represents hydrogen or (Ci-C 4 )alkyl, can be prepared following the procedures outlined in Scheme 9 below.
  • the compounds of formula XXVI wherein R 4 represents trimethylsilyl or hydrogen can be prepared by cyanosilylation of a ketone of formula XXIV using a suitable cyanation reagent such as trimethylsilylcyanide, in the presence of a lewis acid such as gold (III) chloride or zinc iodide in a suitable solvent such as DCM at temperatures around RT ⁇ Synthesis, 2008, 4, 507-510).
  • the compounds of formula XXVI wherein R 4 represents (Ci-C 4 )alkyl can be prepared by cyanation of a ketal of formula XXV with a suitable cyanation reagent such as te/f-butyl isocyanide in the presence of a suitable lewis acid such as titanium tetrachloride in a suitable solvent such as DCM at temperatures between -70°C and RT (Chemistry Lett, 1984, 937-940).
  • the compounds of formula Ilia wherein R 4 represents hydrogen or (Ci-C 4 )alkyl can be prepared by reduction of a compound of formula XXVI using a suitable reducing reagent such as lithium aluminum hydride, in the presence of a suitable solvent such as Et 2 0 or THF at temperatures between 0°C and RT. Under those conditions the consecutive hydrolysis of a trimethylsilyl group, if present as R 4 , is observed.
  • amines of formula 1Mb wherein R 2 represents aryl or heteroaryl can be prepared following the procedures outlined in Scheme 10 below.
  • aryl- or heteroaryl-acetonitriles of formula XXVIII can be prepared by a two step procedure: (i) arylation or heteroarylation of methyl cyanoacetate by treatment with a bromoarene or bromoheteroarene of formula Br-R 2 in the presence of a suitable base such as KOtBu, a suitable palladium catalyst such as Pd(OAc) 2 , a suitable ligand such as dppf in a suitable solvent such as dioxane as described in J. Org.
  • aryl- or heteroaryl-acetonitriles of formula XXVIII (Scheme 10) can be prepared according to J. Am. Chem. Soc, 2011, 133, 6948- 6951.
  • Nitriles of formula XXIX can be prepared by dialkylation of aryl- or heteroaryl-acetonitriles of formula XXVIII with dihaloalkanes such as Br-(CH 2 ) n -CR 3 R 4 - (CH 2 )2-Br wherein n represents 1 , 2, 3 or 4 and R 3 and R 4 represents hydrogen or fluoro in the presence of a base such as NaH or tBuOK in a suitable organic solvent such as THF or DMSO preferably at temperatures between 0°C and RT.
  • dihaloalkanes such as Br-(CH 2 ) n -CR 3 R 4 - (CH 2 )2-Br
  • n represents 1 , 2, 3 or 4 and R 3 and R 4 represents hydrogen or fluoro in the presence of a base such as NaH or tBuOK in a suitable organic solvent such as THF or DMSO preferably at temperatures between 0°C and RT.
  • Amines of formula 1Mb can be prepared by reduction of nitriles of formula XXIX for instance under hydrogenation conditions in the presence of a suitable catalyst such as Raney nickel and a suitable solvent such as methanolic ammonia at temperatures around RT or with a suitable reducing reagent such as borane tetrahydrofuran complex in a suitable solvent such as THF at temperatures around 70°C.
  • a suitable catalyst such as Raney nickel
  • a suitable solvent such as methanolic ammonia
  • a suitable reducing reagent such as borane tetrahydrofuran complex
  • Amines of formula 1Mb wherein n represents 2 and R 3 and R 4 represents fluoro can be prepared for instance following a 4-step sequence: (i) tandem double Michael addition-Dieckmann condensation reaction of acetonitrile derivatives of formula XXVIII with methylacrylate according to J. Org.
  • amines of formula lllc can be prepared following the procedures outlined in Scheme 11 below.
  • amines of formula XXXIV wherein R 5 and R 6 represent hydrogen can be prepared for instance by alkylation of N- (diphenylmethylene)glycine te/f-butyl ester with cycloalkyl bromide or iodide of formula XXXIII (X represents bromo or iodo) according to Angew. Chem. Int. Ed., 2005, 44, 1549- 1551.
  • amines of formula XXXIV wherein R 5 represents hydroxy and R 6 represents hydrogen or R 5 and R 6 form an ethylenedioxy group can be prepared as previously described for the synthesis of amines of formula XXXIV wherein R 5 and R 6 represent hydrogen.
  • compounds of formula XXXV wherein R 7 represents tBu and R 8 represents Boc (or Z respectively) can be prepared by treatment of amines of formula XXXIV wherein R 5 represents hydroxy and R 6 represents hydrogen with Boc-anhydride (or Z-CI respectively) in the presence of a base such as Et 3 N or NaOH in a suitable solvent such as DCM or dioxane/water at temperatures between 0°C and RT. Oxidation of resulting compounds using for instance DMP in a suitable solvent such as DCM at temperatures around RT gives ketones of formula XXXVI wherein R 7 represents tBu or Me and R 8 represents Boc or Z.
  • ketones of formula XXXVI wherein R 7 represents tBu or Me and R 8 represents Z can be prepared by a two step procedure: (i) Z-protection of amines of formula XXXIV wherein R 5 and R 6 form an ethylenedioxy group using conditions as previously described for the synthesis of compounds of formula XXXV and (ii) cleavage of the ketal protecting group using acidic conditions such as aq. HCI and a suitable organic solvent such as MeCN or THF at temperatures around RT.
  • compounds of formula XXXVII wherein R 7 represents tBu or Me and R 8 represents Boc or Z can be prepared by fluorination of ketones of formula XXXVI wherein R 7 represents tBu or Me and R 8 represents Boc or Z using a fluorinating reagent such as DAST or bis(2-methoxyethyl)aminosulfur trifluoride in the presence of a suitable solvent such as THF or DCM at temperatures between 0°C and RT.
  • a fluorinating reagent such as DAST or bis(2-methoxyethyl)aminosulfur trifluoride
  • Amines of formula lllc wherein R 3 and R 4 represent fluoro can be prepared by Boc cleavage (or Z cleavage respectively) from compounds of formula XXXVIII wherein R 8 represents Boc (or Z respectively) using a suitable acid such as HCI or TFA in the presence of a suitable solvent such as dioxane, EtOAc or DCM (or under hydrogenation conditions in the presence of a suitable catalyst such as palladium on charcoal and a suitable solvent such as MeOH or dioxane respectively) at temperatures around RT.
  • a suitable acid such as HCI or TFA
  • a suitable solvent such as dioxane, EtOAc or DCM
  • a suitable catalyst such as palladium on charcoal and a suitable solvent such as MeOH or dioxane respectively
  • PEPPSITM-IPr [1 ,3-Bis(2,6-Diisopropylphenyl)imidazol-2-ylidene](3- chloropyridyl)palladium(ll) dichloride
  • LC-MS (I): Thermo Finnigan MSQ Surveyor MS with Agilent 1 100 Binary Pump and DAD. Eluents (acidic conditions): A: H 2 0 + 0.04% TFA; B: CH 3 CN; gradient: 5% B ⁇ 95% B ; runtime: 1.5 min ; flow: 4.5 mL/min ; detection: UV/Vis + MS, t R is given in min.
  • Atlantis column Waters Atlantis T3, 10 ⁇ , 30x75 mm
  • Method 1 lipophilic gradient: 40% B over 0.1 min, 40% ⁇ 50% B over 0.1 min, 50% ⁇
  • Method 4 (long polar gradient): 10% B over 0.2 min, 10% ⁇ 20% B over 0.1 min, 20% ⁇ 50% B over 4.1 min, 50% ⁇ 95% B over 0.1 min and finally 95%B over 1.1 min
  • Method 5 (polar gradient): 10% B over 0.2 min, 10% ⁇ 20% B over 0.1 min, 20% ⁇ 50% B over 2.9 min, 50% ⁇ 95% B over 0.1 min and finally 95%B over 1 min
  • the crude was purified by CC (SNAP KP-SILTM from Biotage) using Hept/EtOAc/MeOH from 89/11/1 to 81/19/1 to give the mixture of regioisomers as salmon solid.
  • the mixture was enriched from 59 to 66% in methyl 4-amino-2-chloro-3-iodobenzoate by recrystallisation in Hept/EtOAc 75/25, separation of the solid methyl 4-amino-2-chloro-5-iodobenzoate by filtration and evaporation of the mother liquid.
  • This compound was prepared using a method analogous to that of 4-chloro-1 H-indole-5- carboxylic acid, methyl 4-chloro-3-formyl-1 H-indole-5-carboxylate replacing methyl 4- chloro-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-7- methyl-1 H-indole-5-carboxylate, methyl 4-chloro- 7-iodo-2-methyl-3-(methylthio)-1 H- indole-5-carboxylate replacing 4-chloro- 7-methyl-3-(methylthio)-1 H-indole-5-carboxylate except that the reaction mixture was stirred for 48h at RT and further additions of Actimet M Raney Nickel was required until completion of the reaction.
  • This compound was prepared using a method analogous to that of 4-chloro-1 H-indole-5- carboxylic acid, methyl 4-chloro-2-methyl-1 H-indole-5-carboxylate replacing methyl 4- chloro-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-3-fluoro-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-7-iodo- 3-(methylthio)-1 H-indole-5-carboxylate, commercially available methyl 4-amino-5-iodo-2- methoxybenzoate replacing methyl 4-amino-2-chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-7- methyl-1 H-indole-5-carboxylate, methyl 7-iodo-4-methoxy-3-(methylthio)-1 H-indole-5- carboxylate replacing 4-chloro-7-methyl-3-(methylthio)-1 H-indole-5-carboxylate except that the reaction mixture was stirred for 2h at RT and one further addition of Actimet M Raney Nickel was required until completion of the reaction.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-methoxy-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, Methyl 3,4-dichloro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction mixture was stirred ON at 60°C.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 4-amino-2-chloro-5-nitrobenzoic acid replacing 4-amino-2-chlorobenzoic acid except that the crude was additionally purified by CC (SNAP KP-SILTM from Biotage) using Hept/EtOAc from 3/1 to 0/1.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5-nitrobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-nitro-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-nitrobenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate except that the reaction was additionally stirred ON at 45°C until completion.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-nitro-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction was stirred for 2h at RT.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-3-methyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2, 6-dichlorobenzoate replacing methyl 4-amino-2-chlorobenzoate except that no purification was done.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2,6-dichloro-3-iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2,6-dichloro-3-((trimethylsilyl)ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2,6-dichloro-3-ethynylbenzoate replacing methyl 4- amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4,6-dichloro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
  • the crude primary amide was suspended in water (2.54 ml_) and H 2 S0 4 (7.63 ml_) and heated to 80°C.
  • Sodium nitrite (9.16 mmol) was added portionwise and the mixture was stirred for 1 h at 80°C. It was quenched with water, basified with a 32% solution of NaOH until pH 13-14 and washed 3 times with EtOAc.
  • the aqueous phase was acidified with a 24% solution of HCI until pH 1-2 and extracted 3 times with EtOAc.
  • the combined organic phases were dried over MgS0 4 and concentrated in vacuo to give the title compound as brown oil.
  • This compound was prepared using a method analogous to that of methyl 2,6-dichloro-4- nitrobenzoate, 2-chloro-6-methyl-4-nitrobenzoic acid replacing 2,6-dichloro-4-nitrobenzoic acid.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2,6- dichlorobenzoate, methyl 2-chloro-6-methyl-4-nitrobenzoate replacing methyl 2,6-dichloro- 4-nitrobenzoate except that the mixture was heated for 15 min at 100°C under microwave conditions.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-6-methylbenzoate replacing methyl 4-amino-2-chlorobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-6-methyl benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4- amino-2-chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-6-methyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-6-methylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4,6-dichloro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 3-bromo-4-chloro-7-methyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-isobutylbenzoate replacing methyl 4-amino-2-chlorobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5- isobutylbenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-isobutyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-isobutylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-isobutyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-(3-methoxypropyl)benzoate replacing methyl 4-amino-2-chlorobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5-(3- methoxypropyl)benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-(3-methoxypropyl)benzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-(3-methoxypropyl)-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-methyl- 1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction mixture was stirred for 16h at 60°C.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2,6- dichlorobenzoate, 2-chloro-5-methoxy-4-nitrobenzoic acid replacing methyl 2,6-dichloro-4- nitrobenzoate except that the mixture was heated for 15 min at 100°C under microwave conditions.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 4-amino-2-chloro-5-methoxybenzoic acid replacing 4-amino-2- chlorobenzoic acid.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-methoxybenzoate replacing methyl 4-amino-2-chlorobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5- methoxybenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-methoxy-3-((trimethylsilyl)ethynyl)- benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-methoxybenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-methoxy-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, 4-amino- 2,5-dimethylbenzonitrile replacing methyl 4-amino-2-chlorobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, 4-amino-3-iodo-2,5-dimethylbenzonitrile replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- ch I o ro- 5- i odo be nzoate .
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, 4-amino-2,5-dimethyl-3-((trimethylsilyl)ethynyl)benzonitrile replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, 4-amino-3-ethynyl-2,5-dimethylbenzonitrile replacing methyl 4- amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-methyl-1 H- indole-5-carboxylate, vinylboronic acid pinacol ester replacing trimethylboroxine.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-ethyl-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 5-acetyl-4-amino-2-chloro-3- iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 5-acetyl-4-amino-2-chloro-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 5-acetyl-4-amino-2-chloro-3-ethynylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-acetyl-4-chloro-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 4-amino-2-(trifluoromethyl)benzoic acid replacing 4-amino-2- chlorobenzoic acid.
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-(trifluoromethyl)benzoate replacing methyl 4-amino-2-chlorobenzoate except that only the 5-iodo regioisomer was isolated.
  • LC-MS (A): t R 0.88 min, [M+H]+: 345.7
  • This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-5-methyl-2-(trifluoromethyl)benzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 7h at 50°C.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-3-iodo-5-methyl-2- (trifluoromethyl)benzoate replacing the mixture of methyl 4-amino-2-chloro-3- iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate except that the reaction mixture was stirred for 3h30 at 70°C.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-5-methyl-2-(trifluoromethyl)-3-((trimethylsilyl) ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-3-ethynyl-5-methyl-2-(trifluoromethyl)benzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
  • This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-methyl-4-(trifluoromethyl)-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction mixture was stirred ON at 60°C.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-3-iodo-5-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-5-ethyl-3-iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate except that the reaction was stirred for 30 min at 80°C.
  • This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-ethyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
  • This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-5-ethyl-3-ethynylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Description

Indole Carboxamide Derivatives as P2X? Receptor Antagonists
The present invention relates to indole carboxamide derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as P2X7 receptor antagonists.
The P2X7 receptors (P2RX7) belong to the family of P2X ionotropic receptors that are activated by extracellular nucleotides, in particular adenosine triphosphate (ATP). P2RX7 is distinguished from other P2X family members by the high concentrations (mM range) of ATP required to activate it and its ability to form a large pore upon prolonged or repeated stimulation (North, R. A., Physiol. Rev. 2002, 82(4), 1013-67; Surprenant, A., Rassendren, F. et al., Science 1996, 272(5262), 735-8; Virginio, C, MacKenzie, A. et al., J. Physiol., 1999, 519, 335-46). P2RX7 is present on many cell types, especially ones known to be involved in inflammatory and immune processes. This is reflected within both the periphery and the CNS as Lipopolysaccharide S (LPS) priming of monocytes and microglia followed by ATP stimulation has been shown to lead to the local release and processing of I L1 β and other family members including IL18 through a P2RX7 mediated mechanism. Indeed mice lacking the P2X7 receptor are unable to release I L1 β following LPS priming and ATP stimulation providing further evidence of its role in this pathway (Solle, M., Labasi, J. et al., J. Biol. Chem., 2001 , 276(1), 125-32). In addition L-selectin shedding from monocytes, macrophages and lymphocytes, degranulation in mast cells and apoptosis in lymphocytes are all associated with P2RX7 stimulation. P2RX7 is also expressed on epithelial and endothelial cells (Ferrari, D., Chiozzi, P. et al., Neuropharmacology 1997, 36(9), 1295-301 ; Wiley, J. S., Chen, J. R. et al., Ciba Found Symp. 1996, 198, 149-60 and 160-5; North, R. A., Physiol. Rev. 2002, 82(4), 1013-67). In addition to its role in the periphery it may have an important function in neurotransmission within the CNS through its activation on postsynaptic and / or presynaptic central and peripheral neurons and glia (Deuchars, S. A., Atkinson, L. et al., J. Neurosci. 2001 , 21 (18), 7143-52; Sperlagh, B., Kofalvi, A. et al., J. Neurochem. 2002, 81 (6), 1 196-211). Recent data that has emerged using in situ hybridization demonstrated that P2X7 receptor mRNA was widely distributed throughout the rat brain. Specifically, among the areas of high P2X7mRNA expression noted were the piriform cortex, hippocampus, pontine nuclei and the anterior horn of the spinal cord (Yu, Y., Ugawa, S. et al., Brain. Res. 2008, 1 194, 45-55). Hence there is therapeutic rationale for the use of P2X7 ion channel blockers in the treatment of a variety of disease states. These include but are not limited to diseases associated with the central nervous system such as stroke or injury and diseases associated with neuro-degeneration and neuroinflammation such as Alzheimer's disease, Huntington's disease, epilepsy, Amyotrophic lateral sclerosis, acute spinal cord injury additionally to meningitis, sleep disorders, mood and anxiety disorders as well as chronic and neuropathic and inflammatory pain. Furthermore, peripheral inflammatory disorders and autoimmune diseases including but not limited to rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease, airways hyper-responsiveness, septic shock, bronchitis, glomerulonephritis, irritable bowel disease, skin injury, lung emphysema, Limb girdle dystrophy type 2B, fibrosis, Syndrome of synovitis Acne Pustulosis, atherosclerosis, burn injury, spinal cord injury, Hyperostosis Osteitis, Crohn's disease, ulcerative colitis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, trauma, meningitis, osteoporosis, burn injury, ischemic heart disease, and varicose veins and trauma, are all examples where the involvement of P2X7 channels has been implicated. In addition a recent report suggests a link between P2RX7 and chronic, inflammatory and neuropathic pain (Chessell, I. P., Hatcher, J. P. et al., Pain, 2005, 1 14(3), 386-96). Overall, these findings indicate a role for the P2X7 receptor in the process of neuronal synaptic transmission and therefore a potential role for P2X7 antagonists as novel therapeutic tools to treat neuropathic pain.
In view of the above observations, there is significant requirement for P2X7 antagonists that can be efficiently used in treating neuropathic pain, chronic inflammatory pain, inflammation, and neurodegenerative conditions.
Different indole carboxamide derivatives, which are also P2X7 receptor antagonists, have been disclosed in WO 2009/023623, WO 2009/108551 and WO 2009/1 18175.
1) The present invention relates to indole carboxamide derivatives of formula (I),
Figure imgf000003_0001
(I)
wherein
n represents 1 , 2, 3 or 4; R1 represents hydrogen and R2 represents hydroxy; hydroxy-(Ci-C3)alkyl; (Ci-C3)alkoxy; -NHR ; -N(CH3)2; -CN; -CONH2; (d-C4)alkoxy-carbonyl; (Ci-C4)alkylamino-carbonyl; aryl which is unsubstituted or mono- or di-substituted with (CrC3)fluoroalkyl or halogen; or heteroaryl which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl, (C C3)fluoroalkyl or halogen; or
R1 represents (Ci-C3)alkyl or hydroxy-(Ci-C3)alkyl and R2 represents hydrogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen, (Ci-C4)alkyl or halogen;
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkyl-carbonyl, hydroxy-(Ci- C4)alkyl, hydroxy-(C2-C4)alkoxy, (C1-C2)alkoxy-(C1-C4)alkyl, (d-C4)alkoxy-(C2- C4)alkoxy, hydroxy, amino, nitro or halogen;
R7 represents hydrogen or (Ci-C3)alkyl;
R8 represents hydrogen, (Ci-C4)alkyl or hydroxy;
R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkylthio, formyl or halogen;
R10 represents fluoro, chloro, methyl, ethyl, (Ci-C2)fluoroalkyl or methoxy; and
R11 represents hydrogen, benzyl, (Ci-C4)alkyl-carbonyl, (Ci-C4)alkoxy-carbonyl or (Ci- C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci- C4)alkoxy-carbonyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
The compounds of formula (I) according to embodiment 1) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the (Z)- or (/^-configuration unless indicated otherwise. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
Definitions provided herein are intended to apply uniformly to the compounds of formulae (I), Osti) > OHET) and (I0H) as defined in any one of embodiments 1 ) to 42), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein.
The term "alkyl", used alone or in combination, refers to a straight or branched chain alkyl group containing one to four carbon atoms. The term "(Cx-Cy)alkyl" (x and y each being an integer), refers to an alkyl group as defined before containing x to y carbon atoms. For example a (C C4)alkyl group contains from one to four carbon atoms. Representative examples of alkyl groups include methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and tert. -butyl.
In case "R1" represents "(CrC3)alkyl" the term means (C C3)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl and /'so-propyl. Preferred is methyl.
In case "R5" represents "(C C4)alkyl" the term means (C C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
In case "R6" represents "(C C4)alkyl" the term means (C C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and te/t-butyl and notably methyl, ethyl, n-propyl and /'so-butyl. Preferred are methyl and /'so-butyl.
In case "R7" represents "(CrC3)alkyl" the term means (C C3)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl and /'so-propyl. Preferred is methyl.
In case "R8" represents "(C C4)alkyl" the term means (C C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
In case "R9" represents "(C C4)alkyl" the term means (C C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
In case a (C C4)alkyl group is a substituent to a heteroaryl group, the term "(C C4)alkyl" means (C C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl,7-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and te/t-butyl. Preferred is methyl.
The term "alkoxy", used alone or in combination, refers to an alkyl-O- group wherein the alkyl group is as defined above. The term "(Cx-Cy)alkoxy" (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (C C4)alkoxy group contains from one to four carbon atoms. Representative examples of alkoxy groups include methoxy, ethoxy, n-propoxy, /'so-propoxy, n-butoxy, /'so-butoxy, sec.-butoxy and te/t-butoxy.
In case "R2" represents "(CrC3)alkoxy" the term means (C C3)alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy and /'so-propoxy. Preferred is methoxy.
In case "R6" represents "(C C4)alkoxy" the term means (C C4)alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy, /'so-propoxy, n-butoxy, /'so-butoxy, sec.-butoxy and te/t-butoxy and notably methoxy and ethoxy. Preferred is methoxy.
The term "hydroxy-(C C4)alkyl", used alone or in combination, refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with hydroxy. Examples of said groups are hydroxy-methyl, 1-hydroxy- ethyl, 2-hydroxy-ethyl, 1-hydroxy-prop-1-yl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 1- hydroxy-prop-2-yl, 2-hydroxy-prop-2-yl, 1-hydroxy-but-1-yl, 2-hydroxy-but-1-yl, 3-hydroxy- but-1-yl, 4-hydroxy-but-1-yl, 1-hydroxy-but-2-yl, 2-hydroxy-but-2-yl, 3-hydroxy-but-2-yl, 4- hydroxy-but-2-yl, 1-hydroxy-2-methyl-prop-1-yl, 2-hydroxy-2-methyl-prop-1-yl, 3-hydroxy- 2-methyl-prop-1-yl, and 2-hydroxy-1 , 1-dimethyl-eth-1-yl. In analogy, the term "hydroxy- (CrC3)alkyl", used alone or in combination, refers to an alkyl group as defined before containing one to three carbon atoms in which one hydrogen atom has been replaced with hydroxy. Examples of said groups are hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl,
1- hydroxy-prop-1-yl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 1-hydroxy-prop-2-yl and 2- hydroxy-prop-2-yl.
In case "R1" represents "hydroxy-(CrC3)alkyl" the term means hydroxy-(C C3)alkyl groups as defined above. Representative examples of said groups are hydroxy-methyl, 2- hydroxy-ethyl and 3-hydroxy-prop-1-yl. Preferred is hydroxy-methyl.
In case "R2" represents "hydroxy-(C C3)alkyl" the term means hydroxy-(C C3)alkyl groups as defined above. Representative examples of said groups are hydroxy-methyl, 2- hydroxy-ethyl and 3-hydroxy-prop-1-yl. Preferred is hydroxy-methyl.
In case "R6" represents "hydroxy-(C C4)alkyl" the term means hydroxy-(C C4)alkyl groups as defined above. Examples of said groups are hydroxy-methyl, 1-hydroxy-ethyl,
2- hydroxy-ethyl, 1-hydroxy-prop-1-yl, 2-hydroxy-prop-1-yl, 3-hydroxy-prop-1-yl, 1-hydroxy- prop-2-yl, 2-hydroxy-prop-2-yl, 1-hydroxy-but-1-yl, 2-hydroxy-but-1-yl, 3-hydroxy-but-1-yl, 4-hydroxy-but-1-yl, 1-hydroxy-but-2-yl, 2-hydroxy-but-2-yl, 3-hydroxy-but-2-yl, 4-hydroxy- but-2-yl, 1-hydroxy-2-methyl-prop-1-yl, 2-hydroxy-2-methyl-prop-1-yl, 3-hydroxy-2-methyl- prop-1-yl, and 2-hydroxy-1 ,1-dimethyl-eth-1-yl. Preferred are 1-hydroxy-ethyl and 2- hydroxy-prop-2-yl.
The term "hydroxy-(C2-C4)alkoxy", used alone or in combination, refers to an alkoxy group as defined before containing from two to four carbon atoms in which one hydrogen atom has been replaced with hydroxy. Examples of said groups are 2-hydroxy-ethoxy, 2- hydroxy-prop-1-yloxy, 3-hydroxy-prop-1-yloxy, 1-hydroxy-prop-2-yloxy, 2-hydroxy-but-1- yloxy, 3-hydroxy-but-1-yloxy, 4-hydroxy-but-1-yloxy, 1-hydroxy-but-2-yloxy, 3-hydroxy-but- 2-yloxy, 4-hydroxy-but-2-yloxy, 2-hydroxy-2-methyl-prop-1-yloxy, 3-hydroxy-2-methyl- prop-1-yloxy, and 2-hydroxy-1 , 1-dimethyl-eth-1-yloxy. Preferred is 2-hydroxy-ethoxy.
The term "(Ci-C2)alkoxy-(CrC4)alkyl", used alone or in combination, refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with (C C2)alkoxy as defined before. Examples of said groups are methoxy-methyl, methoxy-ethyl, methoxy-propyl, methoxy-butyl, ethoxy-methyl, ethoxy-ethyl, ethoxy-propyl and ethoxy-butyl.
In case "R6" represents "(CrC2)alkoxy-(CrC4)alkyl" the term means "(C C2)alkoxy- (C C4)alkyl groups as defined above. Representative examples of said groups are methoxy-methyl, 2-methoxy-ethyl, 3-methoxy-prop-1-yl, 4-methoxy-but-1-yl, ethoxy- methyl, 2-ethoxy-ethyl, 3-ethoxy-prop-1-yl and 4-ethoxy-but-1-yl. Preferred is 3-methoxy- prop-1-yl. In another embodiment preferred (Ci-C2)alkoxy-(C C4)alkyl groups representing R6 are 2-ethoxy-ethyl, 2-methoxy-prop-2-yl and 3-methoxy-prop-1-yl.
The term "(CrC4)alkoxy-(C2-C4)alkoxy", used alone or in combination, refers to an alkoxy group as defined before containing from two to four carbon atoms in which one hydrogen atom has been replaced with (C C4)alkoxy as defined before. A preferred example of said groups is 2-te/f-butoxy-ethoxy.
The term "alkylthio", used alone or in combination, refers to an alkyl-S- group wherein the alkyl group is as defined above. The term "(Cx-Cy)alkylthio" (x and y each being an integer) refers to an alkylthio group as defined before containing x to y carbon atoms. For example a (C C4)alkylthio group contains from one to four carbon atoms. Examples of alkylthio groups include methylthio, ethylthio, n-propylthio, /'so-propylthio, n-butylthio, iso- butylthio, sec.-butylthio and te/t-butylthio.
In case "R9" represents "(C C4)alkylthio" the term means (C C4)alkylthio groups as defined above. Examples of said groups are methylthio, ethylthio, n-propylthio, /'so-propylthio, n-butylthio, /'so-butylthio, sec.-butylthio and te/t-butylthio. Preferred is methylthio. The term "alkyl-sulfonyl", used alone or in combination, refers to an alkyl-S(0)2- group wherein the alkyl group is as defined above, which is attached to the rest of the molecule via the sulfonyl-S-atom. The term "(Cx-Cy)alkyl-sulfonyl" (x and y each being an integer) refers to an alkyl-sulfonyl group as defined before containing x to y carbon atoms. For example a (C C4)alkyl-sulfonyl group contains from one to four carbon atoms. Examples of alkyl-sulfonyl groups include methyl-sulfonyl, ethyl-sulfonyl, n-propyl-sulfonyl, iso- propyl-sulfonyl, n-butyl-sulfonyl, /'so-butyl-sulfonyl, sec.-butyl-sulfonyl and te/t-butyl- sulfonyl.
In case "R11" represents "(C C4)alkyl-sulfonyl" the term means (C C4)alkyl-sulfonyl groups as defined above. Examples of said groups are methyl-sulfonyl, ethyl-sulfonyl, n- propyl-sulfonyl, /'so-propyl-sulfonyl, n-butyl-sulfonyl, /'so-butyl-sulfonyl, sec.-butyl-sulfonyl and te/t-butyl-sulfonyl. Preferred are methyl-sulfonyl and ethyl-sulfonyl.
The term "alkyl-carbonyl", used alone or in combination, refers to an alkyl-C(O)- group wherein the alkyl group is as defined before, which is attached to the rest of the molecule via the carbonyl-C-atom. The term "(Cx-Cy)alkyl-carbonyl" (x and y each being an integer) refers to an alkyl-carbonyl group as defined before containing in the alkyl radical x to y carbon atoms. For example a (C C4)alkyl-carbonyl group contains in the alkyl radical one to four carbon atoms. Examples of alkyl-carbonyl groups include methyl-carbonyl, ethyl- carbonyl, n-propyl-carbonyl, /'so-propyl-carbonyl, n-butyl-carbonyl, /'so-butyl-carbonyl, sec- butyl-carbonyl and te/t-butyl-carbonyl.
In case "R6" represents "(C C4)alkyl-carbonyl" the term means (C C4)alkyl-carbonyl groups as defined above. Examples of said groups are methyl-carbonyl, ethyl-carbonyl, n- propyl-carbonyl, /'so-propyl-carbonyl, n-butyl-carbonyl, /'so-butyl-carbonyl, sec.-butyl- carbonyl and te/t-butyl-carbonyl. Preferred is methyl-carbonyl.
In case "R11" represents "(C C4)alkyl-carbonyl" the term means (C C4)alkyl-carbonyl groups as defined above. Examples of said groups are methyl-carbonyl, ethyl-carbonyl, n- propyl-carbonyl, /'so-propyl-carbonyl, n-butyl-carbonyl, /'so-butyl-carbonyl, sec.-butyl- carbonyl and te/t-butyl-carbonyl. Preferred is methyl-carbonyl.
The term "alkoxy-carbonyl", used alone or in combination, refers to an alkoxy-C(O)- group wherein the alkoxy group is as defined before, which is attached to the rest of the molecule via the carbonyl-C-atom. The term "(Cx-Cy)alkoxy-carbonyl" (x and y each being an integer) refers to an alkoxy-carbonyl group as defined before containing in the alkoxy radical x to y carbon atoms. For example a (C C4)alkoxy-carbonyl group contains in the alkoxy radical one to four carbon atoms. Examples of alkoxy-carbonyl groups include methoxy-carbonyl, ethoxy-carbonyl, n-propoxy-carbonyl, /'so-propoxy-carbonyl, n-butoxy- carbonyl, /'so-butoxy-carbonyl, sec.-butoxy-carbonyl and te/t-butoxy-carbonyl.
In case "R2" represents "(CrC4)alkoxy-carbonyl" the term means (C C4)alkoxy-carbonyl groups as defined above. Examples of said groups are methoxy-carbonyl, ethoxy- carbonyl, n-propoxy-carbonyl, /'so-propoxy-carbonyl, n-butoxy-carbonyl, /'so-butoxy- carbonyl, sec.-butoxy-carbonyl and te/t-butoxy-carbonyl. Preferred is methoxy-carbonyl. In case "R11" represents "(C C4)alkoxy-carbonyl" the term means (C C4)alkoxy-carbonyl groups as defined above. Examples of said groups are methoxy-carbonyl, ethoxy- carbonyl, 7-propoxy-carbonyl, /'so-propoxy-carbonyl, n-butoxy-carbonyl, /'so-butoxy- carbonyl, sec.-butoxy-carbonyl and te/t-butoxy-carbonyl. Preferred is te/t-butoxy- carbonyl.
In case a (C C4)alkoxy-carbonyl group is a substituent to a (C C4)alkyl-sulfonyl group representing R11, the term "(CrC4)alkoxy-carbonyl" means (C C4)alkoxy-carbonyl groups as defined above. Examples of said groups are methoxy-carbonyl, ethoxy-carbonyl, n- propoxy-carbonyl, /'so-propoxy-carbonyl, n-butoxy-carbonyl, /'so-butoxy-carbonyl, sec.- butoxy-carbonyl and te/t-butoxy-carbonyl. Preferred is methoxy-carbonyl.
The term "alkylamino-carbonyl", used alone or in combination, refers to an alkyl-NH-C(O)- group wherein the alkyl group is as defined before, which is attached to the rest of the molecule via the -NH-C(O)- group. The term "(Cx-Cy)alkylamino-carbonyl" (x and y each being an integer) refers to an alkylamino-carbonyl group as defined before containing in the alkyl radical x to y carbon atoms. For example a (C C4)alkylamino-carbonyl group contains in the alkyl radical one to four carbon atoms. Examples of alkylamino-carbonyl groups include methylamino-carbonyl, ethylamino-carbonyl, n-propylamino-carbonyl, iso- propylamino-carbonyl, n-butylamino-carbonyl, /'so-butylamino-carbonyl, sec.-butylamino- carbonyl and te/t-butylamino-carbonyl.
In case "R2" represents "(CrC4)alkylamino-carbonyl" the term means (C C4)alkylamino- carbonyl groups as defined above. Examples of said groups are methylamino-carbonyl, ethylamino-carbonyl, n-propylamino-carbonyl, /'so-propylamino-carbonyl, n-butylamino- carbonyl, /'so-butylamino-carbonyl, sec.-butylamino-carbonyl and te/t-butylamino- carbonyl. Preferred is methylamino-carbonyl.
The term "(Cx-Cy)fluoroalkyl" (x and y each being an integer) refers to an alkyl group as defined before containing x to y carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluoro. For example a (CrC3)fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluoro. ln case "R10" represents "(CrC2)fluoroalkyl" the term means (C C2)fluoroalkyl groups as defined above. Representative examples of said groups are difluoromethyl, trifluoromethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred is trifluoromethyl.
In case "(CrC3)fluoroalky is a substituent to an aryl or a heteroaryl group, the term "(C C3)fluoroalkyl" means (CrC3)fluoroalkyl groups as defined above. Representative examples of said groups are difluoromethyl, trifluoromethyl, 2,2-difluoroethyl and 2,2,2- trifluoroethyl. Preferred is trifluoromethyl.
The term halogen means fluoro, chloro, bromo or iodo.
In case "R5" represents "halogen" the term means fluoro, chloro, bromo or iodo. Preferred is chloro.
In case "R6" represents "halogen" the term means fluoro, chloro, bromo or iodo. Preferred is iodo. In another embodiment chloro is preferred.
In case "R9" represents "halogen" the term means fluoro, chloro, bromo or iodo. Preferred is fluoro.
In case "halogen" is a substituent to an aryl or a heteroaryl group, the term "halogen" means fluoro, chloro, bromo or iodo. Preferred is chloro.
The term "aryl", used alone or in any combination, means a phenyl or a naphthyl group. Preferred is a phenyl group. The aryl group is unsubstituted or substituted as explicitly defined. Examples are 4-chloro-phenyl and 4-trifluoromethyl-phenyl.
The term "heteroaryl", used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1 , 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Preferred is a 5- or 6-membered monocyclic heteroaryl group. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2, 1 ,3]oxadiazolyl, benzo[2,1 ,3]thiadiazolyl, benzo[1 ,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl and phthalazinyl. Preferred are pyridyl and pyrimidyl. The heteroaryl groups are unsubstituted or substituted as explicitly defined. Examples of such unsubstituted or substituted heteroaryl groups are pyridyl (notably pyridin-3-yl), 2-chloro- pyridyl (notably 2-chloro-pyridin-5-yl), 2-trifluoromethyl-pyridyl (notably 2-trifluoromethyl- pyridin-5-yl), 2-methyl-pyrimidyl (notably 2-methyl-pyrimidin-5-yl) and 2-trifluoromethyl- pyrimidyl (notably 2-trifluoromethyl-pyrimidin-5-yl). The term "5- or 6-membered monocyclic heteroaryl group", used alone or in combination, means a 5- or 6-membered monocyclic aromatic ring containing one nitrogen atom and optionally one additional heteroatom selected from oxygen, nitrogen and sulfur. Preferred are 6-membered monocyclic aromatic rings containing one or two nitrogen atoms. Examples of such heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Preferred are pyridyl and pyrimidyl. The heteroaryl groups are unsubstituted or substituted as explicitly defined. Examples of such unsubstituted or substituted 5- or 6-membered monocyclic heteroaryl groups are pyridyl (notably pyridin-3-yl), 2-chloro-pyridyl (notably 2-chloro- pyridin-5-yl), 2-trifluoromethyl-pyridyl (notably 2-trifluoromethyl-pyridin-5-yl), 2-methyl- pyrimidyl (notably 2-methyl-pyrimidin-5-yl) and 2-trifluoromethyl-pyrimidyl (notably 2- trifluoromethyl-pyrimidin-5-yl).
The term "6-membered monocyclic heteroaryl group", used alone or in combination, means a 6-membered monocyclic aromatic ring containing one or two nitrogen atoms. Examples of such heteroaryl groups are pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Preferred are pyridyl and pyrimidyl. The heteroaryl groups are unsubstituted or substituted as explicitly defined. Examples of such unsubstituted or substituted 6-membered monocyclic heteroaryl groups are pyridyl (notably pyridin-3-yl), 2-chloro-pyridyl (notably 2- chloro-pyridin-5-yl), 2-trifluoromethyl-pyridyl (notably 2-trifluoromethyl-pyridin-5-yl), 2- methyl-pyrimidyl (notably 2-methyl-pyrimidin-5-yl) and 2-trifluoromethyl-pyrimidyl (notably 2-trifluoromethyl-pyrimidin-5-yl).
1 P) A further embodiment of the invention relates to compounds according to embodiment 1), wherein
n represents 1 , 2, 3 or 4;
R1 represents hydrogen and R2 represents hydroxy; hydroxy-(d-C3)alkyl; (Ci-C3)alkoxy;
-NHR ; -N(CH3)2; -CN; -CONH2; (d-C4)alkoxy-carbonyl; (Ci-C4)alkylamino-carbonyl; aryl which is unsubstituted or mono- or di-substituted with (CrC3)fluoroalkyl or halogen; or heteroaryl which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl, (C
C3)fluoroalkyl or halogen; or
R1 represents (Ci-C3)alkyl or hydroxy-(Ci-C3)alkyl and R2 represents hydrogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen, (Ci-C4)alkyl or halogen; R6 represents hydrogen, (d-C4)alkyl, (Ci-C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl, amino, nitro or halogen;
R7 represents hydrogen or (Ci-C3)alkyl;
R8 represents hydrogen, (Ci-C4)alkyl or hydroxy;
R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkylthio, formyl or halogen;
R10 represents chloro, methyl or methoxy; and
R11 represents hydrogen, benzyl, (Ci-C4)alkyl-carbonyl, (Ci-C4)alkoxy-carbonyl or (Ci- C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci- C4)alkoxy-carbonyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
2) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 2, 3 or 4;
R1 represents hydrogen and R2 represents hydroxy; hydroxy-(d-C3)alkyl; -NHR ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono- substituted with (Ci-C4)alkyl, (CrC3)fluoroalkyl or halogen; or
R1 represents (Ci-C3)alkyl or hydroxy-(Ci-C3)alkyl and R2 represents hydrogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl or amino;
R7 represents hydrogen;
R8 represents hydrogen;
R9 represents hydrogen, (Ci-C4)alkyl or halogen;
R10 represents chloro or methyl; and
R11 represents (Ci-C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci-C4)alkoxy-carbonyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 3) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 2, 3 or 4;
R1 represents hydrogen and R2 represents hydroxy; hydroxy-methyl; -NHR11; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono- substituted with methyl, trifluoromethyl or chloro; or R1 represents methyl or hydroxy-methyl and R2 represents hydrogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen, methyl, /'so-butyl, methoxy or 3-methoxy-prop-1-yl;
R7 represents hydrogen;
R8 represents hydrogen;
R9 represents hydrogen, methyl or fluoro;
R10 represents chloro or methyl; and
R11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
4) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 1 , 2, 3 or 4;
R1 represents hydrogen;
R2 represents hydroxy; hydroxy-(d-C3)alkyl; (Ci-C3)alkoxy; -NHR ; -N(CH3)2; -CN; -CONH2; (Ci-C4)alkoxy-carbonyl; (Ci-C4)alkylamino-carbonyl; aryl which is unsubstituted or mono- or di-substituted with (CrC3)fluoroalkyl or halogen; or heteroaryl which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl, (CrC3)fluoroalkyl or halogen; R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen, (Ci-C4)alkyl or halogen;
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl, amino, nitro or halogen;
R7 represents hydrogen or (Ci-C3)alkyl;
R8 represents hydrogen, (Ci-C4)alkyl or hydroxy;
R9 represents hydrogen, (Ci-C4)alkyl, (d— C4)alkylthio, formyl or halogen;
R10 represents chloro, methyl or methoxy; and
R11 represents hydrogen, benzyl, (Ci-C4)alkyl-carbonyl, (Ci-C4)alkoxy-carbonyl or (Ci-
C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci-
C4)alkoxy-carbonyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
5) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein n represents 2, 3 or 4;
R1 represents hydrogen;
R2 represents hydroxy; hydroxy-(Ci-C3)alkyl; -NHR ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with (Ci- C4)alkyl, (CrC3)fluoroalkyl or halogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy or (Ci-C2)alkoxy-(d-C4)alkyl;
R7 represents hydrogen;
R8 represents hydrogen;
R9 represents hydrogen, (Ci-C4)alkyl or halogen;
R10 represents chloro or methyl; and
R11 represents (Ci-C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci-C4)alkoxy-carbonyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
6) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 2, 3 or 4;
R1 represents hydrogen;
R2 represents hydroxy; hydroxy-methyl; -NHR11; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with methyl, trifluoromethyl or chloro;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen, methyl, /'so-butyl, methoxy or 3-methoxy-prop-1-yl;
R7 represents hydrogen;
R8 represents hydrogen;
R9 represents hydrogen, methyl or fluoro;
R10 represents chloro or methyl; and
R11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 7) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 2 or 3;
R1 represents hydrogen;
R2 represents hydroxy; or a 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with methyl, trifluoromethyl or chloro;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen, methyl, /'so-butyl, methoxy or 3-methoxy-prop-1-yl;
R7 represents hydrogen;
R8 represents hydrogen;
R9 represents hydrogen; and
R10 represents chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
8) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 2 or 3;
R1 represents (d-C3)alkyl or hydroxy-(Ci-C3)alkyl;
R2 represents hydrogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen;
R7 represents hydrogen or (Ci-C3)alkyl;
R8 represents hydrogen;
R9 represents hydrogen or formyl; and
R10 represents chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 9) A further embodiment of the invention relates to compounds according to any one of embodiments 1) or 1 P), wherein
n represents 2 or 3;
R1 represents methyl or hydroxy-methyl;
R2 represents hydrogen;
R3 represents hydrogen or fluoro; R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen;
R7 represents hydrogen or methyl;
R8 represents hydrogen;
R9 represents hydrogen; and
R10 represents chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
10) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), wherein
n represents 2 or 3;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
11) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), 8) or 9), wherein
R1 represents hydroxy-methyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
12) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5) or 10), wherein
R2 represents hydroxy; hydroxy-(d-C3)alkyl; -NHR ; or -CN; and
R11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
13) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 10), wherein
R2 represents hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
14) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5) or 10), wherein
R2 represents a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with (d-C4)alkyl, (C C3)fluoroalkyl or halogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
15) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 10), wherein R2 represents a 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with methyl, trifluoromethyl or chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
16) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 15), wherein
R3 and R4 represent hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
17) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 15), wherein
R3 and R4 represent fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
18) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 1 P), 4) or 10) to 17), wherein
R5 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
19) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 7) or 10) to 18), wherein
R6 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 20) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5) or 10) to 18), wherein
R6 represents (d-C4)alkyl, (Ci-C4)alkoxy or (Ci-C2)alkoxy-(Ci-C4)alkyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
21) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 1 P), 4), 8), 9) or 10) to 20), wherein
R7 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
22) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 1 P), 4) or 10) to 21), wherein
R8 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
23) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8) or 10) to 22), wherein R9 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
24) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6) or 10) to 22), wherein
R9 represents methyl or fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
25) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6), 8), 10) to 17), 19) or 20), wherein
R5, R7, R8 and R9 represent hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
26) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 6) or 10) to 25), wherein
R10 represents chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 27) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 2), 4), 5), 10) or 16) to 26), wherein
R11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 28) A further embodiment of the invention relates to compounds according to any one of embodiments 1) to 3), 8) to 1 1) or 16) to 26), wherein, in case R is different from hydrogen, the stereogenic center is as depicted in formula (lSti)
Figure imgf000018_0001
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
29) Preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of:
4-Chloro-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-1 H-indole-5-carboxylic acid [(S)-1-(4,4-difluoro-cyclohexyl)-2-hydroxy-ethyl]- amide;
4-Chloro-1-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-1-methyl-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide; 4-Chloro-3-formyl-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide; 4-Chloro-3-formyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-1 H-indole-5-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(2-trifluoromethyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(6-chloro-pyridin-3-yl)-cyclohexylmethyl]-amide; 4-Chloro-1 H-indole-5-carboxylic acid [1-(6-trifluoromethyl-pyridin-3-yl)-cyclohexylmethyl]- amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(6-chloro-pyridin-3-yl)-4,4-difluoro- cyclohexylmethyl]-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(4-chloro-phenyl)-cyclohexylmethyl]-amide; 4-Chloro-1 H-indole-5-carboxylic acid [1-(4-trifluoromethyl-phenyl)-cyclohexylmethyl]- amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-pyridin-3-yl-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-pyridin-3-yl-cyclopentylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-pyridin-3-yl-cycloheptylmethyl)-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-2-oxo-2,3-dihydro-1 H-indole-5-carboxylic acid (1-hydroxy-cycloheptylmethyl)- amide;
4-Chloro-2-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-7-iodo-3-methylsulfanyl-1 H-indole-5-carboxylic acid (1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-3-fluoro-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Methoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide;
3,4-Dichloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-nitro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexanecarboxylic acid methyl ester;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxymethyl-cyclohexylmethyl)-amide;
7-Amino-4-chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-3-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-1 H-indole-5-carboxylic acid (l-carbamoyl-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-methylcarbamoyl-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-cyano-cyclohexylmethyl)-amide;
(1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexyl)-carbamic acid tert-butyl ester;
4,6-Dichloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-amino-cyclohexylmethyl)-amide;
4-Chloro-6-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclopentylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclooctylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-methoxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid ((R)-1-cyclohexyl-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-acetylamino-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-methanesulfonylarnino-cyclohexylrnethyl)-arTiide;
4-Chloro-1 H-indole-5-carboxylic acid (l-dimethylamino-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-benzylamino-cyclohexylmethyl)-amide;
3- Bromo-4-chloro-7-methyl-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexylmethyl)- amide;
(1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexylsulfamoyl)-acetic acid methyl ester;
4- Chloro-7-isobutyl-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-7-(3-methoxy-propyl)-1 H-indole-5-carboxylic acid (1-hydroxy-cycloheptylmethyl)- amide;
4-Chloro-7-isobutyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-(3-methoxy-propyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(2-hydroxy-ethanesulfonylamino)- cyclohexylmethyl]-amide; 4-Methyl-1 H-indole-5-carboxylic acid (l -hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1 -(2-methyl-pyrimidin-5-yl)-cyclohexylmethyl]- amide;
4-Chloro-7-methoxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [4,4-difluoro-1-(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid [4,4-difluoro-1-(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid [1 -(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4,7-Dimethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide; and
4-Methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide; or salts (in particular pharmaceutically acceptable salts) of such compounds;
it is to be understood for any of the above listed compounds, that a stereogenic center, which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration; for example a compound listed as 4-Chloro-1 H-indole-5-carboxylic acid (1-cycloheptyl-2- hydroxy-ethyl)-amide may be 4-Chloro-1 H-indole-5-carboxylic acid ((S)-1-cycloheptyl-2- hydroxy-ethyl)-amide, 4-Chloro-1 H-indole-5-carboxylic acid ((R)-1-cycloheptyl-2-hydroxy- ethyl)-amide or any mixture thereof.
It is understood that in this specification the phrase "according to any one of embodiments 1 ) to X)", wherein "X" represents an integer between 2 and 29, refers to all embodiments between 1 ) and X) in the alternative, including embodiment 1 P) as one of the alternatives; for instance the phrase "according to any one of embodiments 1 ) to 2)" means "according to any one of embodiments 1 ) or 1 P) or 2)".
30) A further embodiment of the invention relates to compounds according to embodiment 1 ), which are also compounds of formula (I HET)
Figure imgf000021_0001
wherein
n represents 2 or 3;
X represents CH or N;
R2S represents hydrogen, (d-C4)alkyl, (CrC3)fluoroalkyl or halogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro; and
R6 represents hydrogen or (Ci-C4)alkyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
31) A further embodiment of the invention relates to compounds according to embodiment 30), wherein
n represents 2 or 3;
X represents CH or N;
R2S represents hydrogen, methyl, trifluoromethyl or chloro;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro; and
R6 represents hydrogen or methyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
32) A further embodiment of the invention relates to compounds according to any one of embodiments 30) or 31 ), wherein
X represents N;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
33) A further embodiment of the invention relates to compounds according to any one of embodiments 30) to 32), wherein
R2S represents methyl or trifluoromethyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
34) A further embodiment of the invention relates to compounds according to any one of embodiments 30) to 33), wherein
R6 represents methyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
35) A further embodiment of the invention relates to compounds according to embodiment 1), which are also compounds of formula (I0H)
Figure imgf000023_0001
wherein
n represents 2 or 3;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R6 represents (d-C4)alkyl, (Ci-C4)alkoxy, hydroxy-(Ci-C4)alkyl, hydroxy-(C2-C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl or halogen; and
R10 represents chloro, methyl or trifluoromethyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
36) A further embodiment of the invention relates to compounds according to embodiment 35), wherein
R3 and R4 represent fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 37) A further embodiment of the invention relates to compounds according to any one of embodiments 35) or 36), wherein
R6 represents methyl, ethyl, n-propyl, /'so-butyl, methoxy, ethoxy, 1-hydroxy-ethyl, 2- hydroxy-prop-2-yl, 2-hydroxy-ethoxy, 2-ethoxy-ethyl, 2-methoxy-prop-2-yl, 3-methoxy- prop-1-yl or chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
38) A further embodiment of the invention relates to compounds according to any one of embodiments 35) to 37), wherein
R10 represents chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 39) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 10) to 18) or 21) to 28), wherein
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxy-(Ci-C4)alkyl, hydroxy-(C2- C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl or halogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 40) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 10) to 18) or 21) to 28), wherein
R6 represents hydrogen, methyl, ethyl, n-propyl, /'so-butyl, methoxy, ethoxy, 1-hydroxy- ethyl, 2-hydroxy-prop-2-yl, 2-hydroxy-ethoxy, 2-ethoxy-ethyl, 2-methoxy-prop-2-yl, 3- methoxy-prop-1-yl or chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
41) A further embodiment of the invention relates to compounds according to any one of embodiments 1), 10) to 25), 27), 28), 39) or 40), wherein
R10 represents chloro, methyl or trifluoromethyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
42) Further preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of:
4-Ethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide; 7-Acetyl-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-(1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-(1-hydroxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
7-Methyl-4-trifluoromethyl-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexylmethyl)- amide;
7-Methyl-4-trifluoromethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4,7-Dimethyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-ethyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-ethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
7-Chloro-4-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
7-Chloro-4-methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-methoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 7-Methoxy-4-methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
7-Methoxy-4-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-7-ethoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-hydroxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-ethoxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-propyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-propyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
7-(2-tert-Butoxy-ethoxy)-4-chloro-1 H-indole-5-carboxylic acid (1 -hydroxy- cyclohexylmethyl)-amide;
7-(2-tert-Butoxy-ethoxy)-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-(2-hydroxy-ethoxy)-1 H-indole-5-carboxylic acid (1 -hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-(2-hydroxy-ethoxy)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
7-Acetyl-4-chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-(1 -hydroxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (1 -hydroxy- cyclohexylmethyl)-amide;
4,7-Difluoro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4,7-Difluoro-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-amide;
4-Fluoro-7-methoxy-1 H-indole-5-carboxylic acid (l -hydroxy-cyclohexylmethyl)-amide;
4-Fluoro-7-methoxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-(2-ethoxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide; and
4-Chloro-7-(1 -methoxy-1 -methyl-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1- hydroxy-cyclohexylmethyl)-amide;
it is to be understood for any of the above listed compounds, that a stereogenic center, which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration; for example a compound listed as 4-Chloro-7-(1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-amide may be 4-Chloro-7-((R)-1-hydroxy- ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-amide, 4- Chloro-7-((S)-1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1 -hydroxy- cyclohexylmethyl)-amide or any mixture thereof. It is well understood that the invention relates to compounds according to embodiment 1); or according to embodiment 1) limited by the features of an embodiment dependent on embodiment 1; or according to embodiment 1) limited by the features of a cascade of dependent embodiments e.g. in the form of "embodiment 3) depending on embodiment 2) depending on embodiment 1)". In case of an embodiment depending on more than one other embodiment, it is understood that each combination is specifically disclosed. Also, in case an embodiment is dependent on more than one other embodiment and one or more of said other embodiments are themselves dependent on one or more further embodiments, it is understood that each combination is specifically disclosed if obtainable with regard to the given dependencies and multiple dependencies. Notably, embodiments resulting from cascades of more than three embodiments depending on each other may be construed under observance of the given dependencies and multiple dependencies and are thus intended to be specifically disclosed. Representative examples of embodiments which are possible based on the dependencies of the embodiments 1) to 42) as disclosed hereinabove and which are therefore intended and herewith specifically disclosed in individualized form are:
1, 1P+1, 2+1P+1, 3+1P+1, 4+1P+1, 5+1P+1, 6+1P+1, 7+1P+1, 8+1P+1, 9+1P+1, 10+1P+1, 10+2+1P+1, 10+3+1P+1, 10+4+1P+1, 10+5+1P+1, 10+6+1P+1, 11 + 1P+1, 11+8+1P+1, 11+9+1P+1, 12+1P+1, 12+5+1P+1, 13+1P+1, 13+5+1P+1, 13+6+1P+1, 13+10+1P+1, 13+10+2+1P+1, 13+10+3+1P+1, 13+10+4+1P+1, 13+10+5+1 P+1 , 13+10+6+1P+1, 14+1P+1, 14+5+1P+1, 14+10+1P+1, 14+10+2+1 P+1 , 14+10+3+1 P+1 , 14+10+4+1P+1, 14+10+5+1P+1, 14+10+6+1P+1, 15+1P+1, 15+5+1P+1, 15+6+1P+1, 15+10+1P+1, 15+10+2+1P+1, 15+10+3+1P+1, 15+10+4+1P+1, 15+10+5+1 P+1 , 15+10+6+1P+1, 16+1P+1, 16+5+1P+1, 16+6+1P+1, 16+8+1P+1, 16+10+1P+1, 16+10+2+1P+1, 16+10+3+1P+1, 16+10+4+1P+1, 16+10+5+1 P+1 , 16+10+6+1P+1, 16+13+1P+1, 16+13+5+1P+1, 16+13+6+1P+1, 16+13+10+1 P+1 , 16+13+10+2+1 P+1 , 16+13+10+3+1P+1, 16+13+10+4+1P+1, 16+13+10+5+1 P+1 , 16+13+10+6+1P+1, 16+15+1P+1, 16+15+5+1P+1, 16+15+6+1P+1, 16+15+10+1 P+1 , 16+15+10+2+1 P+1 , 16+15+10+3+1P+1, 16+15+10+4+1P+1, 16+15+10+5+1 P+1 , 16+15+10+6+1P+1, 17+1P+1, 17+5+1P+1, 17+6+1P+1, 17+8+1P+1, 17+10+1P+1, 17+10+2+1P+1, 17+10+3+1P+1, 17+10+4+1P+1, 17+10+5+1P+1, 17+10+6+1 P+1 , 17+13+1P+1, 17+13+5+1P+1, 17+13+6+1P+1, 17+13+10+1 P+1 , 17+13+10+2+1 P+1 , 17+13+10+3+ 1P+1, 17+13+10+4+1P+1, 17+13+10+5+1 P+1 , 17+13+10+6+1 P+1 , 17+15+1P+1, 17+15+5+1P+1, 17+15+6+1P+1, 17+15+10+1 P+1 , 17+15+10+2+1 P+1 , 17+15+10+3+ 1P+1, 17+15+10+4+1P+1, 17+15+10+5+1P+1, 17+15+10+6+1 P+1 , 19+1P+1, 19+5+1P+1, 19+6+1P+1, 19+10+1 P+1 , 19+10+2+1P+1, 19+10+3+1 P+1 , 19+10+4+1P+1, 19+10+5+1P+1, 19+10+6+1P+1, 19+13+1P+1, 19+13+5+1 P+1 , 19+13+6+1 P+1 , 19+13+10+1P+1, 19+13+10+2+1P+1, 19+13+10+3+1 P+1 , 19+13+10+4+1P+1, 19+13+10+5+1P+1, 19+13+10+6+1P+1, 19+15+1P+1, 19+15+5+1 P+1 , 19+15+6+1P+1, 19+15+10+1P+1, 19+15+10+2+1P+1, 19+15+10+3+1 P+1 , 19+15+10+4+1P+1, 19+15+10+5+1P+1, 19+15+10+6+1P+1, 19+16+1P+1, 19+16+5+1P+1, 19+16+6+1P+1, 19+16+8+1P+1, 19+16+10+1P+1, 19+16+10+2+1 P+1 , 19+16+10+3+1 P+1 , 19+16+10+ 4+1P+1, 19+16+10+5+1P+1, 19+16+10+6+1 P+1 , 19+16+13+1 P+1 , 19+16+13+5+1 P+1 , 19+16+13+6+1P+1, 19+16+13+10+1 P+1 , 19+16+13+10+2+1 P+1 , 19+16+13+10+3+ 1P+1, 19+16+13+10+4+ 1 P+ 1 , 19+16+13+10+5+1 P+1 , 19+16+13+10+6+1 P+1 , 19+16+ 15+1P+1, 19+16+15+5+1P+1, 19+16+15+6+1 P+1 , 19+16+15+10+1 P+1 , 19+16+15+10+ 2+1P+1, 19+16+15+10+3+1P+1, 19+16+15+10+4+1 P+1 , 19+16+15+10+5+1 P+1 , 19+16+15+10+6+1P+1, 19+17+1P+1, 19+17+5+1 P+1 , 19+17+6+1P+1, 19+17+8+1 P+1 , 19+17+10+1P+1, 19+17+10+2+1P+1, 19+17+10+3+1 P+1 , 19+17+10+4+1P+1, 19+17+10+5+1P+1, 19+17+10+6+1P+1, 19+17+13+1 P+1 , 19+17+13+5+1 P+1 , 19+17+ 13+6+1P+1, 19+17+13+10+1P+1, 19+17+13+10+2+1 P+1 , 19+17+13+10+3+1 P+1 , 19+17+13+10+4+1P+1, 19+17+13+10+5+1 P+1 , 19+17+13+10+6+1 P+1 , 19+17+15+ 1P+1, 19+17+15+5+1P+1, 19+17+15+6+1 P+1 , 19+17+15+10+1 P+1 , 19+17+15+10+ 2+1P+1, 19+17+15+10+3+1P+1, 19+17+15+10+4+1 P+1 , 19+17+15+10+5+1 P+1 , 19+17+15+10+6+1P+1, 20+1P+1, 20+5+1P+1, 20+10+1P+1, 20+10+2+1 P+1 , 20+10+3+1P+1, 20+10+4+1P+1, 20+10+5+1P+1, 20+10+6+1 P+1 , 20+13+1P+1, 20+13+5+1P+1, 20+13+6+1P+1, 20+13+10+1P+1, 20+13+10+2+1P+1, 20+13+10+3+1P+1, 20+13+10+4+1 P+1, 20+13+10+5+1P+1, 20+13+10+6+1P+1, 20+15+1P+1, 20+15+5+1P+1, 20+15+6+1P+1, 20+15+10+1 P+1 , 20+15+10+2+1P+1, 20+15+10+3+1P+1, 20+15+10+4+1 P+1 , 20+15+10+5+1P+1, 20+15+10+6+1P+1, 20+16+1P+1, 20+16+5+1P+1, 20+16+6+1P+1, 20+16+8+1P+1, 20+16+10+1 P+1 , 20+16+10+2+1P+1, 20+16+10+3+1 P+1, 20+16+10+4+1P+1, 20+16+10+5+1P+1, 20+16+10+6+1P+1, 20+16+13+1 P+1, 20+16+13+5+1P+1, 20+16+13+6+1 P+1 , 20+16+13+10+1P+1, 20+16+13+10+2+1P+1, 20+16+13+10+3+1P+1, 20+16+13+10+ 4+1P+1, 20+16+13+10+5+1 P+1, 20+16+13+10+6+1P+1, 20+16+15+1 P+1 , 20+16+15+5+1P+1, 20+16+15+6+1P+1, 20+16+15+10+1 P+1 , 20+16+15+10+2+1P+1, 20+16+15+10+3+1P+1, 20+16+15+10+4+1P+1, 20+16+15+10+5+1P+1,
20+16+15+10+6+1P+1, 20+17+1P+1, 20+17+5+1 P+1 , 20+17+6+1P+1, 20+17+8+1 P+1 , 20+17+10+1P+1, 20+17+10+2+1 P+1, 20+17+10+3+1P+1, 20+17+10+4+1P+1, 20+17+ 10+5+1P+1, 20+17+10+6+1P+1, 20+17+13+1 P+1 , 20+17+13+5+1P+1, 20+17+13+ 6+1P+1, 20+17+13+10+1P+1, 20+17+13+10+2+1P+1, 20+17+13+10+3+1 P+1 , 20+17+13+10+4+1P+1, 20+17+13+10+5+1P+1, 20+17+13+10+6+1 P+1 , 20+17+15+ 1P+1, 20+17+15+5+1 P+1, 20+17+15+6+1 P+1 , 20+17+15+10+1 P+1 , 20+17+15+10+ 2+1P+1, 20+17+15+10+3+1P+1, 20+17+15+10+4+1 P+1 , 20+17+15+10+5+1P+1, 20+17+15+10+6+1P+1, 24+1P+1, 24+13+1P+1, 24+13+5+1 P+1 , 24+13+6+1 P+1 , 24+13+10+1P+1, 24+13+10+2+1P+1, 24+13+10+3+1P+1, 24+13+10+4+1P+1, 24+13+10+5+1P+1, 24+13+10+6+1 P+1 , 25+1P+1, 25+5+1P+1, 25+6+1P+1, 25+8+1P+1, 25+10+1P+1, 25+10+2+1P+1, 25+10+3+1P+1, 25+10+4+1P+1, 25+10+5+1 P+1 , 25+10+6+1P+1, 25+13+1P+1, 25+13+5+1P+1, 25+13+6+1P+1, 25+13+10+1P+1, 25+13+10+2+1P+1, 25+13+10+3+1 P+1 , 25+13+10+4+1P+1, 25+13+10+5+1P+1, 25+13+10+6+1P+1, 25+15+1P+1, 25+15+5+1P+1, 25+15+6+1 P+1 , 25+15+10+1P+1, 25+15+10+2+1P+1, 25+15+10+3+1 P+1 , 25+15+10+4+1P+1, 25+15+10+5+1P+1, 25+15+10+6+1P+1, 25+16+1P+1, 25+16+5+1 P+1 , 25+16+6+1P+1, 25+16+8+1 P+1 , 25+16+10+1P+1, 25+16+10+2+1P+1, 25+16+10+3+1P+1, 25+16+10+4+1P+1, 25+16+10+5+1P+1, 25+16+10+6+1P+1, 25+16+13+1 P+1 , 25+16+13+5+1P+1, 25+16+ 13+6+1P+1, 25+16+13+10+1P+1, 25+16+13+10+2+1P+1, 25+16+13+10+3+1P+1, 25+16+13+10+4+1P+1, 25+16+13+10+5+1P+1, 25+16+13+10+6+1 P+1 , 25+16+15+ 1P+1, 25+16+15+5+1 P+1, 25+16+15+6+1 P+1 , 25+16+15+10+1 P+1 , 25+16+15+10+ 2+1P+1, 25+16+15+10+3+1P+1, 25+16+15+10+4+1 P+1 , 25+16+15+10+5+1P+1, 25+16+15+10+6+1P+1, 25+17+1P+1, 25+17+5+1 P+1 , 25+17+6+1P+1, 25+17+8+1 P+1 , 25+17+10+1P+1, 25+17+10+2+1 P+1, 25+17+10+3+1P+1, 25+17+10+4+1P+1, 25+17+ 10+5+1P+1, 25+17+10+6+1P+1, 25+17+13+1 P+1 , 25+17+13+5+1 P+1 , 25+17+13+6+ 1P+1, 25+17+13+10+1P+1, 25+17+13+10+2+1 P+1 , 25+17+13+10+3+1P+1, 25+17+ 13+10+4+1P+1, 25+17+13+10+5+1P+1, 25+17+13+10+6+1P+1, 25+17+15+1P+1, 25+17+15+5+1P+1, 25+17+15+6+1P+1, 25+17+15+10+1 P+1 , 25+17+15+10+2+1P+1, 25+17+15+10+3+1P+1, 25+17+15+10+4+1P+1, 25+17+15+10+5+1 P+1 , 25+17+15+10+ 6+1P+1, 25+19+1P+1, 25+19+5+1 P+1 , 25+19+6+1P+1, 25+19+10+1P+1, 25+19+10+2+1P+1, 25+19+10+3+1 P+1 , 25+19+10+4+1P+1, 25+19+10+5+1P+1, 25+19+10+6+1P+1, 25+19+13+1 P+1 , 25+19+13+5+1P+1, 25+19+13+6+1 P+1 , 25+19+13+10+1P+1, 25+19+13+10+2+1P+1, 25+19+13+10+3+1P+1, 25+19+13+10+ 4+1P+1, 25+19+13+10+5+1P+1, 25+19+13+10+6+1P+1, 25+19+15+1 P+1 , 25+19+15+ 5+1P+1, 25+19+15+6+1P+1, 25+19+15+10+1P+1, 25+19+15+10+2+1 P+1 , 25+19+15+10+3+1P+1, 25+19+15+10+4+1P+1, 25+19+15+10+5+1P+1,
25+19+15+10+6+1P+1, 25+19+16+1 P+1 , 25+19+16+5+1 P+1 , 25+19+16+6+1P+1, 25+19+16+8+1P+1, 25+19+16+10+1 P+1 , 25+19+16+10+2+1P+1, 25+19+16+10+ 3+1P+1, 25+19+16+10+4+1P+1, 25+19+16+10+5+1 P+1 , 25+19+16+10+6+1P+1, 25+19+16+13+1P+1, 25+19+16+13+5+1P+1, 25+19+16+13+6+1P+1, 25+19+16+13+ 10+1P+1, 25+19+16+13+10+2+1P+1, 25+19+16+13+10+3+1 P+1 , 25+19+16+13+10+4+ 1P+1, 25+19+16+13+10+5+1P+1, 25+19+16+13+10+6+1 P+1 , 25+19+16+15+1P+1, 25+19+16+15+5+1P+1, 25+19+16+15+6+1 P+1 , 25+19+16+15+10+1P+1, 25+19+16+ 15+10+2+1P+1, 25+19+16+15+10+3+1P+1, 25+19+16+15+10+4+1P+1, 25+19+16+15+ 10+5+1P+1, 25+19+16+15+10+6+1P+1, 25+19+17+1P+1, 25+19+17+5+1 P+1 , 25+19+17+6+1P+1, 25+19+17+8+1P+1, 25+19+17+10+1 P+1 , 25+19+17+10+2+1P+1, 25+19+17+10+3+1P+1, 25+19+17+10+4+1P+1, 25+19+17+10+5+1 P+1 , 25+19+17+10+ 6+1P+1, 25+19+17+13+1P+1, 25+19+17+13+5+1P+1, 25+19+17+13+6+1 P+1 , 25+19+17+13+10+1 P+1, 25+19+17+13+10+2+1 P+1 , 25+19+17+13+10+3+1P+1, 25+19+17+13+10+4+1 P+1, 25+19+17+13+10+5+1 P+1 , 25+19+17+13+10+6+1 P+1 , 25+19+17+15+1P+1, 25+19+17+15+5+1P+1, 25+19+17+15+6+1P+1, 25+19+17+15+ 10+1P+1, 25+19+17+15+10+2+1P+1, 25+19+17+15+10+3+1 P+1 , 25+19+17+15+10+4+ 1P+1, 25+19+17+15+10+5+1P+1, 25+19+17+15+10+6+1P+1, 25+20+1P+1, 25+20+5+1P+1, 25+20+ 10+1 P+1, 25+20+10+2+1 P+1, 25+20+10+3+1 P+1 , 25+20+ 10+4+1 P+1, 25+20+10+5+1 P+1, 25+20+10+6+1 P+1 , 25+20+13+1 P+1 , 25+20+ 13+5+1 P+1, 25+20+ 13+6+1 P+1, 25+20+13+10+1 P+1 , 25+20+13+10+2+1P+1, 25+20+13+10+3+1 P+1, 25+20+13+10+4+1P+1, 25+20+13+10+5+1 P+1 , 25+20+13+10+ 6+1P+1, 25+20+15+1 P+1, 25+20+ 15+5+1 P+1, 25+20+ 15+6+1 P+1, 25+20+15+10+1 P+1 , 25+20+15+10+2+1 P+1, 25+20+15+10+3+1P+1, 25+20+15+10+4+1 P+1 , 25+20+15+10+ 5+1 P+1, 25+20+15+10+6+1 P+1, 25+20+16+1 P+1 , 25+20+16+5+1 P+1 , 25+20+16+6+ 1P+1, 25+20+16+8+1 P+1, 25+20+16+10+1 P+1, 25+20+16+10+2+1 P+1, 25+20+16+10+ 3+1P+1, 25+20+16+10+4+1P+1, 25+20+16+10+5+1 P+1 , 25+20+16+10+6+1 P+1, 25+20+16+13+1 P+1, 25+20+ 16+ 13+5+1 P+1, 25+20+16+13+6+1P+1, 25+20+16+13+ 10+1P+1, 25+20+16+13+10+2+1P+1, 25+20+16+13+10+3+1 P+1 , 25+20+16+13+10+ 4+1P+1, 25+20+16+13+10+5+1P+1, 25+20+16+13+10+6+1P+1, 25+20+ 16+ 15+1 P+1, 25+20+16+15+5+1 P+1, 25+20+16+15+6+1 P+1 , 25+20+16+15+10+1P+1, 25+20+16+15+ 10+2+1P+1, 25+20+16+15+10+3+1P+1, 25+20+16+15+10+4+1P+1, 25+20+16+15+10+ 5+1P+1, 25+20+16+15+10+6+1P+1, 25+20+17+1 P+1, 25+20+17+5+1 P+1 , 25+20+ 17+6+1 P+1, 25+20+ 17+8+1 P+1, 25+20+17+10+1 P+1 , 25+20+17+10+2+1P+1, 25+20+17+10+3+1 P+1, 25+20+17+10+4+1P+1, 25+20+17+10+5+1 P+1 , 25+20+17+10+ 6+1P+1, 25+20+17+13+1P+1, 25+20+17+13+5+1 P+1, 25+20+17+13+6+1 P+1 , 25+20+17+13+10+1 P+1, 25+20+17+13+10+2+1 P+1 , 25+20+17+13+10+3+1P+1, 25+20+17+13+10+4+1 P+1, 25+20+17+13+10+5+1 P+1 , 25+20+17+13+10+6+1 P+1 , 25+20+17+15+1 P+1, 25+20+17+15+5+1 P+1, 25+20+17+15+6+1 P+1, 25+20+17+15+ 10+1P+1, 25+20+17+15+10+2+1P+1, 25+20+17+15+10+3+1 P+1 , 25+20+17+15+10+ 4+1P+1, 25+20+17+15+10+5+1 P+1, 25+20+17+15+10+6+1P+1, 26+1P+1, 26+5+1P+1, 26+6+1P+1, 26+19+1P+1, 26+19+5+1P+1, 26+19+6+1P+1, 26+19+10+1P+1, 26+19+10+2+1P+1, 26+19+10+3+1 P+1 , 26+19+10+4+1 P+1, 26+19+10+5+1P+1, 26+19+10+6+1P+1, 26+19+13+1 P+1 , 26+19+13+5+1P+1, 26+19+13+6+1 P+1 , 26+19+13+10+1P+1, 26+19+13+10+2+1P+1, 26+19+13+10+3+1P+1, 26+19+13+10+ 4+1P+1, 26+19+13+10+5+1 P+1, 26+19+13+10+6+1P+1, 26+19+15+1 P+1 , 26+19+15+5+1P+1, 26+19+15+6+1P+1, 26+19+15+10+1 P+1 , 26+19+15+10+2+1P+1, 26+19+15+10+3+1P+1, 26+19+15+10+4+1P+1, 26+19+15+10+5+1 P+1 , 26+19+15+10+ 6+1P+1, 26+19+16+1P+1, 26+19+16+5+1P+1, 26+19+16+6+1P+1, 26+19+16+8+1P+1, 26+19+16+10+1P+1, 26+19+16+10+2+1P+1, 26+19+16+10+3+1 P+1 , 26+19+16+10+4+ 1P+1, 26+19+16+10+5+1P+1, 26+19+16+10+6+1P+1, 26+19+16+13+1 P+1 , 26+19+16+ 13+5+1P+1, 26+19+16+13+6+1P+1, 26+19+16+13+10+1P+1, 26+19+16+13+10+2+ 1P+1, 26+19+16+13+10+3+1P+1, 26+19+16+13+10+4+1P+1, 26+19+16+13+10+5+ 1P+1, 26+19+16+13+10+6+1 P+1, 26+19+16+15+1 P+1 , 26+19+16+15+5+1 P+1 , 26+19+16+15+6+1P+1, 26+19+16+15+10+1 P+1 , 26+19+16+15+10+2+1 P+1 , 26+ 19+ 16+ 15+ 10+3+ 1 P+ 1 , 26+ 19+ 16+ 15+ 10+4+ 1 P+ 1 , 26+ 19+ 16+ 15+ 10+5+ 1 P+ 1 , 26+19+16+15+10+6+1P+1, 26+19+17+1P+1, 26+19+17+5+1P+1, 26+19+17+6+1P+1, 26+19+17+8+1P+1, 26+19+17+10+1P+1, 26+19+17+10+2+1 P+1 , 26+19+17+10+3+ 1P+1, 26+19+17+10+4+1 P+1, 26+19+17+10+5+1P+1, 26+19+17+10+6+1P+1, 26+19+17+13+1P+1, 26+19+17+13+5+1P+1, 26+19+17+13+6+1P+1, 26+19+17+13+ 10+1P+1, 26+19+17+13+10+2+1P+1, 26+19+17+13+10+3+1 P+1 , 26+19+17+13+10+4+ 1P+1, 26+19+17+13+10+5+1P+1, 26+19+17+13+10+6+1 P+1 , 26+19+17+15+1P+1, 26+19+17+15+5+1P+1, 26+19+17+15+6+1P+1, 26+19+17+15+10+1P+1,
26+ 19+ 17+ 15+ 10+2+ 1 P+ 1 , 26+ 19+ 17+ 15+ 10+3+ 1 P+ 1 , 26+ 19+ 17+ 15+ 10+4+ 1 P+ 1 , 26+19+17+15+10+5+1P+1, 26+19+17+15+10+6+1P+1, 26+20+1P+1, 26+20+5+1P+1, 26+20+10+1 P+1, 26+20+10+2+1 P+1, 26+20+ 10+3+1 P+1, 26+20+10+4+1 P+1, 26+20+ 10+5+1 P+1, 26+20+10+6+1 P+1, 26+20+13+1 P+1 , 26+20+ 13+5+1 P+1, 26+20+ 13+6+1P+1, 26+20+13+10+1P+1, 26+20+ 13+ 10+2+1 P+1, 26+20+13+10+3+1 P+1, 26+20+13+10+4+1 P+1, 26+20+13+10+5+1P+1, 26+20+13+10+6+1 P+1 , 26+20+15+ 1P+1, 26+20+15+5+1 P+1, 26+20+15+6+1 P+1 , 26+20+15+10+1 P+1 , 26+20+15+10+ 2+1P+1, 26+20+15+10+3+1 P+1, 26+20+15+10+4+1 P+1 , 26+20+15+10+5+1 P+1, 26+20+15+10+6+1 P+1, 26+20+16+1 P+1 , 26+20+16+5+1 P+1 , 26+20+16+6+1 P+1, 26+20+16+8+1 P+1, 26+20+16+10+1 P+1 , 26+20+ 16+ 10+2+1 P+1, 26+20+16+10+ 3+1P+1, 26+20+16+10+4+1P+1, 26+20+16+10+5+1 P+1 , 26+20+16+10+6+1 P+1, 26+20+16+13+1 P+1, 26+20+16+13+5+1P+1, 26+20+16+13+6+1 P+1, 26+20+16+ 13+10+1P+1, 26+20+16+13+10+2+1 P+1, 26+20+16+13+10+3+1P+1, 26+20+16+13+10+ 4+1P+1, 26+20+16+13+10+5+1P+1, 26+20+16+13+10+6+1P+1, 26+20+ 16+ 15+1 P+1, 26+20+16+15+5+1 P+1, 26+20+16+15+6+1 P+1 , 26+20+16+15+10+1P+1, 26+20+16+15+ 10+2+1P+1, 26+20+16+15+10+3+1P+1, 26+20+16+15+10+4+1P+1, 26+20+16+15+10+ 5+1P+1, 26+20+16+15+10+6+1P+1, 26+20+17+1 P+1, 26+20+17+5+1 P+1 , 26+20+ 17+6+1 P+1, 26+20+ 17+8+1 P+1, 26+20+17+10+1 P+1 , 26+20+17+10+2+1P+1, 26+20+17+10+3+1 P+1, 26+20+17+10+4+1P+1, 26+20+17+10+5+1 P+1 , 26+20+17+10+ 6+1P+1, 26+20+17+13+1P+1, 26+20+17+13+5+1 P+1, 26+20+17+13+6+1 P+1 , 26+20+17+13+10+1 P+1, 26+20+17+13+10+2+1 P+1 , 26+20+17+13+10+3+1P+1, 26+20+ 17+13+10+4+ 1 P+ 1 , 26+20+ 17+13+10+5+1 P+1 , 26+20+ 17+13+10+6+ 1 P+ 1 , 26+20+17+15+1 P+1, 26+20+17+15+5+1 P+1 , 26+20+17+15+6+1 P+1 ,
26+20+17+15+10+1 P+1, 26+20+17+15+10+2+1 P+1 , 26+20+17+15+10+3+1P+1, 26+20+17+15+10+4+1 P+1, 26+20+17+15+10+5+1 P+1 , 26+20+17+15+10+6+1 P+1 , 26+25+1 P+1, 26+25+5+1 P+1, 26+25+6+1 P+1, 26+25+8+1 P+1, 26+25+10+1 P+1 , 26+25+ 10+2+1 P+1, 26+25+10+3+1 P+1 , 26+25+ 10+4+1 P+1, 26+25+10+5+1 P+1, 26+25+ 10+6+1 P+1, 26+25+13+1 P+1 , 26+25+13+5+1 P+1, 26+25+13+6+1 P+1 , 26+25+13+10+1 P+1, 26+25+ 13+ 10+2+1 P+1, 26+25+13+10+3+1 P+1, 26+25+13+10+ 4+1P+1, 26+25+13+10+5+1 P+1, 26+25+ 13+ 10+6+1 P+1, 26+25+15+1 P+1 , 26+25+ 15+5+1 P+1, 26+25+ 15+6+1 P+1, 26+25+15+10+1 P+1 , 26+25+15+10+2+1P+1, 26+25+15+10+3+1 P+1, 26+25+15+10+4+1P+1, 26+25+15+10+5+1 P+1 , 26+25+15+10+ 6+1 P+1, 26+25+ 16+1 P+1, 26+25+16+5+1 P+1, 26+25+16+6+1 P+1, 26+25+16+8+1 P+1, 26+25+16+10+1 P+1, 26+25+ 16+ 10+2+1 P+1, 26+25+16+10+3+1P+1, 26+25+16+10+ 4+1P+1, 26+25+16+10+5+1 P+1, 26+25+ 16+ 10+6+1 P+1, 26+25+16+13+1P+1, 26+25+ 16+13+5+1P+1, 26+25+16+13+6+1P+1, 26+25+16+13+10+1 P+1 , 26+25+16+13+10+ 2+1P+1, 26+25+16+13+10+3+1 P+1, 26+25+ 16+ 13+ 10+4+1 P+1, 26+25+16+13+10+5+ 1P+1, 26+25+16+13+10+6+1 P+1, 26+25+16+15+1 P+1 , 26+25+16+15+5+1 P+1 , 26+25+16+15+6+1 P+1, 26+25+16+15+10+1 P+1 , 26+25+16+15+10+2+1 P+1 , 26+25+16+15+10+3+1 P+1, 26+25+16+15+10+4+1 P+1 , 26+25+16+15+10+5+1 P+1 , 26+25+16+15+10+6+1P+1, 26+25+17+1 P+1, 26+25+ 17+5+1 P+1, 26+25+17+6+1 P+1, 26+25+ 17+8+1 P+1, 26+25+17+10+1P+1, 26+25+17+10+2+1 P+1 , 26+25+17+10+3+ 1P+1, 26+25+17+10+4+1 P+1, 26+25+17+10+5+1P+1, 26+25+17+10+6+1 P+1, 26+25+17+13+1 P+1, 26+25+ 17+ 13+5+1 P+1, 26+25+17+13+6+1 P+1 , 26+25+17+13+10+ 1P+1, 26+25+17+13+10+2+1P+1, 26+25+17+13+10+3+1P+1, 26+25+17+13+10+4+ 1P+1, 26+25+17+13+10+5+1 P+1, 26+25+17+13+10+6+1 P+1 , 26+25+17+15+1P+1, 26+25+17+15+5+1 P+1, 26+25+ 17+ 15+6+1 P+1, 26+25+17+15+10+1P+1,
26+25+ 17+ 15+ 10+2+ 1 P+ 1 , 26+25+ 17+15+10+3+1 P+1 , 26+25+ 17+15+10+4+ 1 P+ 1 , 26+25+17+15+10+5+1P+1, 26+25+17+15+10+6+1P+1, 26+25+19+1 P+1, 26+25+ 19+5+1 P+1, 26+25+ 19+6+1 P+1, 26+25+19+10+1 P+1 , 26+25+19+10+2+1P+1, 26+25+19+10+3+1 P+1, 26+25+19+10+4+1P+1, 26+25+19+10+5+1 P+1 , 26+25+19+10+ 6+1P+1, 26+25+19+13+1P+1, 26+25+19+13+5+1 P+1, 26+25+19+13+6+1 P+1 , 26+25+19+13+10+1 P+1, 26+25+19+13+10+2+1 P+1 , 26+25+19+13+10+3+1P+1, 26+25+ 19+13+10+4+ 1 P+ 1 , 26+25+ 19+13+10+5+1 P+1 , 26+25+ 19+13+10+6+ 1 P+ 1 , 26+25+19+15+1 P+1, 26+25+ 19+ 15+5+1 P+1, 26+25+ 19+ 15+6+1 P+1, 26+25+19+15+ 10+1P+1, 26+25+19+15+10+2+1P+1, 26+25+19+15+10+3+1 P+1 , 26+25+19+15+10+ 4+1P+1, 26+25+19+15+10+5+1P+1, 26+25+19+15+10+6+1P+1, 26+25+ 19+ 16+1 P+1, 26+25+19+16+5+1 P+1, 26+25+19+16+6+1P+1, 26+25+19+16+8+1 P+1 , 26+25+19+16+ 10+1P+1, 26+25+19+16+10+2+1 P+1, 26+25+19+16+10+3+1 P+1 , 26+25+19+16+10+4+ 1P+1, 26+25+19+16+10+5+1 P+1, 26+25+19+16+10+6+1 P+1 , 26+25+19+16+13+1P+1, 26+25+19+16+13+5+1 P+1, 26+25+19+16+13+6+1P+1, 26+25+19+16+13+10+1 P+1 , 26+25+ 19+16+13+10+2+ 1 P+ 1 , 26+25+ 19+16+13+10+3+1 P+1 , 26+25+ 19+16+13+10+4+ 1P+1, 26+25+19+16+13+10+5+1P+1, 26+25+ 19+ 16+ 13+ 10+6+1 P+1, 26+25+19+16+15+ 1P+1, 26+25+19+16+15+5+1P+1, 26+25+19+16+15+6+1P+1, 26+25+19+16+15+10+ 1P+1, 26+25+19+16+15+10+2+1P+1, 26+25+19+16+15+10+3+1P+1, 26+25+19+16+15+ 10+4+1P+1, 26+25+19+16+15+10+5+1P+1, 26+25+19+16+15+10+6+1P+1, 26+25+19+ 17+1P+1, 26+25+19+17+5+1 P+1, 26+25+ 19+ 17+6+1 P+1, 26+25+19+17+8+1 P+1, 26+25+19+17+10+1 P+1, 26+25+19+17+10+2+1 P+1 , 26+25+19+17+10+3+1P+1, 26+25+ 19+17+10+4+ 1 P+ 1 , 26+25+ 19+17+10+5+1 P+1 , 26+25+ 19+17+10+6+ 1 P+ 1 , 26+25+19+17+13+1P+1, 26+25+19+17+13+5+1 P+1 , 26+25+19+17+13+6+1P+1, 26+25+ 19+ 17+ 13+ 10+ 1 P+ 1 , 26+25+ 19+17+13+10+2+ 1 P+ 1 , 26+25+ 19+17+13+10+3+ 1P+1, 26+25+19+17+13+10+4+1P+1, 26+25+19+17+13+10+5+1P+1, 26+25+19+17+13+ 10+6+1 P+1, 26+25+19+17+15+1 P+1, 26+25+19+17+15+5+1 P+1 , 26+25+19+17+15+6+ 1P+1, 26+25+19+17+15+10+1P+1, 26+25+19+17+15+10+2+1P+1, 26+25+19+17+15+ 10+3+1P+1, 26+25+ 19+ 17+ 15+ 10+4+1 P+1, 26+25+19+17+15+10+5+1P+1, 26+25+19+ 17+ 15+ 10+6+1 P+1, 26+25+20+1 P+1, 26+25+20+5+1 P+1, 26+25+20+ 10+1 P+1, 26+25+20+10+2+1 P+1, 26+25+20+ 10+3+1 P+1, 26+25+20+10+4+1 P+1 , 26+25+20+10+ 5+1P+1, 26+25+20+10+6+1 P+1, 26+25+20+ 13+1 P+1, 26+25+20+13+5+1 P+1, 26+25+20+13+6+1 P+1, 26+25+20+13+10+1 P+1, 26+25+20+13+10+2+1 P+1 , 26+25+20+ 13+10+3+1P+1, 26+25+20+13+10+4+1P+1, 26+25+20+13+10+5+1 P+1, 26+25+20+13+ 10+6+1P+1, 26+25+20+15+1 P+1, 26+25+20+15+5+1 P+1, 26+25+20+15+6+1 P+1, 26+25+20+ 15+ 10+ 1 P+ 1 , 26+25+20+ 15+ 10+2+ 1 P+ 1 , 26+25+20+ 15+ 10+3+ 1 P+ 1 , 26+25+20+15+10+4+1 P+1 , 26+25+20+15+10+5+1 P+1 , 26+25+20+15+10+6+1 P+1 , 26+25+20+16+1 P+1, 26+25+20+ 16+5+1 P+1, 26+25+20+ 16+6+1 P+1, 26+25+20+16+ 8+1 P+1, 26+25+20+16+10+1 P+1, 26+25+20+16+10+2+1 P+1, 26+25+20+16+10+3+ 1P+1, 26+25+20+16+10+4+1 P+1, 26+25+20+16+10+5+1 P+1, 26+25+20+16+10+6+ 1P+1, 26+25+20+16+13+1 P+1, 26+25+20+16+13+5+1 P+1, 26+25+20+16+13+6+1 P+1, 26+25+20+ 16+ 13+ 10+ 1 P+ 1 , 26+25+20+ 16+13+10+2+ 1 P+ 1 , 26+25+20+ 16+13+10+3+ 1P+1, 26+25+20+16+13+10+4+1P+1, 26+25+20+16+13+10+5+1 P+1 , 26+25+20+16+13+10+6+1 P+1, 26+25+20+16+15+1 P+1 , 26+25+20+16+15+5+1 P+1, 26+25+20+ 16+ 15+6+ 1 P+ 1 , 26+25+20+ 16+15+10+1 P+1 , 26+25+20+ 16+15+10+2+1 P+1 , 26+25+20+ 16+ 15+ 10+3+ 1 P+ 1 , 26+25+20+ 16+15+10+4+ 1 P+ 1 , 26+25+20+ 16+15+10+5+ 1P+1, 26+25+20+16+15+10+6+1P+1, 26+25+20+ 17+1 P+1, 26+25+20+17+5+1 P+1, 26+25+20+17+6+1 P+1, 26+25+20+17+8+1 P+1 , 26+25+20+17+10+1 P+1, 26+25+20+17+ 10+2+1P+1, 26+25+20+17+10+3+1 P+1, 26+25+20+17+10+4+1 P+1, 26+25+20+17+10+ 5+1P+1, 26+25+20+ 17+ 10+6+1 P+1, 26+25+20+17+13+1P+1, 26+25+20+17+13+5+ 1P+1, 26+25+20+17+13+6+1 P+1, 26+25+20+17+13+10+1P+1, 26+25+20+17+13+ 10+2+1P+1, 26+25+20+17+13+10+3+1P+1, 26+25+20+17+13+10+4+1P+1,
26+25+20+ 17+ 13+ 10+5+ 1 P+ 1 , 26+25+20+ 17+13+10+6+ 1 P+ 1 , 26+25+20+ 17+15+1P+1, 26+25+20+17+15+5+1 P+1, 26+25+20+17+15+6+1 P+1, 26+25+20+17+15+10+1 P+1 , 26+25+20+ 17+15+10+2+ 1 P+ 1 , 26+25+20+ 17+15+10+3+1 P+1 , 26+25+20+ 17+15+10+4+ 1P+1, 26+25+20+17+15+10+5+1P+1, 26+25+20+ 17+ 15+ 10+6+1 P+1, 28+1P+1, 28+8+1 P+1, 28+9+1 P+1, 29+1 P+1, 30+1, 31+30+1, 32+30+1, 32+31+30+1, 33+30+1, 33+31+30+1, 33+32+30+1, 33+32+31+30+1, 34+30+1, 34+31+30+1, 34+32+30+1, 34+32+31+30+1, 34+33+30+1, 34+33+31+30+1, 34+33+32+30+1, 34+33+32+31+30+1, 35+1, 36+35+1, 37+35+1, 37+36+35+1, 38+35+1, 38+36+35+1, 38+37+35+1, 38+37+36+35+1, 39+1, 39+10+1, 39+12+1, 39+12+10+1, 39+13+1, 39+13+10+1, 39+14+1, 39+14+10+1, 39+15+1, 39+15+10+1, 39+16+1, 39+16+10+1, 39+16+12+1, 39+16+12+10+1, 39+16+13+1, 39+16+13+10+1, 39+16+14+1, 39+16+14+10+1, 39+16+15+1, 39+16+15+10+1, 39+17+1, 39+17+10+1, 39+17+12+1, 39+17+12+10+1, 39+17+13+1, 39+17+13+10+1, 39+17+14+1, 39+17+14+10+1, 39+17+15+1, 39+17+15+10+1, 39+25+1, 39+25+10+1, 39+25+12+1, 39+25+12+10+1, 39+25+13+1, 39+25+13+10+1, 39+25+14+1, 39+25+14+10+1, 39+25+15+1, 39+25+15+10+1, 39+25+16+1, 39+25+16+10+1, 39+25+16+12+1, 39+25+16+12+10+1, 39+25+16+13+1, 39+25+16+13+10+1, 39+25+16+14+1, 39+25+16+14+10+1, 39+25+16+15+1, 39+25+ 16+15+10+1, 39+25+17+1, 39+25+17+10+1, 39+25+17+12+1, 39+25+17+12+10+1, 39+25+17+13+1, 39+25+17+13+10+1, 39+25+17+14+1, 39+25+17+14+10+1, 39+25+17+15+1, 39+25+17+15+10+1, 39+26+1, 39+26+25+1, 39+26+25+10+1, 39+26+25+12+1, 39+26+25+12+10+1, 39+26+25+13+1, 39+26+25+13+10+1, 39+26+25+14+1, 39+26+25+14+10+1, 39+26+25+15+1, 39+26+25+15+10+1, 39+26+25+16+1, 39+26+25+16+10+1, 39+26+25+16+12+1, 39+26+25+16+12+10+1, 39+26+25+16+13+1, 39+26+25+16+13+10+1, 39+26+25+16+14+1, 39+26+25+16+14+ 10+1, 39+26+25+16+15+1, 39+26+25+16+15+10+1, 39+26+25+17+1, 39+26+25+17+ 10+1, 39+26+25+17+12+1, 39+26+25+17+12+10+1, 39+26+25+17+13+1, 39+26+25+17+13+10+1, 39+26+25+17+14+1, 39+26+25+17+14+10+1,
39+26+25+17+15+1, 39+26+25+17+15+10+1, 40+1, 40+10+1, 40+12+1, 40+12+10+1, 40+13+1, 40+13+10+1, 40+14+1, 40+14+10+1, 40+15+1, 40+15+10+1, 40+16+1, 40+16+10+1, 40+16+12+1, 40+16+12+10+1, 40+16+13+1, 40+16+13+10+1, 40+16+14+1, 40+16+14+10+1, 40+16+15+1, 40+16+15+10+1, 40+17+1, 40+17+10+1, 40+17+12+1, 40+17+12+10+1, 40+17+13+1, 40+17+13+10+1, 40+17+14+1, 40+17+14+10+1, 40+17+15+1, 40+17+15+10+1, 40+25+1, 40+25+10+1, 40+25+12+1, 40+25+12+10+1, 40+25+13+1, 40+25+13+10+1, 40+25+14+1, 40+25+14+10+1, 40+25+15+1, 40+25+15+10+1, 40+25+16+1, 40+25+16+10+1, 40+25+16+12+1, 40+25+16+12+10+1, 40+25+16+13+1, 40+25+16+13+10+1, 40+25+16+14+1, 40+25+16+14+10+1, 40+25+16+15+1, 40+25+16+15+10+1, 40+25+17+1, 40+25+17+10+1, 40+25+17+12+1, 40+25+17+12+10+1, 40+25+17+13+1, 40+25+17+13+10+1, 40+25+17+14+1, 40+25+17+14+10+1, 40+25+17+15+1, 40+25+17+15+10+1, 40+26+1, 40+26+25+1, 40+26+25+10+1, 40+26+25+12+1, 40+26+25+12+10+1, 40+26+25+13+1, 40+26+25+13+10+1, 40+26+25+14+1, 40+26+25+14+10+1, 40+26+25+15+1, 40+26+25+15+10+1, 40+26+25+16+1, 40+26+25+16+10+1, 40+26+25+16+12+1, 40+26+25+16+12+10+1, 40+26+25+16+13+1, 40+26+25+16+13+10+1, 40+26+25+16+14+1, 40+26+25+16+14+10+1, 40+26+25+16+ 15+1, 40+26+25+16+15+10+1, 40+26+25+17+1, 40+26+25+17+10+1, 40+26+25+17+ 12+1, 40+26+25+17+12+10+1, 40+26+25+17+13+1, 40+26+25+17+13+10+1, 40+26+25+17+14+1, 40+26+25+17+14+10+1, 40+26+25+17+15+1, 40+26+25+17+15+ 10+1, 41+1, 41+39+1, 41+39+10+1, 41+39+12+1, 41+39+12+10+1, 41+39+13+1, 41+39+13+10+1, 41+39+14+1, 41+39+14+10+1, 41+39+15+1, 41+39+15+10+1, 41+39+16+1, 41+39+16+10+1, 41+39+16+12+1, 41+39+16+12+10+1, 41+39+16+13+1, 41+39+16+13+10+1, 41+39+16+14+1, 41+39+16+14+10+1, 41+39+16+15+1, 41+39+ 16+15+10+1, 41+39+17+1, 41+39+17+10+1, 41+39+17+12+1, 41+39+17+12+10+1, 41+39+17+13+1, 41+39+17+13+10+1, 41+39+17+14+1, 41+39+17+14+10+1, 41+39+17+15+1, 41+39+17+15+10+1, 41+39+25+1, 41+39+25+10+1, 41+39+25+12+1, 41+39+25+12+10+1, 41+39+25+13+1, 41+39+25+13+10+1, 41+39+25+14+1, 41+39+25+14+10+1, 41+39+25+15+1, 41+39+25+15+10+1, 41+39+25+16+1, 41+39+25+16+10+1, 41+39+25+16+12+1, 41+39+25+16+12+10+1, 41+39+25+16+13+1, 41+39+25+16+13+10+1, 41+39+25+16+14+1, 41+39+25+16+14+10+1, 41+39+25+ 16+15+1, 41+39+25+16+15+10+1, 41+39+25+17+1, 41+39+25+17+10+1, 41+39+25+ 17+12+1, 41+39+25+17+12+10+1, 41+39+25+17+13+1, 41+39+25+17+13+10+1, 41+39+25+17+14+1, 41+39+25+17+14+10+1, 41+39+25+17+15+1, 41+39+25+17+ 15+10+1, 41+40+1, 41+40+10+1, 41+40+12+1, 41+40+12+10+1, 41+40+13+1, 41+40+13+10+1, 41+40+14+1, 41+40+14+10+1, 41+40+15+1, 41+40+15+10+1, 41+40+16+1, 41+40+16+10+1, 41+40+16+12+1, 41+40+16+12+10+1, 41+40+16+13+1, 41+40+16+13+10+1, 41+40+16+14+1, 41+40+16+14+10+1, 41+40+16+15+1, 41+40+16+15+10+1, 41+40+17+1, 41+40+17+10+1, 41+40+17+12+1, 41+40+17+12+10+1, 41+40+17+13+1, 41+40+17+13+10+1, 41+40+17+14+1, 41+40+17+14+10+1, 41+40+17+15+1, 41+40+17+15+10+1, 41+40+25+1, 41+40+25+10+1, 41+40+25+12+1, 41+40+25+12+10+1, 41+40+25+13+1, 41+40+25+13+10+1, 41+40+25+14+1, 41+40+25+14+10+1, 41+40+25+15+1, 41+40+25+15+10+1, 41+40+25+16+1, 41+40+25+16+10+1, 41+40+25+16+12+1, 41+40+25+16+12+10+1, 41+40+25+16+13+1, 41+40+25+16+13+10+1, 41+40+25+16+ 14+1, 41+40+25+16+14+10+1, 41+40+25+16+15+1, 41+40+25+16+15+10+1, 41+40+ 25+17+1, 41+40+25+17+10+1, 41+40+25+17+12+1, 41+40+25+17+12+10+1, 41+40+ 25+17+13+1, 41+40+25+17+13+10+1, 41+40+25+17+14+1, 41+40+25+17+14+10+1, 41+40+25+17+15+1, 41+40+25+17+15+10+1, and 42+1;
wherein the list above is not to be construed as limiting with respect to further embodiments which are also possible based on the dependencies of the embodiments 1) to 42) as disclosed hereinabove and which are also intended. In the list above the numbers refer to the embodiments according to their numbering provided hereinabove whereas "+" indicates the dependency from another embodiment. The different individualized embodiments are separated by commas. In other words, "10+2+1 P+1" for example refers to embodiment 10) depending on embodiment 2) depending on embodiment 1P) depending on embodiment 1), i.e. embodiment "10+2+1 P+1" corresponds to embodiment 1) further limited by the features of embodiments 1P), 2) and 10). The present invention also includes isotopically labelled, especially 2H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially 2H (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts, Lit. e.g. "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.
The compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for use as medicaments. In particular, compounds of formula (I) modulate the P2X7 receptor, i.e. they act as P2X7 receptor antagonists, and are useful for the prevention or treatment of diseases which are associated with the activation of the P2X7 receptor such as pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
In particular, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of pain. Pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain.
Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.
Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of neurodegenerative and neuroinflammatory diseases. Neurodegenerative and neuro- inflammatory diseases include Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); Amyotrophic lateral sclerosis, amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of bone and joint diseases. Bone and joint diseases include arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis; Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy; septic arthritis and other infection-related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; and drug-induced arthalgias, tendonitis, and myopathies including dystrophies and other inflammatory myopathies.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of obstructive diseases of the airways. Obstructive diseases of the airways include asthma, including bronchial, allergic, intrinsic, and extrinsic asthma, exercise-induced, drug- induced (including aspirin and NSAID-induced) and dust- induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper- responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; and acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cardiovascular diseases. Cardiovascular diseases include atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis; inflammatory and auto- immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; and disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of eye diseases. Eye diseases include blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; and infections of the eyes including viral, fungal, and bacterial infections.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of skin diseases. Skin diseases include psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; and drug-induced disorders including fixed drug eruptions.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of abdominal and gastrointestinal tract diseases. Abdominal and gastrointestinal tract diseases include hepatitis, including autoimmune, alcoholic and viral hepatitis; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; non-inflammatory diarrhea; glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; Coeliac disease, irritable bowel disease/syndrome, and food-related allergies which may have effects remote from the gut, for example migraine, rhinitis or eczema; allograft rejection including acute and chronic allograft rejection following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; and chronic graft versus host disease;
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of genitourinary diseases. Genitourinary diseases include nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, hemorrhagic cystitis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; and erectile dysfunction, both male and female.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cancer. The treatment of cancer includes the treatment of brain tumors, prostate, lung, breast, ovarian, bowel and colon, stomach, pancreatic, skin and bone marrow (including leukaemias) and lymphoproliferative systems, such as non-Hodgkin's and Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumor recurrences, and paraneoplastic syndromes.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other auto-immune and allergic disorders. Other auto-immune and allergic disorders include Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-lgE syndrome, and antiphospholipid syndrome.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other disorders with an inflammatory or immunological component. Other disorders with an inflammatory or immunological component include acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of mood, depression, sleep and anxiety disorders.
Further, the compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of injury induced trauma and spinal cord injury.
Especially, compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
1) Pain, wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia); Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
) Neurodegenerative and neuro-inflammatory diseases such as Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); amyloidosis; Amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease;
) Bone and joint diseases such as arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; and drug-induced arthalgias, tendonitis, and myopathies;) Obstructive diseases of the airways such as chronic obstructive pulmonary disease (COPD); cystic fibrosis; lung emphysema; sarcoidosis; farmer's lung and related diseases; lung fibrosis, including fibrosis complicating tuberculosis; and chronic cough associated with inflammatory and secretory conditions of the airways;
) Cardiovascular diseases such as inflammatory and auto-immune cardiomyopathies;
) Eye diseases such as degenerative or inflammatory disorders affecting the retina; 7) Skin diseases such as psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses; and discoid lupus erythematosus;
8) Abdominal and gastrointestinal tract diseases such as fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; Crohn's disease; colitis including ulcerative colitis; and irritable bowel disease/syndrome;
9) Genitourinary diseases such as nephritis including interstitial and glomerulonephritis; nephrotic syndrome; and cystitis including acute and chronic (interstitial) cystitis; and
10) Other auto-immune and allergic disorders such as Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-lgE syndrome, and antiphospholipid syndrome.
Most preferably, compounds of formula (I) according to any one of embodiments 1) to 42), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
1) Pain, wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain (preferred); lower back and neck pain; inflammatory pain; neuropathic pain (preferred); visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
2) Rheumatoid arthritis and osteoarthritis;
3) Chronic obstructive pulmonary disease (COPD); and
4) Crohn's disease.
The invention also relates to the use of a compound of formula (I) according to any one of embodiments 1) to 42) for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.
The present invention also relates to pharmaceutically acceptable salts and to pharmaceutical compositions and formulations of compounds of formula (I) according to any one of embodiments 1) to 42).
A pharmaceutical composition according to the present invention contains at least one compound of formula (I) according to any one of embodiments 1) to 42) (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants.
The compounds of formula (I) according to any one of embodiments 1) to 42) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such as especially oral) or parenteral administration (including topical application or inhalation).
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I) according to any one of embodiments 1 ) to 42), or a pharmaceutically acceptable salt thereof.
Any reference to a compound of formula (I), (lSti), (IHET) or (I0H), in this text is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient. The preferences indicated for the compounds of formula (I) of course apply mutatis mutandis to the compounds of formula (lSti) , of formula (IHET) and of formula (I0H) as well as to the salts and pharmaceutically acceptable salts of the compounds of formula (I), of formula (lSti), of formula (IHET) and of formula (I0H)- The same applies to these compounds as medicaments, to pharmaceutical compositions containing these compounds as active principles or to the uses of these compounds for the manufacture of a medicament for the treatment of the diseases according to this invention.
Unless used regarding temperatures, the term "about" (or alternatively "around") placed before a numerical value "X" refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term "about" (or alternatively "around") placed before a temperature "Y" refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C. Besides, the term "room temperature" (RT) as used herein refers to a temperature of about 25°C.
Whenever the word "between" is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range. For example: if a temperature range is described to be between 40 °C and 80 °C, this means that the end points 40 °C and 80 °C are included in the range; or if a variable is defined as being an integer between 1 and 4, this means that the variable is the integer 1 , 2, 3, or 4.
The compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
If not indicated otherwise, the generic groups R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and n are as defined for formula (I). Other abbreviations used are defined in the experimental section.
In some instances the generic groups R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and n might be incompatible with the assembly illustrated in the schemes below and will therefore require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups are as necessary in place.
Preparation of compounds of formula (I):
Compounds of formula (I) can be prepared (Scheme 1) by reaction of carboxylic acids of formula II with amines of formula III using standard amide coupling reagents such as TBTU, EDC.HCI/HOBt, HATU or PyBOP in the presence of a suitable base such as DIPEA or Et3N and in a suitable solvent such as DCM, THF or DMF preferably at temperatures between RT and 45°C.
Compounds of formula (I) wherein R6 represents -CH(OH)Me can be prepared by reduction of compounds of formula (I) wherein R6 represents acetyl using a suitable reducing reagent such as NaBH4 in a suitable solvent such as MeOH at temperatures around RT. Other primary or secondary alcohols may be prepared in analogy.
Compounds of formula (I) wherein R6 represents -C(OH)Me2 can be prepared from compounds of formula (I) wherein R6 represents acetyl by addition of a methylmagnesium halide solution in the presence of a suitable solvent such as THF at temperatures between -10°C and RT. Other tertiary alcohols may be prepared in analogy.
Compounds of formula (I) wherein R6 represents hydroxy-(C2-C4)alkoxy can be prepared from compounds of formula (I) wherein R6 represents te/f-butyloxy-(C2-C4)alkoxy by treatment with a suitable acid such as TFA in a suitable solvent such as DCM at temperatures around RT.
Figure imgf000046_0001
II (I)
Scheme 1 : General synthesis of compounds of formula (I) Compounds of formula la wherein m represents 0, 1 or 2 (Scheme 2) can be prepared as described in Scheme 1.
Alcohol derivatives of formula lb wherein m represents 0, 1 or 2 and R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkylthio or halogen (Scheme 2) can be prepared by reduction of methyl esters of formula la wherein m represents 0, 1 or 2 and R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkylthio or halogen using a suitable reducing reagent such as lithium aluminum hydride, lithium borohydride or diisobutylaluminum hydride in a suitable solvent such as THF at temperatures between 0°C and RT.
Amides of formula lc wherein R 2 represents hydrogen or (C C4)alkyl (Scheme 2) can be prepared following a two step procedure: (i) hydrolysis of methyl esters of formula la, wherein m represents 0, by treatment with a suitable base such as LiOH, NaOH or KOH in the presence of water and a suitable organic solvent such as MeOH, EtOH or THF at temperatures around RT and (ii) coupling of the obtained acid with amines of formula R 2NH2 using amide coupling conditions such as those previously described for the synthesis of compounds of formula (I).
Nitriles of formula Id (Scheme 2) can be prepared by dehydration of primary amides of formula lc, wherein R 2 represents hydrogen, using a suitable dehydrating reagent such as Burgess reagent in a suitable solvent such as DCM at temperatures between RT and °C.
Figure imgf000047_0001
Scheme 2: Synthesis of compounds of formula lb, lc and Id
Compounds of formula le (Scheme 3) can be prepared as described in Scheme 1.
Compounds of formula If (Scheme 3) can be prepared by cleavage of the Boc protecting group in compounds of formula le by treatment with a suitable acid such as HCI or TFA in the presence of a suitable solvent such as dioxane, EtOAc or DCM at temperatures around RT.
Compounds of formula Ig (or Ii, respectively) (Scheme 3) can be prepared by reductive alkylation of amines of formula If with benzaldehyde (or an excess of formaldehyde, respectively) in the presence of a suitable reducing agent such as NaBH(OAc)3, NaBH3CN or NaBH4 and carrying out the reaction in a suitable solvent such as dichloroethane or a mixture of solvents such as DCM/MeOH/AcOH at temperatures around RT. Compounds of formula Ij wherein R 3 represents (C C4)alkyl (Scheme 3) can be prepared by acylation of amines of formula If by treatment with a suitable acid chloride of formula R 3COCI or an acid anhydride of formula (R 3CO)20 in the presence of a suitable base such as Et3N or DIPEA and in a suitable solvent such as DCM or THF at temperatures between 0°C and 50°C.
Compounds of formula Ik wherein R 3 represents (C2-C4)alkyl (Scheme 3) can be prepared by alkoxycarbonylation of amines of formula If by treatment with a suitable alkyl chloroformate of formula R 3OCOCI in the presence of a suitable base such as Et3N or DIPEA and in a suitable solvent such as DCM or THF at temperatures between 0°C and 50°C.
Compounds of formula Ih wherein R 3 represents (C C4)alkyl or (Ci-C4)alkoxy-carbonyl- (Ci-C4)alkyl (Scheme 3) can be prepared by sulfonation of amines of formula If by treatment with a suitable alkyl sulfonyl chloride of formula R 3S02CI in the presence of a suitable base such as Et3N or DIPEA and in a suitable solvent such as DCM or THF at temperatures between 0°C and 50°C. Compounds of formula Ih wherein R 3 represents hydroxy-(Ci-C4)alkyl can be prepared by reduction of compounds of formula Ih wherein R 3 represents (Ci-C4)alkoxy-carbonyl-(Ci-C4)alkyl using conditions such as those previously described for the synthesis of compounds of formula lb from compounds of formula la.
Figure imgf000048_0001
Scheme 3: Synthesis of compounds of formula If to Ik Compounds of formula Im and lo (Scheme 4) can be prepared as described in Scheme 1. Oxindoles of formula In (Scheme 4) can be prepared by oxidation of indole derivatives of formula Im with for instance pyridinium tribromide in a suitable solvent such as tert.- butanol at temperatures around RT and subsequent reduction of intermediate isatin derivatives with for instance zinc dust in a suitable solvent such as acetic acid at temperatures around RT.
Compounds of formula Ip (Scheme 4) can be prepared by reduction of nitro derivatives of formula lo with for instance tin(ll) chloride dihydrate in a suitable solvent such as aq. HCI at temperatures between 0°C and RT.
Figure imgf000049_0001
Scheme 4: Synthesis of compounds of formula In and Ip
Indole carboxylic acids of formula I la can be prepared according to the synthetic routes given in scheme 5.
Regioisomer of formula XII wherein Y represents methoxycarbonyl or cyano, together with various amounts of regioisomer XI, (Scheme 5) can be prepared by iodination of anilines of formula XIV wherein Y represents methoxycarbonyl or cyano, using 1.05 equivalents of a suitable iodinating reagent such as iodine in the presence of a catalyst such as silver sulfate and in a suitable solvent such as EtOH at temperatures around RT. The separation of both regioisomers can be achieved by column chromatography.
Compounds of formula IX wherein R6 represents hydrogen and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by Sonogashira type cross- coupling of iodides of formula XI wherein Y represents methoxycarbonyl or cyano with trimethylsilylacetylene in the presence of a suitable palladium catalyst such as bis(triphenylphosphine)palladium(ll) dichloride, in the presence of a suitable copper catalyst such as copper iodide, in the presence of a ligand such as triphenylphosphine, in the presence of a suitable base such as Et3N and heating in a suitable solvent such as toluene at temperatures between 50°C and 100°C.
Alternatively, compounds of formula IX wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C2)alkoxy-(Ci-C4)alkyl, nitro, chloro or fluoro and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared from iodides of formula VII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C2)alkoxy-(Ci-C4)alkyl, nitro, chloro or fluoro and Y represents methoxycarbonyl or cyano using Sonogashira cross-coupling conditions such as those described above. Compounds of formula VII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C2)alkoxy-(Ci-C4)alkyl, nitro, chloro or fluoro and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by iodination of anilines of formula VIII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C2)alkoxy-(Ci-C4)alkyl, nitro, chloro or fluoro and Y represents methoxycarbonyl or cyano following standard iodination conditions such as those previously described for the synthesis of compounds of formula XI and XII. Compounds of formula VIII wherein R6 represents (C C4)alkyl or (C C2)alkoxy-(Ci-C4)alkyl and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by Negishi type cross-coupling of iodides of formula XII wherein Y represents methoxycarbonyl or cyano with organozinc reagents of type R6ZnX wherein R6 represents (C C4)alkyl or (C C2)alkoxy-(Ci-C4)alkyl and X represents chloro, bromo or (C C4)alkyl, in the presence of a suitable palladium catalyst such as Pd(dppf)CI2.DCM and heating in a suitable solvent such as dioxane at temperatures between 50°C and 100°C. Alternatively, compounds of formula VIII wherein R6 represents (C C4)alkyl or (C C2)alkoxy-(Ci- C4)alkyl and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by Suzuki type cross-coupling of iodides of formula XII wherein Y represents methoxycarbonyl or cyano with boronic acid reagents of type R6B(OH)2 wherein R6 represents (C C4)alkyl or (C C2)alkoxy-(Ci-C4)alkyl in the presence of a suitable palladium catalyst such as bis(triphenylphosphine)palladium(ll) dichloride and a base such as K3P04 and heating in a suitable solvent such as a mixture of toluene/water 20/1 at temperatures around 1 10°C. Alternatively, compounds of formula VIII wherein R6 represents (C C2)alkoxy-(C2-C4)alkyl and Y represents methoxycarbonyl (Scheme 5) can be prepared by a two step procedure: (i) Suzuki type cross-coupling of iodides of formula XII wherein Y represents methoxycarbonyl with (C C2)alkoxy-vinyl boronic acid pinacol ester or (Ci-C2)alkoxy-(C C2)alkyl-vinyl boronic acid pinacol ester reagents in the presence of a suitable palladium catalyst such as Pd(OAc)2, a suitable ligand such as 2- dicyclohexylphosphino-2',6'-dimethoxybiphenyl and a base such as KOH and heating in a suitable solvent such as CH3CN at temperatures around 70°C and (ii) reduction of the double bond under hydrogenation conditions in the presence of a suitable catalyst such as Pt02 and a suitable solvent such as EtOH at temperatures around RT.
Alternatively, compounds of formula VI II wherein R6 represents (C3-C4)alkyl or (C C2)alkoxy-(C3-C4)alkyl and Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by Sonogashira type cross-coupling of iodides of formula XI I wherein Y represents methoxycarbonyl or cyano with (C C2)alkylacetylene or (C C2)alkoxy-(Ci- C2)alkylacetylene in the presence of a suitable palladium catalyst such as bis(triphenylphosphine)palladium(l l) dichloride, in the presence of a suitable copper catalyst such as copper iodide, in the presence of a suitable base such as Et3N and heating in a suitable solvent such as THF at temperatures between RT and 80°C. The subsequent reduction of the triple bond can be carried out under hydrogenation conditions in the presence of a suitable catalyst such as Pt02 and a suitable solvent such as EtOH at temperatures around RT. Alternatively, when using (C C2)alkylacetylene as reagent, the subsequent hydration of the triple bond can be carried out by treatment with an acid such as p-toluenesulfonic acid in the presence of a suitable solvent such as toluene at temperatures around 80°C and leads to compounds of formula VI I I wherein R6 represents (C2-C4)alkyl-carbonyl and Y represents methoxycarbonyl or cyano. Alternatively, compounds of formula VII wherein R6 represents acetyl or ethyl, and Y represents methoxycarbonyl (Scheme 5) can be regioselectively prepared by Sonogashira type cross-coupling of iodides of formula XL wherein Y represents methoxycarbonyl with trimethylsilylacetylene following standard conditions such as those previously described for the synthesis of compounds of formula VI I I. The subsequent reduction of the triple bond under hydrogenation conditions as those previously described for the synthesis of compounds of formula VI I I delivers compounds of formula VI I wherein R6 represents ethyl and Y represents methoxycarbonyl. Alternatively, the subsequent hydration of the triple bond can be carried out by treatment with an acid such as p-toluenesulfonic acid in the presence of a suitable solvent such as toluene at temperatures around 80°C and leads to compounds of formula VI I wherein R6 represents acetyl and Y represents methoxycarbonyl. Compounds of formula XL wherein Y represents methoxycarbonyl or cyano can be prepared by bis-iodination of anilines of formula XIV wherein Y represents methoxycarbonyl or cyano following standard iodination conditions such as those previously described for the synthesis of compounds of formula XI and XI I but using 2.2 equivalents of iodinating reagent.
Compounds of formula V wherein Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by protodesilylation of compounds of formula IX wherein Y represents methoxycarbonyl or cyano with a base such as potassium carbonate in the presence of a suitable solvent such as MeOH at temperatures around RT.
Compounds of formula IV wherein Y represents methoxycarbonyl or cyano (Scheme 5) can be prepared by rhodium-catalyzed cycloisomerization of anilines of formula V wherein Y represents methoxycarbonyl or cyano in the presence of a rhodium catalyst such as chloro(1 ,5-cyclooctadiene)rhodium(l) dimer and a ligand such as tris(4- fluorophenylphosphine) and heating in a suitable solvent such as DMF at temperatures between 50°C and 90°C.
Alternatively, compounds of formula IV wherein Y represents methoxycarbonyl or cyano can be prepared by copper-catalyzed cycloisomerization of anilines of formula IX wherein Y represents methoxycarbonyl or cyano using a suitable copper catalyst such as copper iodide and heating in a suitable solvent such as DMF at temperatures between 50°C and 100°C.
Alternatively, compounds of formula IV wherein R6 represents hydrogen and Y represents methoxycarbonyl can be prepared by simultaneous deiodination and desulfurization of methylsulfanyl indoles of formula XIII by treatment with a suitable catalyst such as Raney nickel in the presence of a suitable solvent such as EtOH at temperatures around RT. Alternatively, compounds of formula IV wherein R6 represents (C C4)alkyl and Y represents methoxycarbonyl can be prepared by desulfurization of methylsulfanyl indoles of formula VI wherein R6 represents (C C4)alkyl by treatment with a suitable catalyst such as Raney nickel in the presence of a suitable solvent such as EtOH at temperatures around RT. Compounds of formula VI (Scheme 5) wherein R6 represents (C C4)alkyl can be prepared from compounds of formula XIII by Negishi type cross-coupling with R6ZnX following standard conditions such as those previously described for the synthesis of compounds of formula VIII. Compounds of formula XIII (Scheme 5) can be prepared by Gassman indole synthesis by consecutive treatment of anilines of formula XII with (i) a chlorinating reagent such as N-chlorosuccinimide or te/f-butyl hypochlorite, with (ii) a protected aldehyde such as methylthioacetaldehyde dimethylacetal in the presence for both steps of a suitable solvent such as DCM at temperatures between -50°C and -78°C, with (iii) a base such as Et3N in the presence of a suitable solvent such as chlorobenzene at temperatures between 80°C and 120°C and finally with (iv) an acid such as HCI in the presence of a solvent such as dioxane or Et20 at temperatures around RT.
Alternatively, compounds of formula IV (Scheme 5) wherein R5 represents hydrogen or (C C4)alkyl, R6 represents hydrogen, (C C4)alkyl, (C C4)alkoxy or (CrC2)alkoxy-(Cr C4)alkyl, R 0 represents methyl (or ethyl respectively) and Y represents methoxycarbonyl or cyano can be prepared by Suzuki type cross-coupling of chlorides of formula IV wherein R5 represents hydrogen or (C C4)alkyl, R6 represents hydrogen, (C C4)alkyl, (C C4)alkoxy or (Ci-C2)alkoxy-(CrC4)alkyl, R 0 represents chloro and Y represents methoxycarbonyl or cyano with trimethylboroxine (or vinyl boronic acid pinacol ester respectively) in the presence of a suitable palladium catalyst such as [1 ,3-bis(2,6- diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride, in the presence of a suitable base such as K2C03 and heating in a suitable solvent such as dioxane at temperatures around 110°C. When using vinyl boronic acid pinacol ester as reagent, the subsequent reduction of the double bond was carried out under hydrogenation conditions such as those described above.
Alternatively, compounds of formula IV (Scheme 5) wherein R6 represents -C(OMe)Me2 and Y represents methoxycarbonyl or cyano can be prepared from ketone of formula IV wherein R6 represents acetyl and Y represents methoxycarbonyl or cyano by a two step procedure: (i) addition of a methylmagnesium halide solution in the presence of a suitable solvent such as THF at temperatures around RT and (ii) alkylation with Mel in the presence of a suitable base such as a suspension of NaH in mineral oil and a suitable solvent such as THF at temperatures between 0°C and RT. Other tertiary ethers may be prepared in analogy.
Alternatively, compounds of formula IV (Scheme 5) wherein R6 represents hydroxy (or hydroxy-(Ci-C4)alkyl respectively) and Y represents cyano can be prepared from methyl ether of formula IV wherein R6 represents methoxy (or methoxy-(C C4)alkyl respectively) and Y represents cyano by treatment with BBr3 in the presence of a suitable solvent such as DCM at temperatures between -78°C and 55°C. The possible subsequent alkylation of the phenol of formula IV wherein R4 represents hydroxy and Y represents cyano by treatment with (C C4)alkyl halide or (C C4)alkoxy-(C2-C4)alkyl halide in the presence of a suitable base such as K2C03 and a suitable solvent such as DMF at temperatures between 0°C and 80°C provides compounds of formula IV wherein R6 represents (C C4)alkoxy or (C C4)alkoxy-(C2-C4)alkoxy and Y represents cyano.
Carboxylic acid derivatives of formula I la (Scheme 5) can be prepared by hydrolysis of methyl esters of formula IV wherein Y represents methoxycarbonyl by standard treatment with a suitable base such as LiOH, NaOH or KOH in the presence of water and a suitable organic solvent such as MeOH, EtOH or THF at temperatures between RT and 60°C. Alternatively, carboxylic acid derivatives of formula I la (Scheme 5) can be prepared by hydrolysis of nitriles of formula IV wherein Y represents cyano with a suitable base such as KOH or NaOH in the presence of water and optionally a suitable organic solvent such as 2-propanol at temperatures around 150°C.
Figure imgf000054_0001
Indole carboxylic acids of formula lib can be prepared according to the synthetic routes given in scheme 6.
Hydrazines of formula XVII (Scheme 6) can be prepared by diazotisation of anilines of formula XII wherein R 0 represents chloro with for instance sodium nitrite in a suitable solvent such as aq. HCI at temperatures around 0°C and subsequent reduction of the diazonium salt with for instance tin(ll) chloride dihydrate in a suitable solvent such as aq. HCI at temperatures between 0°C and RT. Indoles of formula XVIII (Scheme 6) can be prepared by Fisher indole reaction between hydrazine derivatives of formula XVII and ketones of formula R8COCH2SMe wherein R8 represents (C C4)alkyl in the presence of a suitable acid such as HCI and a suitable solvent such as EtOH at temperatures between 50°C and 80°C.
Compounds of formula XVI wherein R5 represents hydrogen, (C C4)alkyl or chloro and R6 represents (C C4)alkyl, (Ci-C2)alkoxy-(CrC4)alkyl or (C C4)alkyl-carbonyl (Scheme 6) can be prepared from iodides of formula XVIII by Negishi, Sonogashira or Suzuki type cross-coupling reaction following standard conditions such as those previously described for the synthesis of compounds of formula VIII. The possible subsequent reduction or hydration step can be carried out as previously described for the synthesis of compounds of formula VIII.
Alternatively, compounds of formula XVI (Scheme 6) can be prepared from anilines of formula VIII wherein Y represents methoxycarbonyl by a similar two-step sequence (hydrazine formation and Fisher indole synthesis) using similar conditions such as those previously described for the synthesis of compounds of formula XVIII from compounds of formula XII.
Compounds of formula XV wherein R6 represents fluoro, chloro, (C C4)alkyl, (C C4)alkoxy, (C C4)alkyl-carbonyl, (CrC2)alkoxy-(C C4)alkyl or (C C4)alkoxy-(C2-C4)alkoxy (Scheme 6) can be prepared by desulfurization of compounds of formula XVI following conditions such as those previously described for the synthesis of compounds of formula IV from compounds of formula VI.
Alternatively, compounds of formula XV wherein R6 represents hydrogen can be prepared from compounds of formula XVIII by simultaneous deiodination and desulfurization following conditions such as those previously described for the synthesis of compounds of formula IV from compounds of formula XIII.
Carboxylic acid derivatives of formula lib wherein R8 represents (C C4)alkyl (Scheme 6) can be prepared by hydrolysis of methyl esters of formula XV following conditions such as those previously described for the synthesis of compounds of formula I la.
Figure imgf000056_0001
Scheme 6: Synthesis of carboxylic acid intermediates of formula II wherein R represents
(Ci-C*)alkyl Indole carboxylic acids of formula lie wherein R represents (C C4)alkyl, formyl or halogen (Scheme 7) can be prepared according to procedures well known in the art for the introduction of substituents at the 3-position of indoles. Representative synthetic routes are depicted below and outlined in scheme 7.
Indole derivatives of formula A wherein R9 represents formyl (Scheme 7) can be prepared from indole derivatives of formula IV wherein Y represents methoxycarbonyl by Vilsmeier- Haack reaction with phosphorus oxychloride and DMF at temperatures between 0°C and 40°C. Resulting formylated indole derivatives can be transformed to indole derivatives of formula A wherein R9 represents methyl (Scheme 7) following a two-step one-pot procedure: (i) formation of tosyl hydrazone by condensation with p-toluenesulfonyl hydrazide in the presence of p-toluene sulfonic acid, sulfolane and a suitable solvent such as DMF at temperatures around 100°C and (ii) consecutive reduction of resulting tosyl hydrazone with for instance sodium borohydride at temperatures around 100°C.
Indole derivatives of formula A wherein R9 represents chloro (or bromo, respectively) (Scheme 7) can be prepared by chlorination (or bromination, respectively) of indole derivatives of formula IV wherein Y represents methoxycarbonyl with a suitable halogenating reagent such as NCS (or NBS, respectively) in the presence of a suitable solvent such as DMF or CH2CI2 at temperatures between 0°C and RT. Indole derivatives of formula A wherein R9 represents fluoro (Scheme 7) can be prepared by fluorination of indole derivatives of formula IV wherein Y represents methoxycarbonyl with a suitable fluorinating reagent such as 1-fluoro-2,4,6-trimethylpyridinium triflate in the presence of a suitable solvent such as MeOH at temperatures around 65°C.
Carboxylic acid derivatives of formula lie (Scheme 7) can be prepared by hydrolysis of methyl esters of formula A following conditions such as those previously described for the synthesis of compounds of formula I la.
Indole derivatives of formula B wherein R7 represents (C C3)alkyl (Scheme 7) can be prepared by alkylation of indole derivatives of formula IV, XV or A with a suitable alkylating reagent such as R7Br or R7I wherein R7 represents (C C3)alkyl and a suitable base such as NaH in the presence of a suitable solvent such as DMF at temperatures between 0°C and RT.
Carboxylic acid derivatives of formula lid (Scheme 7) can be prepared by hydrolysis of methyl esters of formula B following conditions such as those previously described for the synthesis of compounds of formula I la.
Figure imgf000057_0001
Scheme 7: Synthesis of carboxylic acid intermediates of formula lie wherein R represents
Figure imgf000057_0002
iClzC_4)a|kyJ
If not commercially available, aniline intermediates of formula XIV wherein Y represents methoxycarbonyl or cyano can be prepared according to procedures known in the art. Two possible synthetic routes are outlined in Scheme 8 below, which also illustrate alternative synthetic accesses to compounds of formula VIII wherein Y represents methoxycarbonyl or cyano. Carboxylic acid derivatives of formula XX wherein R5 represents hydrogen or halogen, R6 represents hydrogen, (C C4)alkoxy or halogen and R 0 represents fluoro, chloro, (C C2)fluoroalkyl or methoxy (Scheme 8) can be prepared by oxidation of toluene derivatives of formula XIX wherein R5 represents hydrogen or halogen, R6 represents hydrogen, (C C4)alkoxy or halogen and R 0 represents fluoro, chloro, (C C2)fluoroalkyl or methoxy with a suitable oxidizing reagent such as KMn04 in the presence of water and a solvent such as pyridine at temperatures around 100°C.
Alternatively, carboxylic acid derivatives of formula XX wherein R6 represents hydrogen, (Ci-C4)alkyl, (C C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen (Scheme 8) can be prepared by hydrolysis of nitriles of formula XXIII wherein R6 represents hydrogen, (C C4)alkyl, (C C4)alkoxy, (Ci-C2)alkoxy-(C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen by treatment with a suitable base such as KOH or NaOH in the presence of water and a suitable organic solvent such as 2-propanol at temperatures around 150°C. An additional treatment with sodium nitrite in the presence of water and an acid such as sulphuric acid at temperatures around 80°C may be required for the hydrolysis of the primary amide intermediates. Nitriles of formula XXIII wherein R6 represents hydrogen, (C C4)alkyl, (C C4)alkoxy, (Ci-C2)alkoxy-(C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen (Scheme 8) can be prepared by treatment of anilines of formula XXII with a suitable diazotisation reagent such as te/f-butyl nitrite in the presence of a suitable cyanating reagent such as copper(l) cyanide in a suitable solvent such as CH3CN at temperatures between 0°C and 80°C.
Alternatively, carboxylic acid derivatives of formula XX wherein R6 represents (C C4)alkoxy (or (C C4)alkoxy-(C2-C4)alkoxy, respectively) (Scheme 8) can be prepared by nucleophilic aromatic substitution of fluorides of formula XX wherein R6 represents fluoro with (C C4)-alcohol (or (C C4)alkoxy-(C2-C4)alcohol, respectively) in the presence of a base such as Cs2C03 and a suitable solvent such as DMF at temperatures between RT and 110°C.
Methyl esters of formula XXI wherein RN represents nitro (Scheme 8) can be prepared by treatment of carboxylic acids of formula XX with a suitable base such as Cs2C03 or K2C03 and a suitable alkylating reagent such as Mel in the presence of a suitable solvent such as DMF at temperatures around RT.
Alternatively, compounds of formula XXI wherein RN represents acetylamino, R5 represents hydrogen, (C C4)alkyl, fluoro or chloro, R6 represents (C C4)alkyl, (C C4)alkoxy, (CrC2)alkoxy-(C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy, fluoro or chloro and R 0 represents methyl or ethyl (Scheme 8) can be prepared from phenols of formula XXI wherein RN represents acetylamino, R5 represents hydrogen, (C C4)alkyl, fluoro or chloro, R6 represents (C C4)alkyl, (C C4)alkoxy, (Ci-C2)alkoxy-(CrC4)alkyl, (C C4)alkoxy-(C2- C4)alkoxy, fluoro or chloro and R 0 represents hydroxy following a two-step procedure: (i) triflate formation by treatment with trifluoromethanesulfonic anhydride in the presence of a base such as Et3N and a suitable solvent such as DCM at temperatures around RT and (ii) consecutive Suzuki type cross coupling with methyl or ethyl boronic acid in the presence of a suitable palladium catalyst such as Pd(dppf)CI2.DCM and a base such as K3PC and heating in a suitable solvent such as THF at temperatures around 65°C.
Anilines of formula XIV wherein Y represents methoxycarbonyl (or VIII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C1-C2)alkoxy-(C1-C4)alkyl, (C C4)alkoxy-(C2- C4)alkoxy or halogen and Y represents methoxycarbonyl, respectively) (Scheme 8) can be prepared by reduction of nitrobenzene derivatives of formula XXI wherein RN represents nitro and R6 represents hydrogen (or XXI wherein RN represents nitro and R6 represents (C C4)alkyl, (C C4)alkoxy, (CrC2)alkoxy-(CrC4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen, respectively) with a suitable reducing reagent such as tin(ll) chloride dihydrate in the presence of a suitable solvent such as DMF at temperatures around 100°C or with zinc dust and ammonium formate in the presence of a suitable solvent such as MeOH at temperatures around RT.
Alternatively, anilines of formula XIV wherein Y represents methoxycarbonyl (or VIII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C4)alkyl-carbonyl, (C C2)alkoxy- (C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen and Y represents methoxycarbonyl, respectively) (Scheme 8) can be prepared by methanolysis of acetylated anilines of formula XXI wherein RN represents acetylamino and R6 represents hydrogen (or XXI wherein RN represents acetylamino and R6 represents (C C4)alkyl, (C C4)alkoxy, (C C4)alkyl-carbonyl, (Ci-C2)alkoxy-(C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen, respectively) with K2C03 in the presence of MeOH at temperatures around RT.
Alternatively, anilines of formula XIV wherein R5 represents hydrogen, (C C4)alkyl, fluoro or chloro and Y represents cyano (or VIII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C4)alkyl-carbonyl, (CrC2)alkoxy-(CrC4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy, fluoro or chloro, R5 represents hydrogen, (C C4)alkyl, fluoro or chloro and Y represents cyano, respectively) (Scheme 8) can be prepared by palladium catalysed cyanation of bromides of formula XXXIX wherein R5 represents hydrogen, (C C4)alkyl, fluoro or chloro and R6 represents hydrogen, (C C4)alkyl, (C C4)alkoxy, (C C4)alkyl-carbonyl, (C C2)alkoxy-(C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy, fluoro or chloro with zinc cyanide in the presence of a suitable palladium catalyst such as Pd(PPh3)4 and heating in a suitable solvent such as DMF at temperatures around 110°C.
Alternatively, anilines of formula XIV wherein Y represents methoxycarbonyl (or VIII wherein R6 represents (C C4)alkyl, (C C4)alkoxy, (C C4)alkyl-carbonyl, (C C2)alkoxy- (C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen and Y represents methoxycarbonyl, respectively) (Scheme 8) can be prepared by esterification of anilines of formula XIV wherein Y represents hydroxycarbonyl (or VIII wherein R6 represents (C C4)alkyl, (C C4)alkoxy , (C C4)alkyl-carbonyl, (CrC2)alkoxy-(C C4)alkyl, (C C4)alkoxy-(C2-C4)alkoxy or halogen and Y represents hydroxycarbonyl, respectively) by standard procedures as for example the treatment with acetylchloride in the presence of MeOH at temperatures around 65°C.
Figure imgf000060_0001
Scheme 8: Synthesis of aniline precursors XIV and VIII If not commercially available, amines of formula Ilia, wherein R 4 represents hydrogen or (Ci-C4)alkyl, can be prepared following the procedures outlined in Scheme 9 below.
The compounds of formula XXVI wherein R 4 represents trimethylsilyl or hydrogen (Scheme 9) can be prepared by cyanosilylation of a ketone of formula XXIV using a suitable cyanation reagent such as trimethylsilylcyanide, in the presence of a lewis acid such as gold (III) chloride or zinc iodide in a suitable solvent such as DCM at temperatures around RT {Synthesis, 2008, 4, 507-510). The compounds of formula XXVI wherein R 4 represents (Ci-C4)alkyl (Scheme 9) can be prepared by cyanation of a ketal of formula XXV with a suitable cyanation reagent such as te/f-butyl isocyanide in the presence of a suitable lewis acid such as titanium tetrachloride in a suitable solvent such as DCM at temperatures between -70°C and RT (Chemistry Lett, 1984, 937-940).
The compounds of formula Ilia wherein R 4 represents hydrogen or (Ci-C4)alkyl (Scheme 9) can be prepared by reduction of a compound of formula XXVI using a suitable reducing reagent such as lithium aluminum hydride, in the presence of a suitable solvent such as Et20 or THF at temperatures between 0°C and RT. Under those conditions the consecutive hydrolysis of a trimethylsilyl group, if present as R 4, is observed.
Figure imgf000061_0001
XXV
Scheme 9: Synthesis of amines of formula Ilia
If not commercially available, amines of formula 1Mb wherein R2 represents aryl or heteroaryl can be prepared following the procedures outlined in Scheme 10 below.
If not commercially available, aryl- or heteroaryl-acetonitriles of formula XXVIII (Scheme 10) can be prepared by a two step procedure: (i) arylation or heteroarylation of methyl cyanoacetate by treatment with a bromoarene or bromoheteroarene of formula Br-R2 in the presence of a suitable base such as KOtBu, a suitable palladium catalyst such as Pd(OAc)2, a suitable ligand such as dppf in a suitable solvent such as dioxane as described in J. Org. Chem., 2008, 73, 4, 1643-1645 and (ii) subsequent Krapcho decarboxylation of the isolated methyl aryl- or heteroarylcyanoacetate intermediates by treatment with a suitable source for halide anions such as LiCI in a suitable sovent such as wet DMSO at temperatures between 100°C and 150°C.
Alternatively, if not commercially available, aryl- or heteroaryl-acetonitriles of formula XXVIII (Scheme 10) can be prepared according to J. Am. Chem. Soc, 2011, 133, 6948- 6951. Nitriles of formula XXIX (Scheme 10) can be prepared by dialkylation of aryl- or heteroaryl-acetonitriles of formula XXVIII with dihaloalkanes such as Br-(CH2)n-CR3R4- (CH2)2-Br wherein n represents 1 , 2, 3 or 4 and R3 and R4 represents hydrogen or fluoro in the presence of a base such as NaH or tBuOK in a suitable organic solvent such as THF or DMSO preferably at temperatures between 0°C and RT.
Amines of formula 1Mb (Scheme 10) can be prepared by reduction of nitriles of formula XXIX for instance under hydrogenation conditions in the presence of a suitable catalyst such as Raney nickel and a suitable solvent such as methanolic ammonia at temperatures around RT or with a suitable reducing reagent such as borane tetrahydrofuran complex in a suitable solvent such as THF at temperatures around 70°C.
Amines of formula 1Mb wherein n represents 2 and R3 and R4 represents fluoro (Scheme 10) can be prepared for instance following a 4-step sequence: (i) tandem double Michael addition-Dieckmann condensation reaction of acetonitrile derivatives of formula XXVIII with methylacrylate according to J. Org. Chem., 2007, 72, 7455-7458 (ii) Krapcho decarboxylation of intermediates of formula XXX following conditions as those already described above for the synthesis of compounds of formula XXVIII (iii) difluorination of ketone intermediates of formula XXXI using DAST in a suitable solvent such as DCM at temperatures between -78°C and RT and (iv) reduction of nitriles of formula XXXII following conditions such as those already described for the synthesis of amines of formula 1Mb from XXIX.
3=R4=F
Figure imgf000062_0001
Scheme 10: Synthesis of amines of formula 1Mb wherein R2 represents aryl or heteroaryl
If not commercially available, amines of formula lllc can be prepared following the procedures outlined in Scheme 11 below.
If not commercially available, amines of formula XXXIV wherein R 5 and R 6 represent hydrogen (Scheme 1 1) can be prepared for instance by alkylation of N- (diphenylmethylene)glycine te/f-butyl ester with cycloalkyl bromide or iodide of formula XXXIII (X represents bromo or iodo) according to Angew. Chem. Int. Ed., 2005, 44, 1549- 1551. Subsequent reduction of resulting esters of formula XXXIV wherein R 5 and R 6 represent hydrogen using for instance lithium aluminum hydride in a suitable solvent such as THF at temperatures between 0°C and RT gives aminoalcohols of formula lllc wherein R3 and R4 represent hydrogen.
If not commercially available, amines of formula XXXIV wherein R 5 represents hydroxy and R 6 represents hydrogen or R 5 and R 6 form an ethylenedioxy group (Scheme 11) can be prepared as previously described for the synthesis of amines of formula XXXIV wherein R 5 and R 6 represent hydrogen.
If not commercially available as methyl ester (R 7 represents Me), compounds of formula XXXV wherein R 7 represents tBu and R 8 represents Boc (or Z respectively) (Scheme 11) can be prepared by treatment of amines of formula XXXIV wherein R 5 represents hydroxy and R 6 represents hydrogen with Boc-anhydride (or Z-CI respectively) in the presence of a base such as Et3N or NaOH in a suitable solvent such as DCM or dioxane/water at temperatures between 0°C and RT. Oxidation of resulting compounds using for instance DMP in a suitable solvent such as DCM at temperatures around RT gives ketones of formula XXXVI wherein R 7 represents tBu or Me and R 8 represents Boc or Z.
Alternatively, ketones of formula XXXVI wherein R 7 represents tBu or Me and R 8 represents Z (Scheme 11) can be prepared by a two step procedure: (i) Z-protection of amines of formula XXXIV wherein R 5 and R 6 form an ethylenedioxy group using conditions as previously described for the synthesis of compounds of formula XXXV and (ii) cleavage of the ketal protecting group using acidic conditions such as aq. HCI and a suitable organic solvent such as MeCN or THF at temperatures around RT.
If not commercially available, compounds of formula XXXVII wherein R 7 represents tBu or Me and R 8 represents Boc or Z (Scheme 1 1) can be prepared by fluorination of ketones of formula XXXVI wherein R 7 represents tBu or Me and R 8 represents Boc or Z using a fluorinating reagent such as DAST or bis(2-methoxyethyl)aminosulfur trifluoride in the presence of a suitable solvent such as THF or DCM at temperatures between 0°C and RT.
Compounds of formula XXXVIII wherein R 8 represents Boc or Z (Scheme 1 1) can be prepared by reduction of esters of formula XXXVII wherein R 7 represents tBu or Me and R 8 represents Boc or Z following conditions such as those already described for the reduction of esters of formula XXXIV wherein R 5 and R 6 represent hydrogen. Amines of formula lllc wherein R3 and R4 represent fluoro (Scheme 1 1) can be prepared by Boc cleavage (or Z cleavage respectively) from compounds of formula XXXVIII wherein R 8 represents Boc (or Z respectively) using a suitable acid such as HCI or TFA in the presence of a suitable solvent such as dioxane, EtOAc or DCM (or under hydrogenation conditions in the presence of a suitable catalyst such as palladium on charcoal and a suitable solvent such as MeOH or dioxane respectively) at temperatures around RT.
Figure imgf000064_0001
Scheme 11 : Synthesis of amines of formula lllc
EXPERIMENTAL PART
Abbreviations
Ac acetyl
AIBN 2,2'-azobis(2-methylpropionitrile)
anh. anhydrous
aq. aqueous
ATP adenosine-5'-triphoshate
Bn benzyl
Boc fe/f.-butyloxycarbonyl
Burgess reagent (methoxycarbonylsulfamoyl)triethylammonium hydroxide, tBu fe/f.-butyl
CC column chromatography
cDNA complementary desoxyribonucleic acid
CNS central nervous system
DAST diethylaminosulfur trifluoride DCM dichloromethane
DIPEA diisopropylethylamine
DMEM Dulbecco's modified eagle's medium
DMF dimethylformamide
DMP Dess Martin periodinane
DMSO dimethylsulfoxide
DNA desoxyribonucleic acid
dppf 1 , 1 '-bis(diphenylphosphino)ferrocene
EDC.HCI N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride eq equivalent
Et ethyl
FCS fetal calf serum
FLIPR fluorescent imaging plate reader
h hour(s)
HATU 2-(7-aza-1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
Hept heptanes
HOBt 1-hydroxybenzotriazole hydrate
HV high vacuum
LC-MS liquid chromatography - mass spectrometry
M molar(ity)
Me methyl
min minute(s)
MS mass spectrometry
NBS N-bromosuccinimide
NCS N-chlorosuccinimide
NMR nuclear magnetic resonance
ON overnight
PBS phosphate buffered saline
PEPPSI™-IPr [1 ,3-Bis(2,6-Diisopropylphenyl)imidazol-2-ylidene](3- chloropyridyl)palladium(ll) dichloride
PG protecting group
Ph phenyl
PyBOP benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium
hexafluorophosphate PyCloP chlorotripyrrolidinophosphonium hexafluorophosphate
RNA ribonucleic acid
RT room temperature
sat. saturated
TBTU 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate
TFA trifluoroacetic acid
THF tetrahydrofuran
TMS trimethylsilyl
tR retention time
UV ultra-violet
Vis visible
Z benzyloxycarbonyl
I. SYNTHESIS OF EXAMPLES A. Characterization methods used
NMR: Brucker Avance 400, 400 MHz ; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, br = broad, coupling constants are given in Hz.
LC-MS (I): Thermo Finnigan MSQ Surveyor MS with Agilent 1 100 Binary Pump and DAD. Eluents (acidic conditions): A: H20 + 0.04% TFA; B: CH3CN; gradient: 5% B→ 95% B ; runtime: 1.5 min ; flow: 4.5 mL/min ; detection: UV/Vis + MS, tR is given in min.
LC-MS (A): column Zorbax SB-AQ, 3.5 μηι, 4.6x50 mm
LC-MS (B): column Waters XBridge C18, 2.5μηι, 4.6x30 mm
LC-MS (C): column Waters Atlantis T3, 5μηι, 4.6x30 mm; Eluents (basic conditions): A: H20 + 13 mmol/L NH4OH; B: CH3CN ; gradient: 5% B→ 95% B ; runtime: 1.5 min ; flow: 4.5 mL/min:
LC-MS (D): column Waters XBridge C18, 5μηι, 4.6x50 mm.
LC-MS (D*): column Zorbax Extend C18, 5μηι, 4.6x50 mm.
LC-MS (II): Dionex Ultimate 3000 with Thermo MSQ MS, HPG-3000 pump and photodiode array detector
Eluents (acidic conditions): A: H20 + 0.05% HCOOH; B: CH3CN + 0.05% HCOOH; gradient: 5% B→ 95% B ; runtime: 2.0 min ; flow: 1.8 mL/min ; detection: UV/Vis + MS, tR is given in min.
LC-MS (E): column Ascentis Express C18, 2.7 μηι, 2.1x50 mm B. Purification methods used
Preparative LC-MS (A): flow: 75 mL/min. Detection: UV/Vis and/or MS.
Additional informations for the purification are summerized in the tables below using following explanations:
XBridge: column Waters XBridge C18, 10μηι, 30x75 mm
Atlantis: column Waters Atlantis T3, 10μηι, 30x75 mm
Acidic: eluant: A = H20 with 0.5% HCOOH, B = CH3CN
Basic: eluant: A = H20 with 0.125% NH4OH, B = CH3CN
Lipophilic gradient: 30% B→ 95% B over 4 min then 95%B over 2 min
Normal gradient: 20% B→ 95% B over 4 min then 95%B over 2 min
Polar gradient: 10% B→ 95% B over 4 min then 95%B over 2 min
Very polar gradient: 5% B→ 50% B over 3 min then 50% B→ 95% B over 1 min and finally 95%B over 2 min
XBridge Atlantis acidic basic acidic
Lipophilic gradient Method III
Normal gradient Method II Method IV Method VII
Polar gradient Method VI Method V Method VIII
Very polar gradient Method I
Preparative LC-MS (B): flow: 40 mL/min. Detection: UV/Vis and MS.
XBridge: column Waters XBridge C18 OBD™, 5μηι, 19x50 mm
Acidic: eluant: A = H20 with 0.1 % HCOOH, B = CH3CN with 0.1 % HCOOH
Method 1 (lipophilic gradient): 40% B over 0.1 min, 40%→ 50% B over 0.1 min, 50%→
80% B over 2.9 min, 80%→ 95% B over 0.1 min and finally 95%B over 1 min
Method 2 (long normal gradient): 25% B over 0.1 min, 25%→ 35% B over 0.1 min, 35%
→ 65% B over 4.1 min, 65%→ 95% B over 0.1 min and finally 95%B over 1.1 min
Method 3 (normal gradient): 25% B over 0.2 min, 25%→ 35% B over 0.1 min, 35%→ 65% B over 2.9 min, 65%→ 95% B over 0.1 min and finally 95%B over 1 min
Method 4 (long polar gradient): 10% B over 0.2 min, 10%→ 20% B over 0.1 min, 20%→ 50% B over 4.1 min, 50% → 95% B over 0.1 min and finally 95%B over 1.1 min Method 5 (polar gradient): 10% B over 0.2 min, 10%→ 20% B over 0.1 min, 20%→ 50% B over 2.9 min, 50%→ 95% B over 0.1 min and finally 95%B over 1 min
Column chromatography (CC) was performed using silica gel 60 Merck (0.063- 0.200mm) or using prepacked cartridges (SNAP KP-SIL™, SNAP KP-NH™, Isolute™ Silica II, Isolute™ NH2 or Isolute™ C 8) from Biotage. Additional information for the purification are summarized in the table below:
SNAP P-SILI M Isolute I Silica II SNAP KP-NH
Hept/EtOAc Method b Method c
EtOAc/MeOH Method e Method f
DCM/MeOH Method g Method d Method a
The following examples illustrate the invention but do not at all limit the scope thereof.
PREPARATION OF PRECURSORS AND INTERMEDIATES A. Synthesis of carboxylic acids
A.1. Synthesis of 4-chloro-1 H-indole-5-carboxylic acid
A.1.a. Methyl 4-amino-2-chlorobenzoate
To a solution of 4-amino-2-chlorobenzoic acid (54.2 mmol) in MeOH (325 mL) was added dropwise acetylchloride (163 mmol) and the mixture was refluxed for 5h. It was concentrated in vacuo and partitioned between EtOAc and a sat. solution of NaHC03. The organic phase was washed with a sat. solution of NaHC03, dried over MgS04 and concentrated in vacuo to give the title compound as beige solid.
LC-MS (B): tR = 0.57 min; [M+CH3CN+H]+: 227.29 A.1.b. Mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro- 5-iodobenzoate
To a suspension of methyl 4-amino-2-chlorobenzoate (55.8 mmol) in EtOH (558 mL) was added silver sulfate (55.8 mmol) and iodine (58.6 mmol) under argon. The mixture was stirred for 15 min, filtered and the filtrate was concentrated in vacuo. The residue was partitioned between DCM and a 1 M aq. solution of NaOH. The organic phase was washed with a 1 M aq. solution of NaOH, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc/MeOH from 89/11/1 to 81/19/1 to give the mixture of regioisomers as salmon solid. The mixture was enriched from 59 to 66% in methyl 4-amino-2-chloro-3-iodobenzoate by recrystallisation in Hept/EtOAc 75/25, separation of the solid methyl 4-amino-2-chloro-5-iodobenzoate by filtration and evaporation of the mother liquid.
LC-MS (B): tR = 0.72 min; [M+CH3CN+H]+: 352.79
In addition, pure methyl 4-amino-2-chloro-5-iodobenzoate regioisomer was isolated as pink to orange solid.
LC-MS (B): tR = 0.75 min; [M+CH3CN+H]+: 352.80
A. I.e. Methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate
A solution of mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate from previous step (13.3 mmol) in Et3N (1 10 mL) and toluene (110 mL) was heated to 60°C under argon and treated with PPh3 (1.33 mmol), Cul (1.33 mmol), Pd(PPh3)2CI2 (0.66 mmol) and trimethylsilylacetylene (19.9 mmol). The mixture was stirred for 30 min at 60°C and 1 h at 70°C, quenched with a 10% aq. solution of NH4CI and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 1/0 to 8/2 to give the title compound (second eluting product) as light yellow solid.
LC-MS (B): tR = 0.93 min; [M+CH3CN+H]+: 322.70
In addition, methyl 4-amino-2-chloro-5-((trimethylsilyl)ethynyl)benzoate was isolated as orange solid (first eluting product).
LC-MS (B): tR = 0.97 min; [M+CH3CN+H]+: 323.22 A.1.d. Methyl 4-amino-2-chloro-3-ethvnylbenzoate
To a solution of methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate (8.81 mmol) in MeOH (8.81 mL) was added K2C03 (9.69 mmol). The mixture was stirred for 15 min and the solvent was evaporated off. The residue was partitioned between DCM and water. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Isolute™ Silica II from Biotage) using DCM to give the title compound as yellowish solid.
LC-MS (B): tR = 0.66 min; [M+H]+: 210.04
A. I.e. Methyl 4-chloro- 1 H-indole-5-carboxylate
To a mixture of methyl 4-amino-2-chloro-3-ethynylbenzoate (5.57 mmol), chloro(1 ,5- cyclooctadiene)rhodium(l) dimer (0.28 mmol) and tris(4-fluorophenyl)phosphine (3.34 mmol) was added under argon degassed DMF (28 mL). The mixture was heated to 85°C for 50 min, cooled to RT and partitioned between Et20 and water. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/DCM 1/0 to 0/1 to give the title compound as brownish solid.
LC-MS (B): tR = 0.69 min; [M+H]+: 210.14
A.1.f. 4-Chloro-1 H-indole-5-carboxylic acid (Saponification: general procedure I)
To a suspension of methyl 4-chloro-1 H-indole-5-carboxylate (4 mmol) in MeOH (24 mL) was added a 2M aq. solution of LiOH (4 mL). The mixture was stirred for 5h at 65°C then ON at 45°C. It was evaporated off and partitioned between EtOAc and H20. The aq. phase was acidified with a 25% solution of HCI and extracted 3 times with DCM. The combined organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as off-white solid.
LC-MS (A): tR = 0.65 min; [M+H]+: 196.06
A.2. Synthesis of4-chloro-1-methyl-1H-indole-5-carboxylic acid
To a solution of methyl 4-chloro-1 H-indole-5-carboxylate (0.48 mmol) in anh. DMF (1.2 mL) was added at 0°C NaH as a 60% suspension in mineral oil (1.2 mmol). The mixture was stirred for 5 min and Mel (0.72 mmol) was added dropwise at 0°C. The mixture was stirred for 1 h at RT, quenched with water and partitioned between Et20 and water. The aq. phase was acidified with a 1 M aq. solution of HCI and extracted 3 times with DCM. The combined organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as brown solid.
LC-MS (B): tR = 0.61 min; [M+H]+: 210.05
A.3. Synthesis of 4-chloro-3-formyl-1 H-indole-5-carboxylic acid
A.3. a. Methyl 4-chloro-3-formyl- 1 H-indole-5-carboxylate
Phosphoryl chloride (1.43 mmol) was added at 0°C to anh. DMF (4 ml_). To this mixture was added dropwise at 0°C a solution of methyl 4-chloro-1 H-indole-5-carboxylate (0.95 mmol) in anh. DMF (2 ml_). The mixture was stirred for 5 min at 0°C, heated to 40°C and stirred for 4h30. It was poured onto ice, treated with a 1 M aq. solution of NaOH to adjust pH to 10-1 1 and heated to 100°C for 5 min. The mixture was acidified with a 1 M solution of HCI and extracted 3 times with DCM. The combined organic phases were dried and concentrated in vacuo. The crude was purified by CC (SNAP KP-SI L™ from Biotage) using Hept/EtOAc from 1/0 to 35/65 to give the title compound as orange solid.
LC-MS (A): tR = 0.71 min; [M+H]+: 238.05
A.3.b. 4-Chloro-3-formyl-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-1 H-indole-5- carboxylic acid, methyl 4-chloro-3-formyl-1 H-indole-5-carboxylate replacing methyl 4- chloro-1 H-indole-5-carboxylate.
LC-MS (B): tR = 0.41 min; [M+H]+: 224.07
A.4. Synthesis of 4-chloro-7-methyl-1 H-indole-5-carboxylic acid
A.4. a. Methyl 4-chloro-7-iodo-3-(methylthio)-1H-indole-5-carboxylate (Gassman indole)
To a suspension of methyl 4-amino-2-chloro-5-iodobenzoate (6.21 mmol) in anh. DCM (29 mL) was added at -60°C NCS (7.45 mmol) and the mixture was stirred for 10 min. A solution of (methylthio)acetaldehyde dimethyl acetal (7.45 mmol) in anh. DCM (5.8 mL) was added at -60°C and the mixture was stirred allowing temperature to reach -30°C. A solution of Et3N (7.45 mmol) in anh. DCM (5 mL) was added at -30°C and the mixture was stirred allowing temperature to reach RT. It was concentrated in vacuo, PhCI (17.4 mL) and Et3N (20.5 mmol) were added and the mixture was heated to 125°C and stirred for 2h. The volatiles were evaporated off and the residue was taken up in Et20 (28.7 mL) and treated with a 4M solution of HCI in dioxane (1 1 mL) for 30 min. It was partitioned between EtOAc and a sat. solution of NaHC03, the organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SI L™ from Biotage) using Hept/EtOAc from 9/1 to 65/35 to give the title compound as yellow solid.
LC-MS (A): tR = 0.93 min; [M+H]+: 381 .71
A.4.b. Methyl 4-chloro-7-methyl-3-(methylthio)-1H-indole-5-carboxylate
To a solution of methyl 4-chloro-7-iodo-3-(methylthio)-1 H-indole-5-carboxylate (0.42 mmol) in dioxane (1 mL) was added under argon a 2M solution of methylzinc chloride in TH F (1.04 mmol) and a solution of Pd(dppf)CI2.DCM (0.03 mmol) in dioxane (0.5 mL). The mixture was stirred ON at 65°C in a sealed vial, diluted with EtOAc and washed with a sat. solution of Rochelle salt and brine. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SI L™ from Biotage) using DCM to give the title compound as yellow solid.
LC-MS (A): tR = 0.86 min; [M+H]+: 270.1 1
A.4.C. Methyl 4-chloro- 1 -methyl- 1 H-indole-5-carboxylate
To a solution of methyl 4-chloro-7-methyl-3-(methylthio)-1 H-indole-5-carboxylate (0.24 mmol) in EtOH (4.1 1 mL) was added Actimet M Raney Nickel (14 mg). The mixture was stirred for 2h at RT and filtered over a pad of celite. The filtrate was concentrated in vacuo to give the title compound as white solid.
LC-MS (A): tR = 0.82 min; [M+H]+: 224.16
A.4.d. 4-Chloro-7-methyl-1H-indole-5-carboxylic acid (Saponification II)
To a solution of methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate (0.1 1 mmol) in MeOH (0.4 mL), THF (0.4 mL) and H20 (0.4 mL) was added LiOH. H20 (0.44 mmol). The mixture was stirred for 2h at 60°C. It was evaporated off and partitioned between EtOAc and H20. The aq. phase was acidified with a 25% solution of HCI and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as pink solid.
LC-MS (A): tR = 0.69 min; [M+H]+: 209.98
A.5. Synthesis of 4-chloro-2-methyl-1 H-indole-5-carboxylic acid
A.5. a. Methyl 2-chloro-4-hydrazinyl-5-iodobenzoate
To a solution of methyl 4-amino-2-chloro-5-iodobenzoate (6.42 mmol) in 37% HCI (4.40 mL) was added dropwise at 0°C a solution of sodium nitrite (7.49 mmol) in water (2.15 mL). The mixture was stirred for 15 min at 0°C and a solution of tin(ll) chloride dihydrate (16 mmol) in water (1 mL) and 37% HCI (4.28 ml_) was added dropwise at 0°C. The mixture was stirred for 15 min and quenched with consecutive addition of water, a 10% solution of Na2C03 and a 20% solution of NaOH. It was extracted 3 times with DCM, the combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 95/5 to 62/38 to give the title compound as beige solid.
LC-MS (A): tR = 0.73 min; [M+CH3CN+H]+: 367.75
A.5.b. Methyl 4-chloro- 7-iodo-2-methyl-3-(methylthio) - 1 H-indole-5-carboxylate
To a solution of methyl 2-chloro-4-hydrazinyl-5-iodobenzoate (0.76 mmol) in a 1.25 M solution of HCI in EtOH (1.8 mL) was added 1-methylthio-2-propanone (1.38 mmol). The mixture was stirred for 2h at 65°C and filtered. The filtrate was concentrated in vacuo and the crude was purified by preparative LC-MS using method I.
LC-MS (A): tR = 0.96 min; [M+H]+: 395.73
A.5.C. Methyl 4-chloro-2-methyl- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-7- methyl-1 H-indole-5-carboxylate, methyl 4-chloro- 7-iodo-2-methyl-3-(methylthio)-1 H- indole-5-carboxylate replacing 4-chloro- 7-methyl-3-(methylthio)-1 H-indole-5-carboxylate except that the reaction mixture was stirred for 48h at RT and further additions of Actimet M Raney Nickel was required until completion of the reaction.
LC-MS (A): tR = 0.83 min; [M+H]+: 224.10
A.5.d. 4-Chloro-2-methyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-1 H-indole-5- carboxylic acid, methyl 4-chloro-2-methyl-1 H-indole-5-carboxylate replacing methyl 4- chloro-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.69 min; [M+H]+: 210.04
A.6. Synthesis of 4-chloro-7-iodo-3-(methylthio)-1 H-indole-5-carboxylic acid
To a solution of methyl 4-chloro- 7-iodo-3-(methylthio)-1 H-indole-5-carboxylate (0.52 mmol) in MeOH (0.45 mL) and H20 (0.45 mL) was added KOH (1.57 mmol). The mixture was stirred ON at 70°C. It was evaporated off and partitioned between Et20 and water. The aq. phase was acidified with a 1 M solution of HCI and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as brownish solid. LC-MS (A): tR = 0.78 min; [M+H]+: 368.91
A.7. Synthesis of 4-chloro-3-fluoro-1 H-indole-5-carboxylic acid
A.7.a. Methyl 4-chloro-3-fluoro- 1 H-indole-5-carboxylate
To a solution of methyl 4-chloro-1 H-indole-5-carboxylate (0.24 mmol) in MeOH (2.09 mL) was added 1-fluoro-2,4,6-trimethylpyridinium triflate (0.31 mmol). The mixture was heated to 65°C and stirred for 24h. It was concentrated in vacuo and the residue was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 1/0 to 1/1 to give the title compound as beige solid.
LC-MS (A): tR = 0.80 min
H NMR ((CD3)2SO) <5: 1 1.54 (s, 1 H), 7.60 (d, J = 8.6 Hz, 1 H), 7.57 (t, J = 2.5 Hz, 1 H), 7.41 (dd, i = 8.6 Hz, J2 = 2.4 Hz, 1 H), 3.86 (s, 3 H)
A.7.b. 4-Chloro-3-fluoro- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-3-fluoro-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.67 min; [M+CH3CN+H]+: 255.04
A.8. Synthesis of 4-methoxy-1 H-indole-5-carboxylic acid
A.8. a. Methyl 7-iodo-4-methoxy-3-(methylthio)- 1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-7-iodo- 3-(methylthio)-1 H-indole-5-carboxylate, commercially available methyl 4-amino-5-iodo-2- methoxybenzoate replacing methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 0.90 min; [M+H]+: 377.76
A.8.b. Methyl 4-methoxy- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-7- methyl-1 H-indole-5-carboxylate, methyl 7-iodo-4-methoxy-3-(methylthio)-1 H-indole-5- carboxylate replacing 4-chloro-7-methyl-3-(methylthio)-1 H-indole-5-carboxylate except that the reaction mixture was stirred for 2h at RT and one further addition of Actimet M Raney Nickel was required until completion of the reaction.
LC-MS (A): tR = 0.69 min; [M+H]+: 206.28 A.8.C. 4-Methoxy- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-methoxy-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.60 min; [M+H]+: 192.28
A.9. Synthesis of 3,4-dichloro-1 H-indole-5-carboxylic acid
A.9. a. Methyl 3, 4-dichloro- 1 H-indole-5-carboxylate
To a solution of methyl 4-chloro-1 H-indole-5-carboxylate (0.72 mmol) in DMF (1 mL) was added portionwise at 0°C NCS (0.79 mmol). The mixture was stirred ON at RT, quenched with a 10% solution of Na2S203 and extracted with EtOAc. The organic phase was washed with a 10% solution of Na2S203 and brine, dried over MgS04 and concentrated in vacuo to give the title compound as light orange solid.
LC-MS (A): tR = 0.83 min
H NMR ((CD3)2SO) <5: 12.02 (s, 1 H), 7.74 (d, J = 2.7 Hz, 1 H), 7.57 (d, J = 8.53 Hz, 1 H), 7.47 (d, J = 8.53 Hz, 1 H), 3.86 (s, 3 H)
A.9.b. 3,4-Dichloro- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, Methyl 3,4-dichloro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction mixture was stirred ON at 60°C.
LC-MS (D*): tR = 0.18 min; [M-H]-: 228.04
A.10. Synthesis of 4-chloro-7-nitro-1 H-indole-5-carboxylic acid
A.10. a. 4-Aminc-2-chlorc-5-nitrobenzoic acid
This compound was synthesized according to Helv. Chim. Acta, 1937, 20, 1407-1412. A.10. b. Methyl 4-aminc-2-chlorc-5-nitrobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 4-amino-2-chloro-5-nitrobenzoic acid replacing 4-amino-2-chlorobenzoic acid except that the crude was additionally purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 3/1 to 0/1.
LC-MS (A): tR = 0.79 min H NMR ((CD3)2SO) <5: 8.57 (s, 1 H), 7.96 (s, 2 H), 7.14 (s, 1 H), 3.79 (s, 3 H)
A.10. c. Methyl 4-amino-2-chloro-3-iodo-5-nitrobenzoate
To a solution of methyl 4-amino-2-chloro-5-nitrobenzoate (13.5 mmol) in DCM (33.7 mL) was added bis(pyridine)iodinium tetrafluoroborate (27 mmol) and trifluoromethansulfonic acid (53.9 mmol). The mixture was stirred for 1 h at RT and partitioned between water and DCM. The organic phase was washed with a 10% solution of Na2S203, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using DCM/MeOH from 1/0 to 95/5 to give the title compound as brown solid.
LC-MS (A): tR = 0.88 min
H NMR ((CD3)2SO) <5: 8.62 (s, 1 H), 7.77 (s broad, 2 H), 3.84 (s, 3 H)
A.10.d. Methyl 4-amino-2-chloro-5-nitro-3-((trimethylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5-nitrobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate.
LC-MS (A): tR = 1.03 min
H NMR ((CD3)2SO) <5: 8.59 (s, 1 H), 7.55 (s very broad, 2 H), 3.84 (s, 3 H), 0.31 (s, 9 H)
A.10. e. Methyl 4-amino-2-chloro-3-ethvnyl-5-nitrobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-nitro-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.85 min
H NMR ((CD3)2SO) <5: 8.57 (s, 1 H), 7.73 (s very broad, 2 H), 5.17 (s, 1 H), 3.81 (s, 3 H)
A.10.f. Methyl 4-chloro-7-nitro- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-nitrobenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate except that the reaction was additionally stirred ON at 45°C until completion.
LC-MS (A): tR = 0.86 min H NMR ((CD3)2SO) <5: 12.52 (s, 1 H), 8.56 (s, 1 H), 7.74 (m, 1 H), 6.91 (dd, λ = 3.2 Hz, J2 = 1.9 Hz, 1 H), 3.93 (s, 3 H)
A.10. g. 4-Chloro-7-nitro- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-nitro-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction was stirred for 2h at RT.
LC-MS (A): tR = 0.71 min
H NMR ((CD3)2SO) <5: 13.56 (s br, 1 H), 12.47 (s, 1 H), 8.58 (s, 1 H), 7.72 (dd, J1 = J2 = 2.6 Hz, 1 H), 6.91 (m, 1 H)
A.11. Synthesis of 4-chloro-3-methyl-1 H-indole-5-carboxylic acid
A.11.a. Methyl 4-chloro-3-methyl- 1 H-indole-5-carboxylate
To a solution of methyl 4-chloro-3-formyl-1 H-indole-5-carboxylate (0.21 mmol) in DMF (0.5 mL) was added p-toluenesulfonic acid monohydrate (0.03 mmol), p-toluenesulfonyl hydrazide (0.27 mmol) and sulfolane (0.25 mmol). The mixture was heated for 1 h at 100°C. It was cooled to RT, sodium cyanoborohydride (0.84 mmol) was added and it was heated for 1 h at 100°C. The mixture was quenched with water and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 1/0 to 6/4 to give the title compound as white solid.
LC-MS (A): tR = 0.83 min; [M+H]+: 224.03
A.11.b. 4-Chloro-3-methyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-3-methyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.69 min; [M+H]+: 210.18
A.M. Synthesis of 4,6-dichloro-1 H-indole-5-carboxylic acid
A.12. a. 2.6-Dichlorc-4-nitrobenzoic acid
A solution of 1 ,3-dichloro-2-methyl-5-nitrobenzene (4.85 mmol) in pyridine (5 mL) and water (10 mL) was heated to 90°C and KMn04 (29.1 mmol) was added portionwise. The mixture was refluxed for 2h and stirred ON at RT. It was heated to 90°C, additional amount of KMn04 (12.7 mmol) was added and it was refluxed for 7h. The mixture was filtered, the filtrate was basified with a 1 M solution of NaOH until pH 12-13 and washed with EtOAc. The aq. phase was acidified with a 1 M solution of HCI until pH 1-2 and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo to give the crude acid as orange solid.
LC-MS (A): tR = 0.45 min
LC-MS (D*): tR = 0.17 min; [M-H]-: 234.01
A.12.b. Methyl 2, 6-dichloro-4-nitrobenzoate
To a solution of 2,6-dichloro-4-nitrobenzoic acid (1.63 mmol) in DMF (5 ml_) was added cesium carbonate (2.44 mmol). The suspension was stirred for 30 min at RT and Mel (1.63 mmol) was added. The mixture was stirred for 2h, quenched with water and extracted 3 times with EtOAc. The combined organic phases were dried and concentrated in vacuo to give the title compound as yellow solid.
LC-MS (A): tR = 0.88 min
H NMR ((CD3)2SO) <5: 8.48 (s, 2 H), 3.99 (s, 3 H)
A.12.C. Methyl 4-amino-2, 6-dichlorobenzoate
To a solution of methyl 2,6-dichloro-4-nitrobenzoate (1.44 mmol) in DMF (2 ml_) was added tin(ll) chloride dihydrate (5.04 mmol). The mixture was stirred at 100°C for 40 min under microwave condition and quenched with water. It was basified with a 1 M solution of NaOH until pH 11-12 and extracted 3 times with EtOAc. The combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-NH™ from Biotage) using Hept/EtOAc from 1/0 to 1/1 to give the title compound as yellow solid.
LC-MS (A): tR = 0.78 min; [M+H]+: 220.07
A.12.d. Methyl 4-amino-2,6-dichloro-3-iodobenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2, 6-dichlorobenzoate replacing methyl 4-amino-2-chlorobenzoate except that no purification was done.
LC-MS (A): tR = 0.86 min; [M+CH3CN+H]+: 386.57 A. 12. e. Methyl 4-amino-2, 6-dichloro-3-((trimethylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2,6-dichloro-3-iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate.
LC-MS (A): tR = 1 .00 min; [M+H]+: 316.07
A. 12.f. Methyl 4-amino-2, 6-dichloro-3-ethvnylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2,6-dichloro-3-((trimethylsilyl)ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.83 min; [M+H]+: 243.91
A. 12.g. Methyl 4, 6-dichloro- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2,6-dichloro-3-ethynylbenzoate replacing methyl 4- amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.84 min
H NMR ((CD3)2SO) <5: 1 1.79 (s, 1 H), 7.62 (dd, λ = 2.9 Hz, J2 = 2.5 Hz, 1 H), 7.59 (d, J = 0.9 Hz, 1 H), 6.58 (m, 1 H), 3.91 (s, 3 H)
A. 12. h. 4.6-Dichloro- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4,6-dichloro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.68 min
LC-MS (D*): tR = 0.15 min; [M-H]-: 228.06
A.13. Synthesis of 4-chloro-6-methyl-1 H-indole-5-carboxylic acid
A. 13. a. 2-Chlorc-6-methyl-4-nitrobenzonitrile
To a solution of copper(l) cyanide (46.4 mmol) in CH3CN (60 mL) was added tert- butylnitrite (36.3 mmol). The mixture was cooled to 0°C and a solution of 2-chloro-6- methyl-4-nitroaniline (20.2 mmol) was added dropwise for 10 min. The mixture was heated for 2h at 70°C, quenched with a 10% solution of Na2C03 and the pH was adjusted to 1 1 with a 1 M solution of NaOH. It was extracted 3 times with EtOAc and the combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 1/0 to 94/6 to give the title compound as yellow solid.
LC-MS (A): tR = 0.85 min
H NMR ((CD3)2SO) <5: 8.41 (s, 1 H), 8.36 (s, 1 H), 2.66 (s, 3 H)
A.13.b. 2-Chloro-6-methyl-4-nitrobenzoic acid
To a suspension of 2-chloro-6-methyl-4-nitrobenzonitrile (5.09 mmol) in 2-propanol (1 1 ml_) and water (1 1 ml_) was added KOH (25.4 mmol). The mixture was heated for 1 h at 60°C, diluted with water and extracted 3 times with EtOAc. The combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo to give the primary amide intermediate as brown oil (LC-MS (A): tR = 0.58 min).
The crude primary amide was suspended in water (2.54 ml_) and H2S04 (7.63 ml_) and heated to 80°C. Sodium nitrite (9.16 mmol) was added portionwise and the mixture was stirred for 1 h at 80°C. It was quenched with water, basified with a 32% solution of NaOH until pH 13-14 and washed 3 times with EtOAc. The aqueous phase was acidified with a 24% solution of HCI until pH 1-2 and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as brown oil.
LC-MS (A): tR = 0.62 min
H NMR ((CD3)2SO) <5: 12.07 (s br, 1 H), 8.22 (dd, λ = 2.2 Hz, J2 = 0.4 Hz, 1 H), 8.20 (dd, i = 2.1 Hz, J2 = 0.6 Hz, 1 H), 2.43 (s, 3 H)
A.13.C. Methyl 2-chlorc-6-methyl-4-nitrobenzoate
This compound was prepared using a method analogous to that of methyl 2,6-dichloro-4- nitrobenzoate, 2-chloro-6-methyl-4-nitrobenzoic acid replacing 2,6-dichloro-4-nitrobenzoic acid.
LC-MS (A): tR = 0.87 min
H NMR ((CD3)2SO) <5: 8.26 (dd, λ = 2.0 Hz, J2 = 0.4 Hz, 1 H), 8.23 (dd, λ = 2.0 Hz, J2 = 0.6 Hz, 1 H), 3.96 (s, 3 H), 2.41 (s, 3 H) A.13.d. Methyl 4-amino-2-chloro-6-methylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2,6- dichlorobenzoate, methyl 2-chloro-6-methyl-4-nitrobenzoate replacing methyl 2,6-dichloro- 4-nitrobenzoate except that the mixture was heated for 15 min at 100°C under microwave conditions.
LC-MS (A): tR = 0.72 min; [M+CH3CN+H]+: 241.05
A.13.e. Methyl 4-amino-2-chloro-3-iodo-6-methylbenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-6-methylbenzoate replacing methyl 4-amino-2-chlorobenzoate.
LC-MS (A): tR = 0.84 min; [M+CH3CN+H]+: 366.86
The other regioisomer, methyl 4-amino-2-chloro-5-iodo-6-methylbenzoate, was additionally isolated.
LC-MS (A): tR = 0.85 min; [M+CH3CN+H]+: 366.87
A.13.f. Methyl 4-amino-2-chloro-6-methyl-3-((trimethylsilyl)ethynyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-6-methyl benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4- amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 0.98 min; [M+H]+: 296.12
A.13.g. Methyl 4-amino-2-chloro-3-ethynyl-6-methylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-6-methyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.80 min; [M+H]+: 224.09
A.13.h. Methyl 4-chloro-6-methyl- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-6-methylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.82 min; [M+H]+: 224.09 A.13.1. 4-Chloro-6-methyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4,6-dichloro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.66 min
LC-MS (D*): tR = 0.16 min; [M-H]-: 208.13
A.14. Synthesis of 3-bromo-4-chloro-7-methyl-1 H-indole-5-carboxylic acid
A.14. a. Methyl 3-bromo-4-chloro- 1 -methyl- 1 H-indole-5-carboxylate
To a solution of methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate (0.47 mmol) in chlorobenzene (0.47 ml_) was added at 55°C NBS (0.52 mmol) and AIBN (0.05 mmol). The mixture was stirred for 30 min at 55°C, diluted with DCM and filtered. The filtrate was washed with a 1 M solution of HCI, dried over MgS04 and concentrated in vacuo. The crude was purified by preparative LC-MS using method II to give the title compound as orange solid.
LC-MS (A): tR = 0.90 min
H NMR ((CD3)2SO) <5: 12.45 (s br, 1 H), 7.44 (s, 1 H), 6.73 (s, 1 H), 3.85 (s, 3 H), 2.47 (s, 3 H)
A.14.b. 3-Bromo-4-chloro-7-methyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 3-bromo-4-chloro-7-methyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.77 min
LC-MS (D*): tR = 0.43 min; [M-H]-: 287.94
A.15. Synthesis of 4-chloro-7-isobutyl-1 H-indole-5-carboxylic acid
A.15. a. Methyl 4-amino-2-chloro-5-isobutylbenzoate
To a solution of methyl 4-amino-2-chloro-5-iodobenzoate (3.36 mmol) in toluene/water 20/1 (40 mL) was added under argon K3P04 (11.8 mmol), PdCI2(PPh3)2 (0.34 mmol) and (2-methylpropyl)boronic acid (6.72 mmol). The mixture was heated ON at 110°C in a sealed vial, quenched with water and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 1/0 to 0/1 to give the title compound as yellow oil.
LC-MS (A): tR = 0.90 min; [M+CH3CN+H]+: 283.06
A.15.b. Methyl 4-amino-2-chloro-3-iodo-5-isobutylbenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-isobutylbenzoate replacing methyl 4-amino-2-chlorobenzoate.
LC-MS (A): tR = 0.97 min; [M+CH3CN+H]+: 408.77
A.15.C. Methyl 4-amino-2-chloro-5-isobutyl-3-((t methylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5- isobutylbenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.07 min; [M+H]+: 337.90
A.15.d. Methyl 4-amino-2-chloro-3-ethvnyl-5-isobutylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-isobutyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.94 min; [M+H]+: 266.07
A.15.e. Methyl 4-chloro-7-isobutyl-1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-isobutylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.94 min; [M+H]+: 266.16
A.15.f. 4-Chloro-7-isobutyl-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-isobutyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.82 min, [M+H]+: 252.06 A.16. Synthesis of 4-chloro-7-(3-methoxypropyl)-1 H-indole-5-carboxylic acid
A.16. a. Methyl 4-amino-2-chloro-5-(3-methoxyprop- 1-yn- 1-yl)benzoate
To a mixture of methyl 4-amino-2-chloro-5-iodobenzoate (3.51 mmol), Pd(PPh3)2CI2 (0.18 mmol) and Cul (0.18 mmol) was sequentially added under argon THF (12 ml_), Et3N (14 mmol) and methyl propargyl ether (14 mmol). The mixture was stirred for 1 h at RT, diluted with EtOAc and filtered. The filtrate was concentrated in vacuo and the crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 85/15 to 40/60 to give the title compound as orange solid.
LC-MS (A): tR = 0.82 min, [M+H]+: 253.99
A.16.b. Methyl 4-amino-2-chloro-5-(3-methoxypropyl)benzoate
To a solution of methyl 4-amino-2-chloro-5-(3-methoxyprop-1-yn-1-yl)benzoate (3.48 mmol) in EtOH (14 ml_) was added Pt02 (0.35 mmol). The mixture was stirred under a hydrogen atmosphere for 2h. It was filtered over Celite, washed with EtOH and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 1/0 to 8/2 to give the title compound as yellow oil.
LC-MS (A): tR = 0.80 min, [M+H]+: 257.90
A.16.C. Methyl 4-amino-2-chloro-3-iodo-5-(3-methoxypropyl)benzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-(3-methoxypropyl)benzoate replacing methyl 4-amino-2-chlorobenzoate.
LC-MS (A): tR = 0.90 min; [M+H]+: 383.91
A.16.d. Methyl 4-amino-2-chloro-5-(3-methoxypropyl)-3-((trimethylsilyl)ethynyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5-(3- methoxypropyl)benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.00 min; [M+H]+: 353.85
A.16.e. Methyl 4-amino-2-chloro-3-ethynyl-5-(3-methoxypropyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-(3-methoxypropyl)-3-((trimethylsilyl) ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate. LC-MS (A): tR = 0.85 min; [M+H]+: 281.83
A.16.f. Methyl 4-chloro-7-(3-methoxypropyl)- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-(3-methoxypropyl)benzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.86 min; [M+H]+: 282.07
A.16.g. 4-Chloro-7-(3-methoxypropyl)- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-(3-methoxypropyl)-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.72 min, [M+H]+: 268.07
A.17. Synthesis of 4-methyl-1 H-indole-5-carboxylic acid
A.17. a. Methyl 4-methyl- 1 H-indole-5-carboxylate
Methyl 4-chloro-1 H-indole-5-carboxylate (0.48 mmol), K2C03 (1.91 mmol) and PEPPSI™- IPr (0.05 mmol) were placed in a pressure vessel and anh. dioxane (2 mL) and trimethylboroxine (0.23 mL) were added sequentially. The tube was sealed under argon and heated at 115°C. After 17h, the reaction mixture was cooled to RT, filtered over a pad of Celite and the cake was washed with EtOAc. The filtrate was concentrated in vacuo and the crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 96/4 to 50/50 to give the title compound as white solid.
LC-MS (A): tR = 0.78 min, [M+H]+: 190.10
A.17.b. 4-Methyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-methyl- 1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction mixture was stirred for 16h at 60°C.
LC-MS (A): tR = 0.64 min
LC-MS (D*): tR = 0.15 min, [M-H]-: 173.91 A.18. Synthesis of 4-chloro-7-methoxy-1 H-indole-5-carboxylic acid
A.18. a. 1-Chloro-4-methoxy-2-methyl-5-nitrobenzene
To a suspension of 4-chloro-5-methyl-2-nitrophenol (5.33 mmol) and K2C03 (10.70 mmol) in DMF (11 ml_) was added methyl iodide (5.86 mmol) and the mixture was stirred for 6h at RT. It was quenched with half saturated NaHC03 solution and extracted three times with EtOAc. The organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Isolute Flash Si II from Biotage) using Hept/EtOAc from 85/15 to 80/20 to give the title compound as yellow solid.
LC-MS (A): tR = 0.88 min
H NMR ((CD3)2SO) <5: 8.01 (s, 1 H), 7.44 (s, 1 H), 3.93 (s, 3 H), 2.42 (s, 3 H)
A.18.b. 2-Chloro-5-methoxy-4-nitrobenzoic acid
To a suspension of 1-chloro-4-methoxy-2-methyl-5-nitrobenzene (4.32 mmol) in H20 (207 ml_) was added KMn04 (17.30 mmol) and the mixture was refluxed for 3h and filtered to remove solids. The filtrate was quenched with a 40% NaHS03 solution, acidified with a 1 M HCI solution until pH 1-2 and extracted three times with EtOAc. The organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as light yellow solid.
LC-MS (A): tR = 0.69 min
LC-MS (D*): tR = 0.26 min, [M-H]-: 230.04
A.18.C. 4-Aminc-2-chlorc-5-methoxybenzoic acid
This compound was prepared using a method analogous to that of methyl 4-amino-2,6- dichlorobenzoate, 2-chloro-5-methoxy-4-nitrobenzoic acid replacing methyl 2,6-dichloro-4- nitrobenzoate except that the mixture was heated for 15 min at 100°C under microwave conditions.
LC-MS (A): tR = 0.59 min; [M+CH3CN+H]+: 242.70
A.18.d. Methyl 4-aminc-2-chlorc-5-methoxybenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 4-amino-2-chloro-5-methoxybenzoic acid replacing 4-amino-2- chlorobenzoic acid.
LC-MS (A): tR = 0.75 min; [M+H]+: 216.14 A.18.e. Methyl 4-amino-2-chloro-3-iodo-5-methoxybenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-methoxybenzoate replacing methyl 4-amino-2-chlorobenzoate.
LC-MS (A): tR = 0.85 min; [M+H]+: 341.67
A.18.f. Methyl 4-amino-2-chloro-5-methoxy-3-((trimethylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5- methoxybenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 0.99 min; [M+H]+: 311.94
A.18.g. Methyl 4-amino-2-chloro-3-ethvnyl-5-methoxybenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-methoxy-3-((trimethylsilyl)ethynyl)- benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.81 min; [M+H]+: 240.02
A.18. h. Methyl 4-chloro-7-methoxy- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-methoxybenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.82 min; [M+H]+: 239.95
A.181 4-Chloro- 7-methoxy- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-methoxy-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.68 min, [M+H]+: 226.08
A.19. Synthesis of 4,7-dimethyl-1 H-indole-5-carboxylic acid
A.19. a. 4-Aminc-2,5-dimethylbenzonitrile
4-Bromo-2,5-dimethylaniline (5 mmol), zinc cyanide (6 mmol) and Pd(PPh3)4 (0.1 mmol) were placed in a pressure vessel and anh. DMF (3 mL) was added. The tube was sealed under argon and heated at 110°C. After 35h, it was quenched with a 10% Na2C03 solution and extracted three times with EtOAc. The organic phase was washed with a sat. NaHC03 solution, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 92/8 to 40/60 to give the title compound as white solid.
LC-MS (A): tR = 0.72 min, [M+H]+: 147.16
A.19. b. 4-Amino-3-iodo-2,5-dimethylbenzonitrile
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, 4-amino- 2,5-dimethylbenzonitrile replacing methyl 4-amino-2-chlorobenzoate.
LC-MS (A): tR = 0.85 min; [M+CH3CN+H]+: 313.83
A.19.C. 4-Amino-2,5-dimethyl-3-((trimethylsilyl)ethvnyl)benzonitrile
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, 4-amino-3-iodo-2,5-dimethylbenzonitrile replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- ch I o ro- 5- i odo be nzoate .
LC-MS (A): tR = 1.00 min; [M+H]+: 243.13
A.19.d. 4-Amino-3-ethvnyl-2,5-dimethylbenzonitrile
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, 4-amino-2,5-dimethyl-3-((trimethylsilyl)ethynyl)benzonitrile replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.81 min; [M+CH3CN+H]+: 212.12
A.19.e. 4, 7-Di methyl- 1 H-indole-5-carbonitrile
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, 4-amino-3-ethynyl-2,5-dimethylbenzonitrile replacing methyl 4- amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.81 min; [M+CH3CN+H]+: 212.13
H NMR ((CD3)2SO) <5: 1 1.64 (s br, 1 H), 7.52 (dd, J1 = J2 = 2.8 Hz, 1 H), 7.17 (s, 1 H), 6.67 (dd, 4 = 2.9 Hz, J2 = 1.9 Hz, 1 H), 2.63 (s, 3 H), 2.47 (s, 3 H) A.19.f. 4, 7-Di methyl- 1 H-indole-5-carboxylic acid
To a solution of 4,7-dimethyl-1 H-indole-5-carbonitrile (0.19 mmol) in EtOH (1 mL) was added a 4M KOH solution (3.9 mL) and the mixture was heated for 18h at 120°C. It was partitioned between water and EtOAc, the aqueous phase was acidified with a 25% HCI solution until pH 1-2 and extracted three times with EtOAc. The organic phases were dried over MgS04 and concentrated in vacuo to give the title compound as white solid.
LC-MS (A): tR = 0.68 min; [M+H]+: 190.18
A.20. Synthesis of 4-ethyl-1 H-indole-5-carboxylic acid
A.20.a. Methyl 4-ethyl- 1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-methyl-1 H- indole-5-carboxylate, vinylboronic acid pinacol ester replacing trimethylboroxine.
LC-MS (A): tR = 0.80 min, [M+H]+: 202.20
A.20.b. Methyl 4-ethyl- 1H-indole-5-carboxylate
To a solution of methyl 4-vinyl-1 H-indole-5-carboxylate (0.21 mmol) in EtOH (2 mL) was added platinum dioxide (0.021 mmol). The mixture was stirred under a hydrogen atmosphere for 2h, filtered over Celite and concentrated in vacuo to give the title compound as pinkish solid.
LC-MS (A): tR = 0.83 min, [M+H]+: 204.18
A.20.C. 4-Ethyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-ethyl-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.70 min, [M+CH3CN+H]+: 231.08
A.21. Synthesis of 4-chloro-7-acetyl-1 H-indole-5-carboxylic acid
A.21. a. Methyl 4-amino-2-chloro-3.5-diiodobenzoate
To a suspension of methyl 4-amino-2-chlorobenzoate (10.8 mmol) in EtOH (100 mL) was added iodine (23.7 mmol) and silver sulfate (10.8 mmol) under argon. The mixture was stirred for 2h, filtered and the filtrate was treated with a 10% aq. solution of sodium thiosulfate. After evaporation of EtOH, the residue was partitioned between EtOAc and a 1 M aq. solution of NaOH. The organic phase was washed with a 1 M aq. solution of NaOH and brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC using DCM and the solid was triturated in CH3CN and filtered to give the title compound as beige solid.
LC-MS (A): tR = 0.92 min
H NMR ((CD3)2SO) <5: 8.13 (s, 1 H), 6.02 (s, 2 H), 3.79 (s, 3 H)
A.21.b. Methyl 4-amino-2-chloro-3-iodo-5-((trimethylsilyl)ethvnyl)benzoate
A solution of methyl 4-amino-2-chloro-3,5-diiodobenzoate (9.6 mmol) in Et3N (80 mL) and toluene (80 mL) was treated under argon with PPh3 (0.96 mmol), Cul (4.80 mmol), Pd(PPh3)2CI2 (0.48 mmol) and trimethylsilylacetylene (10.1 mmol). The mixture was stirred for 2h at RT, quenched with a 10% aq. solution of NH4CI and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 100/0 to 85/15 to give the title compound as light orange solid.
LC-MS (A): tR = 1.05 min; [M+H]+: 408.02
A.21.C. Methyl 5-acetyl-4-amino-2-chloro-3-iodobenzoate
A solution of methyl 4-amino-2-chloro-3-iodo-5-((trimethylsilyl)ethynyl)benzoate (4.39 mmol) in toluene (20 mL) was treated with 4-toluene sulfonic acid monohydrate (1 1 mmol). The mixture was stirred for 3h at 80°C and poured into water. The aq. phase was basified with a 32% aq. solution of NaOH until pH=12-13 and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept/EtOAc from 100/0 to 75/25 to give the title compound as light yellow solid.
LC-MS (A): tR = 0.88 min
H NMR ((CD3)2SO) <5: 8.37 (s, 1 H), 8.00 (s br, 2 H), 3.83 (s, 3 H), 2.63 (s, 3 H)
A.21.d. Methyl 5-acetyl-4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 5-acetyl-4-amino-2-chloro-3- iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.03 min; [M+H]+: 324.25 A.21.e. Methyl 5-acetyl-4-amino-2-chloro-3-ethvnylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 5-acetyl-4-amino-2-chloro-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.84 min; [M+H]+: 251 .99
A.21.f. Methyl 7-acetyl-4-chloro- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 5-acetyl-4-amino-2-chloro-3-ethynylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.83 min
H NMR ((CD3)2SO) <5: 1 1.96 (s, 1 H), 8.32 (s, 1 H), 7.56 (dd, J1 = J2 = 2.9 Hz, 1 H), 6.74 (dd, ^ = 2.1 Hz, J2 = 3.2 Hz, 1 H), 3.92 (s, 3 H), 2.72 (s, 3 H)
A.21.g. 7-Acetyl-4-chloro- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-acetyl-4-chloro-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.69 min
H NM R ((CD3)2SO) <5: 13.25 (s, 1 H), 1 1 .91 (s, 1 H), 8.34 (s, 1 H), 7.54 (dd, J1 = J2 = 2.9 Hz, 1 H), 6.72 (dd, λ = 2.1 Hz, J2 = 3.1 Hz, 1 H), 2.72 (s, 3 H)
A.22. Synthesis of 7-methyl-4-(trifluoromethyl)-1H-indole-5-carboxylic acid
A.22.a. Methyl 4-amino-2-(trifluoromethyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 4-amino-2-(trifluoromethyl)benzoic acid replacing 4-amino-2- chlorobenzoic acid.
LC-MS (A): tR = 0.77 min, [M+H]+: 220.04
A.22.b. Methyl 4-amino-5-iodo-2-(trifluoromethyl)benzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-(trifluoromethyl)benzoate replacing methyl 4-amino-2-chlorobenzoate except that only the 5-iodo regioisomer was isolated. LC-MS (A): tR = 0.88 min, [M+H]+: 345.7
A.22.C. Methyl 4-amino-5-methyl-2-(trifluoromethyl)benzoate
To a solution of methyl 4-amino-5-iodo-2-(trifluoromethyl)benzoate (24.6 mmol) in dioxane (49 ml_) was added under argon a 2M solution of methylzinc chloride in THF (61.6 mmol) followed by Pd(dppf)CI2.DCM (1.72 mmol). The mixture was stirred for 30 min at 65°C in a sealed vial, diluted with EtOAc and filtered. The filtrate was washed with a sat. solution of Rochelle salt and with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using DCM to give the title compound as brown solid.
LC-MS (A): tR = 0.81 min; [M+H]+: 234.01
A.22.d. Methyl 4-amino-3-iodo-5-methyl-2-(trifluoromethyl)benzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-5-methyl-2-(trifluoromethyl)benzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 7h at 50°C.
LC-MS (A): tR = 0.88 min, [M+H]+: 400.78
A.22.e. Methyl 4-amino-5-methyl-2-(trifluoromethyl)-3-((t methylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-3-iodo-5-methyl-2- (trifluoromethyl)benzoate replacing the mixture of methyl 4-amino-2-chloro-3- iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate except that the reaction mixture was stirred for 3h30 at 70°C.
LC-MS (A): tR = 1.02 min; [M+H]+: 330.09
A.22.f. Methyl 4-amino-3-ethynyl-5-methyl-2-(trifluoromethyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-5-methyl-2-(trifluoromethyl)-3-((trimethylsilyl) ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.85 min; [M+H]+: 257.90 A.22.g. Methyl 7-methyl-4-(trifluoromethyl)-1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-3-ethynyl-5-methyl-2-(trifluoromethyl)benzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.86 min
H NMR ((CD3)2SO) <5: 1 1.87 (s, 1 H), 7.68 (dd, J1 = J2 = 2.8 Hz, 1 H), 7.22 (s, 1 H), 6.65 (m, 1 H), 3.85 (s, 3 H), 2.58 (s, 3 H)
A.22.h. 7-Methyl-4-(trifluoromethyl)- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-methyl-4-(trifluoromethyl)-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate except that the reaction mixture was stirred ON at 60°C.
LC-MS (A): tR = 0.73 min
H NMR ((CD3)2SO) <5: 13.07 (s br, 1 H), 11.79 (s, 1 H), 7.65 (dd, J1 = J2 = 2.7 Hz, 1 H), 7.21 (s, 1 H), 6.63 (m, 1 H), 2.57 (s, 3 H)
A.23. Synthesis of 4-chloro-7-ethyl-1 H-indole-5-carboxylic acid
A.23.a. Methyl 4-aminc-2-chlorc-5-ethvnyl-3-iodobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-3-iodo-5-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.88 min
H NMR ((CD3)2SO) <5: 7.76 (s, 1 H), 6.17 (s, 2 H), 4.65 (s, 1 H), 3.78 (s, 3 H)
A.23.b. Methyl 4-amino-2-chloro-5-ethyl-3-iodobenzoate
To a solution of methyl 4-amino-2-chloro-5-ethynyl-3-iodobenzoate (0.99 mmol) in EtOH (4 mL) was added platinum (IV) oxide (0.099 mmol). The mixture was stirred under a hydrogen atmosphere for 1 h, filtered over Celite and concentrated in vacuo. The crude was purified by CC using DCM to give the title compound as light yellow solid.
LC-MS (A): tR = 0.90 min, [M+H]+: 339.83 A.23.C. Methyl 4-amino-2-chloro-5-ethyl-3-((trimethylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-5-ethyl-3-iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- chloro-5-iodobenzoate except that the reaction was stirred for 30 min at 80°C.
LC-MS (A): tR = 1.03 min; [M+H]+: 310.22
A.23.d. Methyl 4-amino-2-chloro-5-ethyl-3-ethvnylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-ethyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.86 min; [M+H]+: 238.21
A.23.e. Methyl 4-chloro- 7 -ethyl- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-5-ethyl-3-ethynylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.86 min, [M+H]+: 238.05
A.23.f. 4-Chloro-l '-ethyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-methyl-4-(trifluoromethyl)-1 H-indole-5-carboxylate replacing methyl 4-chloro- 7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.73 min, [M+H]+: 224.20
A.24. Synthesis of 7-chloro-4-methyl-1H-indole-5-carboxylic acid
A.24.a. Methyl 4-acetamido-5-chloro-2-(((trifluoromethyl)sulfonyl)oxy)benzoate
To a solution of methyl 4-acetamido-5-chloro-2-hydroxybenzoate (20.5 mmol) in DCM (100 mL) was added at 0°C Et3N (22.6 mmol) and trifluoromethanesulfonic anhydride (22.6 mmol). The mixture was stirred for 1 h at RT, quenched with a sat. solution of NaHC03 and extracted with DCM. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 100/0 to 65/35 to give the title compound as light yellow solid.
LC-MS (A): tR = 0.90 min H NMR ((CD3)2SO) <5: 9.94 (s, 1 H), 8.35 (s, 1 H), 8.14 (s, 1 H), 3.88 (s, 3 H), 2.23 (s, 3 H)
A.24.b. Methyl 4-acetamido-5-chloro-2-methylbenzoate
A suspension of methyl 4-acetamido-5-chloro-2-(((trifluoromethyl)sulfonyl)oxy)benzoate (2.61 mmol), K3P04 (5.23 mmol), methylboronic acid (5.23 mmol) and Pd(dppf)CI2.DCM (0.26 mmol) in THF (26 ml_) was stirred under argon for 2h at 65°C. The reaction mixture was quenched with a sat. solution of NaHC03 and extracted three times with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 100/0 to 60/40 to give the title compound as white solid.
LC-MS (A): tR = 0.77 min, [M+H]+: 241.90
A.24.C. Methyl 4-amino-5-chloro-2-methylbenzoate
To a solution of methyl 4-acetamido-5-chloro-2-methylbenzoate (2.25 mmol) in MeOH (14 ml_) was added K2C03 (2.48 mmol). The suspension was stirred for 3 days at RT, MeOH was evaporated off and the residue was partitioned between EtOAc and a 1 M solution of HCI. The aq. phase was extracted twice with EtOAc and the combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 100/0 to 80/20 to give the title compound as white solid.
LC-MS (A): tR = 0.81 min, [M+H]+: 200.12
A.24.d. Methyl 4-amino-5-chloro-3-iodo-2-methylbenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-5-chloro-2-methylbenzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 1 h at RT.
LC-MS (A): tR = 0.91 min
H NMR ((CD3)2SO) <5: 7.76 (s, 1 H), 6.02 (s, 2 H), 3.77 (s, 3 H), 2.65 (s, 3 H)
A.24.e. Meth yl 4-amino-5-chloro-2-meth yl-3- ((trimethylsilyl) eth yn yl) benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-5-chloro-3-iodo-2-methyl benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4- amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.06 min; [M+H]+: 296.14
A.24.f. Methyl 4-amino-5-chloro-3-ethvnyl-2-methylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-5-chloro-2-methyl-3-
((trimethylsilyl)ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-
((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.88 min; [M+H]+: 224.03
A.24.Q. Methyl 7-chloro-4-methyl-1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-5-chloro-3-ethynyl-2-methylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.86 min, [M+H]+: 223.46
A.24.h. 7-Chloro-4-methyl-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-chloro-4-methyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.72 min
H NMR ((CD3)2SO) <5: 12.62 (s, 1 H), 1 1.77 (s, 1 H), 7.67 (s, 1 H), 7.49 (dd, J1 = J2 = 2.8 Hz, 1 H), 6.78 (dd, λ = 2.0 Hz, J2 = 3.0 Hz, 1 H), 2.75 (s, 3 H)
A.25. Synthesis of 7-methoxy-4-methyl-1H-indole-5-carboxylic acid
A.25.a. 5-Methoxy-2-methyl-4-nitrobenzonitrile
This compound was prepared using a method analogous to that of 2-chloro-6-methyl-4- nitrobenzonitrile, 5-methoxy-2-methyl-4-nitroaniline replacing 2-chloro-6-methyl-4- nitroaniline except that the reaction mixture was stirred for 1 h at 85°C and ON at RT.
LC-MS (A): tR = 0.82 min
H NMR ((CD3)2SO) <5: 8.00 (s, 1 H), 7.88 (s, 1 H), 3.95 (s, 3 H), 2.47 (s, 3 H) A.25.b. 5-Methoxy-2-methyl-4-nitrobenzoic acid
This compound was prepared using a method analogous to that of 2-chloro-6-methyl-4- nitrobenzoic acid, 5-methoxy-2-methyl-4-nitrobenzonitrile replacing 2-chloro-6-methyl-4- nitrobenzonitrile.
LC-MS (A): tR = 0.82 min
LC-MS (D*): tR = 0.17 min; [M-H]-: 210.19
A.25.C. Methyl 5-methoxy-2-methyl-4-nitrobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 5-methoxy-2-methyl-4-nitrobenzoic acid replacing 4-amino-2-chloro- benzoic acid.
LC-MS (A): tR = 0.85 min
H NMR ((CD3)2SO) <5: 7.87 (s, 1 H), 7.64 (s, 1 H), 3.95 (s, 3 H), 3.89 (s, 3 H), 2.46 (s, 3 H)
A.25.d. Methyl 4-aminc-5-methoxy-2-methylbenzoate
To a solution of methyl 5-methoxy-2-methyl-4-nitrobenzoate (2.13 mmol) in MeOH (21 ml_) was added zinc dust (21.3 mmol) at RT followed by ammonium formate (21.3 mmol) at 0°C. The mixture was stirred for 1 h at RT, filtered over Celite and the filtrate was concentrated in vacuo. The residue was partitioned between EtOAc and a sat. solution of NaHC03. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC using DCM/MeOH from 100/0 to 99/1 to give the title compound as light yellow solid.
LC-MS (A): tR = 0.71 min; [M+H]+: 196.15
A.25.e. Methyl 4-aminc-3-iodc-5-methoxy-2-methylbenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-5-methoxy-2-methylbenzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 1 h at RT.
LC-MS (A): tR = 0.87 min, [M+H]+: 321.73 A.25.f. Methyl 4-amino-5-methoxy-2-methyl-3-((trimethylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-3-iodo-5-methoxy-2-methyl benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4- amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.01 min; [M+H]+: 292.21
A.25.g. Methyl 4-amino-3-ethvnyl-5-methoxy-2-methylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino- 5-methoxy-2-methyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.83 min; [M+H]+: 220.13
A.25.h. Methyl 7-methoxy-4-methyl- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-3-ethynyl-5-methoxy-2-methylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.81 min; [M+H]+: 220.07
Α.25.Ί. l-Methoxy-4- ethyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 7-methoxy-4-methyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.67 min; [M+H]+: 206.15
A.26. Synthesis of 4-chloro-7-ethoxy-1 H-indole-5-carboxylic acid
A.26.a. 4-Aminc-2-chlorc-5-methoxybenzonitrile
This compound was prepared using a method analogous to that of 4-amino-2,5- dimethylbenzonitnle, 4-bromo-5-chloro-2-methoxyaniline replacing 4-bromo-2,5-dimethyl aniline except that the reaction mixture was stirred ON at 110°C.
LC-MS (A): tR = 0.76 min, [M+H]+: 183.19
A.26.b. 4-Amino-2-chloro-3-iodo-5-methoxybenzonitrile
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, 4-amino- 2-chloro-5-methoxybenzonitrile replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 45 min at RT.
LC-MS (A): tR = 0.86 min
H NMR ((CD3)2SO) <5: 7.33 (s, 1 H), 6.1 1 (s, 2 H), 3.85 (s, 3 H)
A.26.C. 4-Amino-2-chloro-5-methoxy-3-((trimethylsilyl)ethvnyl)benzonit le
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, 4-amino-2-chloro-3-iodo-5-methoxybenzonitrile replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- ch I o ro- 5- i odo be nzoate .
LC-MS (A): tR = 1.00 min; [M+H]+: 279.04
A.26.d. 4-Amino-2-chloro-3-ethvnyl-5-methoxybenzonitrile
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, 4-amino-2-chloro-5-methoxy-3-((trimethylsilyl)ethynyl) benzonitrile replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.82 min; [M+CH3CN+H]+: 248.23
A.26.e. 4-Chloro-7-methoxy-1H-indole-5-carbonitrile
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, 4-amino-2-chloro-3-ethynyl-5-methoxybenzonitrile replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.83 min, [M+CH3CN+H]+: 248.23
H NMR ((CD3)2SO) <5: 12.23 (s, 1 H), 7.56 (d, J = 3.1 Hz, 1 H), 7.14 (s, 1 H), 6.61 (d, J = 3.1 Hz, 1 H), 3.99 (s, 3 H)
A.26.f. 4-Chloro-7-hvdroxy-1H-indole-5-carbonitrile
To a solution of 4-chloro-7-methoxy-1 H-indole-5-carbonitrile (2.53 mmol) in DCM (106 mL) was added dropwise a 1 M solution of BBr3 in DCM (14.8 mmol) at -78°C. The mixture was allowed to warm up to RT and stirred for 15h at 45°C then for 4h30 at 55°C. It was quenched with MeOH (40 mL) and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using EtOAc/MeOH from 100/0 to 90/10 to give the title compound as brownish solid.
LC-MS (A): tR = 0.75 min H NMR ((CD3)2SO) <5: 11.99 (s, 1 H), 10.69 (s, 1 H), 7.54 (dd, J1 = J2 = 2.8 Hz, 1 H), 6.80 (s, 1 H), 6.57 (m, 1 H)
A26.g. 4-Chloro-7-ethoxy-1H-indole-5-carbonitrile
To a solution of 4-chloro-7-hydroxy-1 H-indole-5-carbonitrile (1.31 mmol) in DMF (2.6 ml_) was added at 0°C K2C03 (1.58 mmol) and ethyl bromide (1.44 mmol). The mixture was stirred ON at RT, quenched with water and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP- Sil™ from Biotage) using Hept/EtOAc from 100/0 to 50/50 to give the title compound as white solid.
LC-MS (A): tR = 0.88 min, [M+CH3CN+H]+: 262.10
A.26.h. 4-Chloro-7-ethoxy- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4,7-dimethyl-1 H- indole-5-carboxylic acid, 4-chloro-7-ethoxy-1 H-indole-5-carbonitrile replacing 4,7-dimethyl- 1 H-indole-5-carbonitrile.
LC-MS (A): tR = 0.73 min; [M+H]+: 240.05
A.27. Synthesis of 4-chloro-7-hydroxy-1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4,7-dimethyl-1 H- indole-5-carboxylic acid, 4-chloro-7-hydroxy-1 H-indole-5-carbonitrile replacing 4,7- dimethyl-1 H-indole-5-carbonitrile.
LC-MS (A): tR = 0.60 min; [M+CH3CN+H]+: 253.02
A.28. Synthesis of 4-chloro-7-propyl-1 H-indole-5-carboxylic acid
A.28.a. Methyl 4-aminc-2-chlorc-5-propylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-5-isobutylbenzoate, 1-propylboronic acid replacing (2-methylpropyl)boronic acid. LC-MS (A): tR = 0.86 min; [M+H]+: 228.15
A.28.b. Methyl 4-aminc-2-chlorc-3-iodc-5-propylbenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-propylbenzoate replacing methyl 4-amino-2-chlorobenzoate.
LC-MS (A): tR = 0.94 min; [M+H]+: 353.66 A.28.C. Methyl 4-amino-2-chloro-5-propyl-3-((trimethylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-3-iodo-5- propylbenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.05 min; [M+H]+: 324.10
A.28.d. Methyl 4-amino-2-chloro-3-ethvnyl-5-propylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-propyl-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.90 min; [M+H]+: 252.25
A.28.e. Methyl 4-chloro-l '-propyl- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-3-ethynyl-5-propylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.91 min; [M+H]+: 252.21
A.28.f. 4-Chloro-l -propyl- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-propyl-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.78 min, [M+H]+: 238.19
A.29. Synthesis of 7-(2-(tert-butoxy)ethoxy)-4-chloro-1H-indole-5-carboxylic acid
A.29.a. 7-(2-(tert-Butoxy)ethoxy)-4-chloro-1H-indole-5-carbonitrile
This compound was prepared using a method analogous to that of 4-chloro-7-ethoxy-1 H- indole-5-carbonitrile, 2-(2-bromoethoxy)-2-methylpropane replacing ethyl bromide except that the reaction mixture was stirred for 8h at 80°C.
LC-MS (A): tR = 0.94 min, [M+CH3CN+H]+: 334.12 A.29.b. 7-(2-(tert-Butoxy)ethoxy)-4-chloro-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4,7-dimethyl-1 H- indole-5-carboxylic acid, 7-(2-(tert-butoxy)ethoxy)-4-chloro-1 H-indole-5-carbonitrile replacing 4,7-dimethyl-1 H-indole-5-carbonitrile.
LC-MS (A): tR = 0.80 min; [M+CH3CN+H]+: 353.16
H NMR ((CD3)2SO) <5: 12.86 (s very br, 1 H), 11.74 (s, 1 H), 7.43 (dd, = J2 = 2.7 Hz, 1 H), 7.17 (s, 1 H), 6.58 (m, 1 H), 4.26 (m, 2 H), 3.74 (m, 2 H), 1.18 (s, 9 H)
A.30. Synthesis of 4,7-difluoro-1 H-indole-5-carboxylic acid
A.30.a. Methyl 2, 5-difluorc-4-nitrobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 2,5-difluoro-4-nitrobenzoic acid replacing 4-amino-2-chlorobenzoic acid.
LC-MS (A): tR = 0.80 min
H NMR ((CD3)2SO) <5: 8.31 (dd, λ = 6.0 Hz, J2 = 9.7 Hz, 1 H), 8.07 (dd, λ = 5.8 Hz, J2 = 10.9 Hz, 1 H), 3.92 (s, 3 H)
A.30.b. Methyl 4-amino-2,5-difluorobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-5- methoxy-2-methylbenzoate, methyl 2,5-difluoro-4-nitrobenzoate replacing methyl 5- methoxy-2-methyl-4-nitrobenzoate.
LC-MS (A): tR = 0.70 min, [M+H]+: 188.22
A.30.C. Methyl 4-amino-2, 5-difluorc-3-iodobenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2,5-difluorobenzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 1 h at RT.
LC-MS (A): tR = 0.81 min
H NMR ((CD3)2SO) <5: 7.52 (dd, λ = 6.7 Hz, 2 = 11.7 Hz, 1 H), 6.43 (s, 2 H), 3.78 (s, 3 H)
A.30.d. Methyl 4-amino-2,5-difluoro-3-((trimethylsilyl)ethynyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2,5-difluoro-3-iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2- ch I o ro- 5- i odo be nzoate .
LC-MS (A): tR = 0.98 min; [M+H]+: 284.22
A.30.e. Methyl 4-amino-3-ethynyl-2, 5-difluorobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2,5-difluoro-3-((trimethylsilyl)ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.78 min
H NMR ((CD3)2SO) <5: 7.48 (dd, λ = 6.6 Hz, J2 = 1 1.8 Hz, 1 H), 6.66 (s, 2 H), 4.80 (s, 1 H), 3.78 (s, 3 H)
A.30.f. Methyl 4, 7-difluoro- 1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-3-ethynyl-2, 5-difluorobenzoate replacing methyl 4- amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.79 min, [M+H]+: 212.21
A.30.g. 4, 7-Difluoro-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4,7-difluoro-1 H-indole-5-carboxylate replacing methyl 4- chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.64 min
H NMR ((CD3)2SO) <5: 12.96 (s, 1 H), 12.29 (s, 1 H), 7.56 (dd, J1 = J2 = 2.6 Hz, 1 H), 7.32 (dd, = 4.9 Hz, J2 = 11.3 Hz, 1 H), 6.73 (m, 1 H)
A.31. Synthesis of 4-fluoro-7-methoxy-1 H-indole-5-carboxylic acid
A.31. a. 2-Fluorc-5-methoxy-4-nitrobenzoic acid
To a suspension of 2,5-difluoro-4-nitrobenzoic acid (2.46 mmol) and Cs2C03 (12.3 mmol) in DMF was added MeOH (16.5 mmol) and the mixture was stirred for 3h30 at RT. It was diluted with water, acidified with a 1 M solution of HCI until pH=1-2 and extracted three times with EtOAc. The organic phases were washed with brine, dried over MgS04 and concentrated in vacuo to give the title compound as light yellow solid.
LC-MS (A): tR = 0.67 min H NMR ((CD3)2SO) <5: 13.96 (s br, 1 H), 8.03 (d, J = 9.6 Hz, 1 H), 7.68 (d, J = 5.8 Hz, 1 H), 3.97 (s, 3 H)
A.31.b. Methyl 2-fluoro-5-methoxy-4-nitrobenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chlorobenzoate, 2-fluoro-5-methoxy-4-nitrobenzoic acid replacing 4-amino-2- chlorobenzoic acid.
LC-MS (A): tR = 0.81 min
H NMR ((CD3)2SO) <5: 8.09 (d, J = 9.7 Hz, 1 H), 7.70 (d, J = 5.7 Hz, 1 H), 3.98 (s, 3 H), 3.92 (s, 3 H)
A.31.C. Methyl 4-amino-2-fluoro-5-methoxybenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-5- methoxy-2-methylbenzoate, methyl 2-fluoro-5-methoxy-4-nitrobenzoate replacing methyl 5-methoxy-2-methyl-4-nitrobenzoate.
LC-MS (A): tR = 0.70 min, [M+H]+: 200.19
A.31.d. Methyl 4-amino-2-fluoro-3-iodo-5-methoxybenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-fluoro-5-methoxybenzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 2h at RT.
LC-MS (A): tR = 0.83 min, [M+H]+: 325.97
A.31.e. Methyl 4-amino-2-fluoro-5-methoxy-3-((trimethylsilyl)ethynyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-fluoro-3-iodo-5-methoxy benzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4- amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 0.97 min; [M+H]+: 296.03
A.31.f. Methyl 4-amino-3-ethynyl-2-fluoro-5-methoxybenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-fluoro-5-methoxy-3-((trimethylsilyl)ethynyl) benzoate replacing methyl 4-amino-2-chloro-3-((trimethylsilyl)ethynyl)benzoate. LC-MS (A): tR = 0.78 min; [M+H]+: 223.92
A.31.g. Methyl 4-fluoro-7-methoxy- 1 H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-3-ethynyl-2-fluoro-5-methoxybenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.78 min, [M+H]+: 223.76
H NMR ((CD3)2SO) <5: 1 1.96 (s, 1 H), 7.41 (dd, J1 = J2 = 2.6 Hz, 1 H), 6.99 (d, J = 4.9 Hz, 1 H), 6.62 (m, 1 H), 3.95 (s, 3 H), 3.85 (s, 3 H)
A.31.h. 4-Fluoro-7-methoxy- 1 H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-fluoro-7-methoxy-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.64 min, [M+H]+: 210.15
A.32. Synthesis of 4-chloro-7-(2-ethoxyethyl)-1 H-indole-5-carboxylic acid
A.32. a. Methyl 4-aminc-2-chlorc-5-(2-ethoxyvinyl)benzoate
To a mixture of methyl 4-amino-2-chloro-5-iodobenzoate (1.05 mmol), KOH (2.1 mmol) Pd(OAc)2 (0.03 mmol) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.08 mmol) was added under argon CH3CN (10 mL) and trans-2-ethoxyvinylboronic acid pinacol ester (2.1 mmol). The mixture was stirred for 1 h at 70°C in a sealed vial, quenched with a 10% solution of NH4CI and extracted three times with DCM. The organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 100/0 to 27/63 to give the title compound as brown oil.
LC-MS (A): tR = 0.85 min; [M+CH3CN+H]+: 297.04
A.32.b. Methyl 4-amino-2-chloro-5-(2-ethoxyethyl)benzoate
To a solution of methyl 4-amino-2-chloro-5-(2-ethoxyvinyl)benzoate (0.63 mmol) in EtOH (4.2 mL) was added platinum (IV) oxide (0.13 mmol). The mixture was stirred under a hydrogen atmosphere for 3h, filtered over Celite and concentrated in vacuo. The crude was purified by CC (SNAP KP-Sil™ from Biotage) using Hept/EtOAc from 100/0 to 63/37 to give the title compound as brownish oil.
LC-MS (A): tR = 0.81 min, [M+H]+: 257.95 A.32.C. Methyl 4-amino-2-chloro-5-(2-ethoxyethyl)-3-iodobenzoate
This compound was prepared using a method analogous to that of the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate, methyl 4- amino-2-chloro-5-(2-ethoxyethyl)benzoate replacing methyl 4-amino-2-chlorobenzoate except that the reaction mixture was stirred for 1 h at RT.
LC-MS (A): tR = 0.91 min, [M+H]+: 384.10
A.32.d. Methyl 4-amino-2-chloro-5-(2-ethoxyethyl)-3-((t methylsilyl)ethvnyl)benzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-((trimethylsilyl)ethynyl)benzoate, methyl 4-amino-2-chloro-5-(2-ethoxyethyl)-3- iodobenzoate replacing the mixture of methyl 4-amino-2-chloro-3-iodobenzoate and methyl 4-amino-2-chloro-5-iodobenzoate.
LC-MS (A): tR = 1.05 min; [M+H]+: 353.87
A.32.e. Methyl 4-amino-2-chloro-5-(2-ethoxyethyl)-3-ethvnylbenzoate
This compound was prepared using a method analogous to that of methyl 4-amino-2- chloro-3-ethynylbenzoate, methyl 4-amino-2-chloro-5-(2-ethoxyethyl)-3-
((trimethylsilyl)ethynyl)benzoate replacing methyl 4-amino-2-chloro-3-
((trimethylsilyl)ethynyl)benzoate.
LC-MS (A): tR = 0.87 min; [M+H]+: 282.15
A.32.f. Methyl 4-chloro-7-(2-ethoxyethyl)-1H-indole-5-carboxylate
This compound was prepared using a method analogous to that of methyl 4-chloro-1 H- indole-5-carboxylate, methyl 4-amino-2-chloro-5-(2-ethoxyethyl)-3-ethynylbenzoate replacing methyl 4-amino-2-chloro-3-ethynylbenzoate.
LC-MS (A): tR = 0.87 min, [M+H]+: 282.14
H NMR ((CD3)2SO) <5: 1 1.77 (s, 1 H), 7.55 (dd, J1 = J2 = 2.8 Hz, 1 H), 7.49 (s, 1 H), 6.63 (dd, = 2.0 Hz, J2 = 3.1 Hz, 1 H), 3.85 (s, 3 H), 3.66 (t, J = 7.0 Hz, 2 H), 3.45 (q, J = 7.0 Hz, 2 H), 3.12 (t, J = 6.9 Hz, 2 H), 1.09 (t, J = 7.0 Hz, 3 H)
A.32.g. 4-Chloro-7-(2-ethoxyethyl)-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-(2-ethoxyethyl)-1 H-indole-5-carboxylate replacing methyl 4-chloro-7-methyl-1 H-indole-5-carboxylate. LC-MS (A): tR = 0.74 min, [M+H]+: 268.03
A.33. Synthesis of 4-chloro-7-(2-methoxypropan-2-yl)-1 H-indole-5-carboxylic acid
A.33. a. Methyl 4-chloro-7-(2-hvdroxypropan-2-yl)-1H-indole-5-carboxylate
To a solution of methyl 7-acetyl-4-chloro-1 H-indole-5-carboxylate (0.56 mmol) in THF (1 1 ml_) was added dropwise at -10°C a 3M solution of methylmagnesium bromide in diethyl ether (1.12 mmol). The mixture was stirred for 1 h at RT and an additional amount of a 3M solution of methylmagnesium bromide in diethyl ether (1.12 mmol) was added at -10°C. The mixture was further stirred for 1 h at RT and cooled to 0°C. It was quenched with a sat. solution of NH4CI and extracted three times with EtOAc. The organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Isolute™ Silica II from Biotage) using DCM/MeOH from 100/0 to 99/1 to give the title compound as grey solid.
LC-MS (A): tR = 0.79 min; [M+H]+: 268.15
A.33.b. Methyl 4-chloro- 7-(2-methoxypropan-2-yl)- 1 H-indole-5-carboxylate
To a solution of methyl 4-chloro- 7-(2-hydroxypropan-2-yl)-1 H-indole-5-carboxylate (0.39 mmol) in THF (1 ml_) was added at 0°C a 60% suspension of NaH in mineral oil (1.18 mmol) followed by methyl iodide (0.39 mmol). The mixture was stirred for 10 min at 0°C, ON at RT and cooled to 0°C. It was quenched with a sat. solution of NaHC03 and extracted three times with EtOAc. The organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by preparative LC-MS using method II to give the title compound as white solid.
LC-MS (A): tR = 0.88 min
H NMR ((CD3)2SO) <5: 1 1.25 (s br, 1 H), 7.47 (s, 1 H), 7.45 (dd, J1 = J2 = 2.9 Hz, 1 H), 6.64 (m, 1 H), 3.86 (s, 3 H), 2.97 (s, 3 H), 1.61 (s, 6 H)
A.33.C. 4-Chloro-7-(2-methoxypropan-2-yl)-1H-indole-5-carboxylic acid
This compound was prepared using a method analogous to that of 4-chloro-7-methyl-1 H- indole-5-carboxylic acid, methyl 4-chloro-7-(2-methoxypropan-2-yl)-1 H-indole-5- carboxylate replacing methyl 4-chloro- 7-methyl-1 H-indole-5-carboxylate.
LC-MS (A): tR = 0.75 min B. Synthesis of amines
B.1. Synthesis of(1-aminomethyl)cycloheptanol
This compound was synthesized according to WO2012/114268.
B.2. Synthesis of 1-(aminomethyl)-4,4-difluorocyclohexanol
This compound was synthesized according to WO2012/114268.
B.3. Synthesis of(S)-2-amino-2-(4,4-difluorocyclohexyl)ethanol hydrochloride
B.3.a. (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hvdroxycvclohexyl)acetate
This compound was synthesized according to Bioorg. Med. Chem. Lett., 2004, 14(1), 43- 46.
B.3.b. (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-oxocvclohexyl)acetate
To a solution of (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxycyclohexyl)acetate (4.7 g) in DCM (45 ml_) was added dropwise a 15% solution of DMP in DCM (51 ml_, 1.5 eq). The mixture was stirred ON at RT, diluted with DCM and washed with a sat. solution of NaHC03 and water. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/1) to give 4.6 g of the title compound as colorless oil.
LC-MS (B): tR = 0.64 min; [M+H]+: 286.03
B.3.C. (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4,4-difluorocvclohexyl)acetate
To a solution of (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-oxocyclohexyl)acetate (4.6 g) in DCM (45 ml_) was slowly added at 0°C a 50% solution of bis(2- methoxyethyl)aminosulfur trifluoride in THF (26 ml_). The mixture was stirred for 30 min at 0°C and ON at RT and quenched at 0°C with a sat. solution of NaHC03. It was extracted with DCM and washed with water. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 2/1) to give 4.0 g of the title compound as light yellow oil.
LC-MS (B): tR = 0.81 min; [M+H]+: 308.08
B.3.d. (S)-tert-butyl (1-(4,4-difluorocvclohexyl)-2-hvdroxyethyl)carbamate
To a solution of (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4,4-difluorocyclohexyl) acetate (4.1 g) in EtOH (54 ml_) was slowly added at 0°C CaCI2 (27 mg), THF (18 ml_) and NaBH4 (2 g). The mixture was stirred for 3h at 0°C and quenched with a citric acid solution. It was extracted with DCM and washed with water. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/1 ) to give 1 .8 g of the title compound as white solid.
LC-MS (B): tR = 0.69 min; [M+H]+: 280.01
B.3.e. ( S) -2-amino-2-(4, 4-difluorocvclohexyl) ethanol hydrochloride
To a solution of (S)-tert-butyl (1 -(4,4-difluorocyclohexyl)-2-hydroxyethyl)carbamate (1 .8 g) in EtOAc (25 ml_) was added a 4M solution of HCI in dioxane (6.5 ml_). The mixture was stirred for 24h at RT, concentrated in vacuo and dried at HV to give the title compound as white solid.
LC-MS (B): tR = 0.31 min; [M+H]+: 180.18
B.4. Synthesis of 2-amino-2-cycloheptylethanol
B.4.a. 2-Amino-2-cvcloheptylacetic acid tert-butyl ester
To a solution of N-(diphenylmethylene)glycerine tert-butyl ester (6.83 mmol) and (R)-4,4- dibutyl-2,6-bis(3,4,5-trifluorophenyl)-4,5-dihydro-3/-/-dinaphthol[7,6, 1 ,2-cde]azepinium bromide (6.84 μηιοΙ) in 45 ml_ toluene were sequentially added cycloheptyl bromide (8.2 mmol) and CsOH H2O (34.2 mmol) at -10°C. The reaction mixture was stirred at -10°C for 10 min and then at RT for 4 days. Another portion of (f?)-4,4-dibutyl-2,6-bis(3,4,5- trifluorophenyl)-4,5-dihydro-3/-/-dinaphthol[7,6, 1 ,2-cde]azepinium bromide (6.84 μηιοΙ) was added and stirring was continued at RT for another 24 h. The reaction was quenched with water and extracted 3 times with DCM. The combined organic layers were combined, concentrated and the residue was redissolved in 100 ml_ THF. A solution of 100 ml_ aq. 0.5M citric acid solution was added and the mixture was stirred at RT for 4 h. The mixture was concentrated to half of its volume and extracted twice with Et20. The aqueous layer was basified with solid NaHCOs and extracted 3 times with DCM. The combined organic layers were dried over MgS04 and concentrated in vacuo to obtain the desired product as yellow oil.
LC-MS (B): tR = 0.61 min; [M+H]+: 228.29
B.4.b. 2-Amino-2-cycloheptylethanol
To a solution of 3.43 mL LiAIH4 (1 M in THF) in 8 mL THF was added a solution of 2- amino-2-cycloheptylacetic acid tert-butyl ester (1.72 mmol) in 3 mL THF at 0°C. The ice bath was removed and stirring was continued at RT for 1 h. The reaction mixture was cooled to 0°C, quenched with water and a 1 M NaOH solution, filtered over a pad of celite and washed with EtOAc. The filtrate was basified with a 1 M NaOH solution to pH 8-9 and extracted 3 times with EtOAc. The combined organic layers were dried over MgSCn and concentrated in vacuo to obtain the crude product as yellow oil. The crude was dissolved in 3 mL Et20 and a solution of 4M HCI in dioxane was dropwise added at 0°C. The resulting precipitate was separated by filtration and dried in vacuo to give the corresponding HCI salt as yellow solid.
LC-MS (B): tR = 0.39 min; [M+H]+: 158.14
B.5. Synthesis of (1 -(hetero)aryl)cycloalkyl)methanamine
B.5.a. Synthesis of 2-(hetero)arylcyanoacetate
These compounds were synthesized according to J. Org. Chem., 2008, 73 (4), 1643- 1645.
B.5.a.1. Methyl 2-cyano-2-(2-(trifluoromethyl)pyrimidin-5-yl)acetate
To a suspension of KO'Bu (618 mg) in dioxane (10 mL) were added methylcyanoacetate (0.194 mL), 5-bromo-2-(trifluoromethyl)pyrimidine (500 mg) followed by a solution of Pd(OAc)2 (30 mg) and dppf (98 mg) in dioxane (2 mL). The mixture was flushed with argon and the vial sealed and heated ON at 90°C. It was quenched with a 2M aq. solution of AcOH and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (KP-SNTM from Biotage) using EtOAc/MeOH from 1/0 to 8/2 to give the title compound as brown oil (303 mg).
H NMR (CDCI3) <5: 9.04 (s, 2 H), 4.90 (s, 1 H), 3.92 (s, 3 H)
B.5.a.2. Methyl 2-cvano-2-(6-(trifluoromethyl)pyridin-3-yl)acetate
This compound was prepared using a method analogous to that of methyl 2-cyano-2-(2- (trifluoromethyl)pyrimidin-5-yl)acetate, 5-bromo-2(trifluoromethyl)pyridine replacing 5- bromo-2-(trifluoromethyl)pyrimidine except that the mixture was heated for 1 h at 70°C.
LC-MS (B): tR = 0.66 min; [M+ H]+: 245.13
H NMR (CDCI3) δ: 8.81 (d, J = 2.1 Hz, 1 H), 8.05 (m, 1 H), 7.79 (dd, 4 = 8.2 Hz, J2 = 0.6 Hz, 1 H), 4.88 (s, 1 H), 3.87 (s, 3 H)
B.5.b. Synthesis of 2-(hetero)arylacetonitrile
B.5.b.1. 2-(2-(Trifluoromethyl)pyrimidin-5-yl)acetonitrile
To a solution of methyl 2-cyano-2-(2-(trifluoromethyl)pyrimidin-5-yl)acetate (330 mg) in DMSO/water 9/1 (1 .5 mL) was added LiCI (231 mg). The mixture was heated to 140°C for 30 min under microwave conditions, poured onto water and extracted 2 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC (KP-NH™ from Biotage) using DCM/MeOH from 99/1 to 95/5 to give the title compound as yellow solid (96 mg).
Figure imgf000111_0001
H NMR (CDCI3) <5: 8.94 (s, 2 H), 3.89 (s, 2 H)
B.5.b.2. 2-(6-(Trifluoromethyl)pyridin-3-yl)acetonitrile
This compound was prepared using a method analogous to that of 2-(2- (trifluoromethyl)pyrimidin-5-yl)acetonitrile, methyl 2-cyano-2-(6-(trifluoromethyl)pyridin-3- yl)acetate replacing methyl 2-cyano-2-(2-(trifluoromethyl)pyrimidin-5-yl)acetate except that the mixture was heated for 1 h at 70°C.
LC-MS (B): tR = 0.57 min; [M+CH3CN+H]+: 228.17
A.1.a.1 2-(2-Methypyrimidin-5-yl)acetonitrile
This compound was synthezised according to J. Am. Chem. Soc, 2011, 133, 6948-6951.
To a solution of 5-bromo-2-methylpyrimidine (5.78 mmol) and 4-isoxazoleboronic acid pinacol ester (6.07 mmol) in DMSO (40 ml_) was added a solution of potassium fluoride (17.30 mmol) in water (17 ml_). The mixture was flushed with argon, Pd(dppf)CI2.DCM (0.58 mmol) was added and the mixture was heated for 48h at 130°C. It was filtered over a pad of Celite and washed with EtOAc. The filtrate was partitioned between water and EtOAc and the aqueous phase was extracted twice with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC using DCM/MeOH from 1/0 to 95/5 to give the title compound as brown oil.
LC-MS (A): tR = 0.43 min; [M+ H]+: 134.10
B.5.C. Alkylation (general procedure III)
To a solution of 2-(hetero)arylacetonitrile (0.51 mmol) and α,ω-dibromoalkane (0.51 mmol) in THF/DMSO 1/1 (6 mL) was added portionwise at 0°C a 60% suspension of NaH in mineral oil (1.07 mmol). The mixture was allowed to warm to RT and stirred for 2h. It was poured onto water and extracted with EtOAc. The combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (KP-NH™ from Biotage) using DCM/MeOH from 99/1 to 90/10 to give the desired 1- (hetero)arylcycloalkylcarbonitriles which are listed in the table below. LC-MS
Name
type tR (min) [M+H]+
no
1-(2-(trifluoromethyl)pyrimidin-5-yl)cyclohexanecarbonitrile B 0.80
ionisation
1-(6-chloropyridin-3-yl)cyclohexanecarbonitrile B 0.78 221.20
1-(6-(trifluoromethyl)pyridin-3-yl)cyclohexanecarbonitrile B 0.83 255.20 no
1-(4-(trifluoromethyl)phenyl)cyclohexanecarbonitrile B 0.95
ionisation
1 -(pyridin-3-yl)cyclohexanecarbonitrile B 0.44 187.29
1-(pyridin-3-yl)cyclopentanecarbonitrile B 0.35 173.07
1-(pyridin-3-yl)cycloheptanecarbonitrile B 0.50 201.20
1 -(2-methylpyrimidin-5-yl)cyclohexanecarbonitrile A 0.73 202.08
B.5.d. Hydrogenation of nitrite (general procedure IV)
To a solution of the 1 -(hetero)arylcycloalkylcarbonitrile (0.47 mmol) from the previous step in a 7M solution of NH3 in MeOH (0.57 mL) was added Actimet M Raney nickel. The mixture was stirred under a hydrogen atmosphere for 2h. It was filtered over Celite, washed with MeOH and concentrated in vacuo to give the desired (1- (hetero)arylcycloalkyl)methanamines which are listed in the table below
LC-MS
Name tR
type [M+H]+
(min)
(1-(2-(trifluoromethyl)pyrimidin-5- [M+CH3CN+H]+:
B 0.51
yl)cyclohexyl)methanamine 301.09
(1 -(6-chloropyridin-3-yl)cyclohexyl)methanamine B 0.47 225.27
(1-(6-(trifluoromethyl)pyridin-3-
B 0.53 259.22 yl)cyclohexyl)methanamine
(1 -(4-(trifluoromethyl)phenyl)cyclohexyl)methanamine B 0.65 257.96
(1 -(pyridin-3-yl)cyclohexyl)methanamine B 0.26 191 .31
(1-(pyridin-3-yl)cyclopentyl)methanamine B 0.20 177.32 (1-(pyridin-3-yl)cycloheptyl)methanamine B 0.32 205.28
(1-(2-methylpyrirnidin-5-yl)cyclohexyl)methanarTiine A 0.45 206.13
B.5.e. Synthesis of (4,4-difluoro- 1-(6-chloropyridin-3-yl)cvclohexyl)methanamine
B.5.e.1. Methyl 5-(6-chloropyridin-3-yl)-5-cvano-2-hvdroxycvclohex-1-enecarboxylate To a solution of 2-(6-chloro-3-pyridinyl)acetonitrile (13.1 mmol) in 35 mL THF were added methylacrylate (26.2 mmol) and KOtBu (15.7 mmol). The reaction mixture was stirred at RT for 1 h. The mixture was acidifed with 1 N HCI solution and then extracted with DCM. The combined organic layers were washed with brine, dried over MgSC and concentrated in vacuo. Purification with CC (KP-SI LTM from Biotage) using Hept/EtOAc (90/10 to 50/50) gives the desired compound as white solid.
LC-MS (B): tR = 0.74 min; [M+CHsCN+H]+: 334.03
B.5.e.2. 1-(6-Chloropyridin-3-yl)-4-oxocvclohexanecarbonitrile
A mixture of methyl 5-(6-chloropyridin-3-yl)-5-cyano-2-hydroxycyclohex-1-enecarboxylate (10.6 mmol) and LiCI (21.1 mmol) in 15 mL wet DMSO was heated to 120°C under microwave conditions for 2 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSC and concentrated in vacuo. Purification with CC (KP-SI LTM from Biotage) using Hept/EtOAc (95/5 to 20/80) gives the desired compound as yellow solid.
LC-MS (B): tR = 0.56 min; [M+CHsCN+H]+: 276.12
B.5.e.3. 1-(6-Chloropyridin-3-yl)-4,4-difluorocyclohexanecarbonitrile
A solution of 1-(6-chloropyridin-3-yl)-4-oxocyclohexanecarbonitrile (3.89 mmol) in 4 mL DCM was cooled to -78°C, (diethylamino)sulfur trifluoride (7.78 mmol) was dropwise added and the mixture was stirred for 24 h allowing to reach slowly RT. The reaction mixture was quenched with sat. aq. NaHC03 solution under ice cooling and diluted with DCM. The organic phase was washed with brine, dried over MgSC and concentrated in vacuo. Purification with CC (KP-SI LTM from Biotage) using Hept/EtOAc (90/10 to 50/50) gives the desired compound as beige solid.
LC-MS (B): tR = 0.74 min; [M+CHsCN+H]+: 298.00
B.5.e.4. (4,4-Difluoro-1-(6-chloropyridin-3-yl)cvclohexyl)methanamine
A solution of 1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexanecarbonitrile (2.02 mmol) in 20 mL THF was added to a solution of BH3 in THF (6.07 mmol, 1 M). After heating to reflux for 1 h, the reaction mixture was cooled in an ice bath before a 2N HCI solution was slowly added. The mixture was then heated to reflux for another 20 min. The reaction mixture was washed with DCM, basified with 1 N NaOH solution and extracted 3 times with DCM. The combined organic layers were washed with brine, dried over MgSC and concentrated in vacuo to give the desired product as yellow oil.
LC-MS (B): tR = 0.46 min; [M+CHsCN+H]+: 302.03
B.5.f. Synthesis of ( 1-(4-chlorophenyl)cvclohexyl)methanamine
To a 1 M solution of BH3.THF complex (6.8 ml_) was added a solution of 1-(4- chlorophenyl)-1-cyclohexanecarbonitrile (500 mg) in anh. THF (23 ml_). The mixture was refluxed for 1 h, acidified at RT with a 2M solution of HCI (14 ml_) and refluxed for 20 min. It was washed with DCM, basified with 1 M NaOH and extracted 3 times with DCM. The combined organic phases were dried and concentrated in vacuo to give the title compound as yellow oil (275 mg).
LC-MS (B): tR = 0.61 min; [M+H]+: 224.24
B.5.g. Synthesis of (4,4-difluoro- 1-(2-methylpyrimidin-5-yl)cvclohexyl)methanamine
B.5.g.1. Methyl 5-cvano-2-hvdroxy-5-(2-methylpyrimidin-5-yl)cyclohex-1- enecarboxylate
This compound was prepared using a method analogous to that of methyl 5-(6- chloropyridin-3-yl)-5-cyano-2-hydroxycyclohex-1-enecarboxylate, 2-(2-methypyrimidin-5- yl)acetonitrile replacing 2-(6-chloro-3-pyridinyl)acetonitrile.
LC-MS (A): tR = 0.73 min; [M+H]+: 273.93
B.5.g.2. 1-(2-Methylpyrimidin-5-yl)-4-oxocyclohexanecarbonitrile
This compound was prepared using a method analogous to that of 1-(6-chloropyridin-3- yl)-4-oxocyclohexanecarbonitrile, methyl 5-cyano-2-hydroxy-5-(2-methylpyrimidin-5- yl)cyclohex-1 -enecarboxylate replacing methyl 5-(6-chloropyridin-3-yl)-5-cyano-2- hydroxycyclohex- 1 -enecarboxylate.
LC-MS (A): ta = 0.53 min; [M+H]+: 216.16
B.5.g.3. 4,4-Difluoro-1-(2-methylpyrimidin-5-yl)cyclohexanecarbonitrile
This compound was prepared using a method analogous to that of 1-(6-chloropyridin-3- yl)-4,4-difluorocyclohexanecarbonitrile, 1-(2-methylpyrimidin-5-yl)-4-oxocyclohexane- carbonitrile replacing 1-(6-chloropyridin-3-yl)-4-oxocyclohexanecarbonitrile.
LC-MS (A): ta = 0.71 min; [M+H]+: 238.1 1
B.5.g.4. (4,4-Difluoro-1-(2-methylpyrimidin-5-yl)cvclohexyl)methanamine
This compound was prepared according the general procedure IV (hydrogenation of nitriles) engaging 4,4-difluoro-1-(2-methylpyrimidin-5-yl)cyclohexanecarbonitrile. LC-MS (A): tR = 0.45 min; [M+CH3CN+H]+: 283.14
B.6. Synthesis of(1-aminomethyl)cyclopentanol
This compound was synthesized according to WO2012/114268.
B.7. Synthesis of(1-aminomethyl)cyclooctanol
This compound was synthesized according to WO2012/114268.
B.8. Synthesis of(1-methoxycyclohexyl)methanamine
This compound was synthesized according to WO2012/114268.
PREPARATION OF EXAMPLES
A. Synthesis of compounds of formula I (general procedure V)
To a solution of the respective carboxylic acid precursor (II) (0.23 mmol) in a mixture of DCM/DMF (0.4 ml_) were consecutively added DIPEA (0.69 mmol), HOBt (0.28 mmol) and EDC.HCI (0.28 mmol) followed by a solution of the respective amine precursor (III) (0.25 mmol) in DCM (0.1 ml_). The mixture was stirred ON at RT, diluted with DCM and washed twice with a 5% solution of KHS04 (for non basic product), with a sat. solution of NaHC03 and with brine. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified using conditions which are detailed in the table below. All compounds in the following table were synthesized according to the aforementioned general procedure except compounds which are marked with "see below under section B"; such compounds were synthesized according to the specific procedures given in section "B. Post amide coupling steps" below.
Purification
Compound Name LC-MS
method
tR
type [M+H]+
(min)
4-Chloro-1 H-indole-5-carboxylic
Example 1 acid ((S)-1 -cyclohexyl-2- a B 0.69 321 .1 1 hydroxy-ethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
precipitate
Example 2 acid (1 -hydroxy- B 0.62 307.14 from DCM
cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 3 acid (1 -hydroxy- a B 0.68 321 .00 cycloheptylmethyl)-amide 4-Chloro-1 H-indole-5-carboxylic
Example 4 acid (4,4-difluoro-1 -hydroxy- b B 0.62 343.1 1 cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
acid [(S)-1 -(4,4-difluoro-
Example 5 a B 0.63 357.1 1 cyclohexyl)-2-hydroxy-ethyl]- amide
4-Chloro-1 -methyl-1 H-indole-5-
Example 6 carboxylic acid (1 -hydroxy- a B 0.68 321 .10 cyclohexylmethyl)-amide
4-Chloro-1 -methyl-1 H-indole-5- carboxylic acid ((S)-1 -
Example 7 a B 0.74 335.04 cyclohexyl-2-hydroxy-ethyl)- amide
4-Chloro-3-formyl-1 H-indole-5- carboxylic acid ((S)-1 -
Example 8 I B 0.59 349.19 cyclohexyl-2-hydroxy-ethyl)- amide
4-Chloro-3-formyl-1 H-indole-5-
Example 9 carboxylic acid (1 -hydroxy- I B 0.53 335.12 cyclohexylmethyl)-amide
rac-4-Chloro-1 H-indole-5-
Example 10 carboxylic acid (1 -cycloheptyl-2- c B 0.74 335.19 hydroxy-ethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
acid [1 -(2-trifluoromethyl-
Example 1 1 d+ll C 0.90 436.90 pyrimidin-5-yl)- cyclohexylmethyl]-amide
4-Chloro-1 H-indole-5-carboxylic
d+precipitate
Example 12 acid [1 -(6-chloro-pyridin-3-yl)- C 0.89 401 .65 from MeCN
cyclohexylmethyl]-amide
4-Chloro-1 H-indole-5-carboxylic
Example 13 acid [1 -(6-trifluoromethyl-pyridin- d+ll B 0.87 436.29
3-yl)-cyclohexylmethyl]-amide 4-Chloro-1 H-indole-5-carboxylic
acid [1 -(6-chloro-pyridin-3-yl)-
Example 14 II B 0.78 437.86
4,4-difluoro-cyclohexylmethyl]- amide
4-Chloro-1 H-indole-5-carboxylic
Example 15 acid [1 -(4-chloro-phenyl)- III B 0.97 400.91 cyclohexylmethyl]-amide
4-Chloro-1 H-indole-5-carboxylic
Example 16 acid [1 -(4-trifluoromethyl- III B 0.97 434.86 phenyl)-cyclohexylmethyl]-amide
4-Chloro-1 H-indole-5-carboxylic
Example 17 acid (1 -pyridin-3-yl- IV B 0.54 367.99 cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 18 acid (1 -pyridin-3-yl- VI B 0.51 353.77 cyclopentylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 19 acid (1 -pyridin-3-yl- e B 0.58 381 .98 cycloheptylmethyl)-amide
4-Chloro-7-methyl-1 H-indole-5-
Example 20 carboxylic acid (1 -hydroxy- a+VII A 0.76 321 .18 cyclohexylmethyl)-amide
4-Chloro-2-oxo-2,3-dihydro-1 H- indole-5-carboxylic acid (1 -
Example 21 see below under section B
hydroxy-cycloheptylmethyl)- amide
4-Chloro-2-methyl-1 H-indole-5-
Example 22 carboxylic acid (1 -hydroxy- a A 0.76 321 .25 cyclohexylmethyl)-amide
4-Chloro-7-iodo-3- methylsulfanyl-1 H-indole-5-
Example 23 VII A 0.84 478.78 carboxylic acid (1 -hydroxy- cyclohexylmethyl)-amide
Example 24 4-Chloro-7-methyl-1 H-indole-5- a+VII A 0.76 357.10 carboxylic acid (4,4-difluoro-1 - hydroxy-cyclohexylmethyl)- amide
4-Chlorc-7-methyl-1 H-indole-5- precipitate
Example 25 carboxylic acid (1 -hydroxy- A 0.80 335.04 from MeCN
cycloheptylmethyl)-amide
4-Chloro-3-fluoro-1 H-indole-5-
Example 26 carboxylic acid (1 -hydroxy- Vll+c A 0.78 338.99 cycloheptylmethyl)-amide
4-Methoxy-1 H-indole-5-
Example 27 carboxylic acid (1 -hydroxy- a A 0.76 317.29 cycloheptylmethyl)-amide
3,4-Dichloro-1 H-indole-5-
Example 28 carboxylic acid (1 -hydroxy- e A 0.77 340.90 cyclohexylmethyl)-amide
4-Chloro-7-nitro-1 H-indole-5-
Example 29 carboxylic acid (1 -hydroxy- VI A 0.77 351 .91 cyclohexylmethyl)-amide
1 -{[(4-Chloro-1 H-indole-5- carbonyl)-amino]-methyl}-
Example 30 a A 0.85 348.94 cyclohexanecarboxylic acid
methyl ester
4-Chloro-1 H-indole-5-carboxylic
Example 31 acid (1 -hydroxymethyl- see below under section B
cyclohexylmethyl)-amide
7-Amino-4-chloro-1 H-indole-5-
Example 32 carboxylic acid (1 -hydroxy- see below under section B
cyclohexylmethyl)-amide
4-Chloro-3-methyl-1 H-indole-5-
Example 33 carboxylic acid (1 -hydroxy- c A 0.80 335.15 cycloheptylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 34 acid (1 -carbamoyl- see below under section B
cyclohexylmethyl)-amide 4-Chloro-1 H-indole-5-carboxylic
Example 35 acid (1 -methylcarbamoyl- see below under section B
cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 36 acid (1 -cyano- see below under section B
cyclohexylmethyl)-amide
(1 -{[(4-Chloro-1 H-indole-5- carbonyl)-amino]-methyl}- precipitate
Example 37 A 0.90 406.08 cyclohexyl)-carbamic acid tert- from MeCN
butyl ester
4,6-Dichloro-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 38 Vl+c A 0.76 376.92 hydroxy-cyclohexylmethyl)- amide
4-Chloro-1 H-indole-5-carboxylic
acid (1 -amino-
Example 39 see below under section B
cyclohexylmethyl)-amide
hydrochloride
4-Chloro-6-methyl-1 H-indole-5-
Example 40 carboxylic acid (1 -hydroxy- e+c+VI A 0.74 321 .16 cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 41 acid (1 -hydroxy- 5 E 0.78 292.99 cyclopentylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 42 acid (1 -hydroxy- 2 E 1 .06 335.04 cyclooctylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 43 acid (1 -methoxy- 2 E 1 .12 321 .02 cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 44 acid ((S)-l -cyclohexyl-ethyl)- 3 E 1 .28 305.02 amide
Example 45 4-Chloro-1 H-indole-5-carboxylic 3 E 1 .28 305.01 acid ((R)-l -cyclohexyl-ethyl)- amide
4-Chloro-1 H-indole-5-carboxylic
Example 46 acid (1 -acetylamino- see below under section B
cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 47 acid (1 -methanesulfonylamino- see below under section B
cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 48 acid (1 -dimethylamino- see below under section B
cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
Example 49 acid (1 -benzylamino- see below under section B
cyclohexylmethyl)-amide
3-Bromo-4-chloro-7-methyl-1 H- indole-5-carboxylic acid (1 -
Example 50 VII A 0.83 398.78 hydroxy-cyclohexylmethyl)- amide
(1 -{[(4-Chloro-1 H-indole-5- carbonyl)-amino]-methyl}-
Example 51 see below under section B
cyclohexylsulfamoyl)-acetic acid
methyl ester
4-Chloro-7-isobutyl-1 H-indole-5-
Example 52 carboxylic acid (1 -hydroxy- II A 0.90 376.94 cycloheptylmethyl)-amide
4-Chloro-7-(3-methoxy-propyl)- 1 H-indole-5-carboxylic acid (1 -
Example 53 b A 0.83 393.05 hydroxy-cycloheptylmethyl)- amide
4-Chloro-7-isobutyl-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 54 b A 0.87 398.97 hydroxy-cyclohexylmethyl)- amide
4-Chloro-7-(3-methoxy-propyl)-
Example 55 b A 0.80 415.03
1 H-indole-5-carboxylic acid (4,4- difluoro-1 -hydroxy- cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
acid [1 -(2-hydroxy-
Example 56 see below under section B
ethanesulfonylamino)- cyclohexylmethyl]-amide
4-Methyl-1 H-indole-5-carboxylic
Example 57 acid (1 -hydroxy- d A 0.70 287.18 cyclohexylmethyl)-amide
4-Chloro-1 H-indole-5-carboxylic
precipitate
Example 58 acid [1 -(2-methyl-pyrimidin-5-yl)- A 0.76 382.98 from MeCN
cyclohexylmethyl]-amide
4- Chloro-7-methoxy-1 H-indole-
5- carboxylic acid (4,4-difluoro-1 -
Example 59 b A 0.76 372.88 hydroxy-cyclohexylmethyl)- amide
4-Chloro-1 H-indole-5-carboxylic
acid [4,4-difluoro-1 -(2-methyl-
Example 60 b+e A 0.76 418.89 pyrimidin-5-yl)- cyclohexylmethyl]-amide
4-Chloro-7-methyl-1 H-indole-5- carboxylic acid [4,4-difluoro-1 -
Example 61 c A 0.79 432.90
(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide
4-Chloro-7-methyl-1 H-indole-5- carboxylic acid [1 -(2-methyl-
Example 62 b A 0.79 397.01 pyrimidin-5-yl)- cyclohexylmethyl]-amide
4,7-Dimethyl-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 63 b A 0.75 336.98 hydroxy-cyclohexylmethyl)- amide
4-Methyl-1 H-indole-5-carboxylic
Example 64 acid (4,4-difluoro-1 -hydroxy- b+a A 0.72 322.95 cyclohexylmethyl)-amide 4-Ethyl-1 H-indole-5-carboxylic
Example 65 acid (4,4-difluoro-1 -hydroxy- d A 0.76 337.08 cyclohexylmethyl)-amide
7-Acetyl-4-chloro-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 66 b A 0.77 384.97 hydroxy-cyclohexylmethyl)- amide
rac-4-Chloro-7-(1 -hydroxy- ethyl)-1 H-indole-5-carboxylic
Example 67 see below under section B
acid (4,4-difluoro-1 -hydroxy- cyclohexylmethyl)-amide
4-Chloro-7-(1 -hydroxy-1 -methyl- ethyl)-1 H-indole-5-carboxylic
Example 68 see below under section B
acid (4,4-difluoro-1 -hydroxy- cyclohexylmethyl)-amide
7-Methyl-4-trifluoromethyl-1 H- indole-5-carboxylic acid (1 -
Example 69 b A 0.79 354.96 hydroxy-cyclohexylmethyl)- amide
7-Methyl-4-trifluoromethyl-1 H- indole-5-carboxylic acid (4,4-
Example 70 b A 0.80 391 .02 difluoro-1 -hydroxy- cyclohexylmethyl)-amide
4,7-Dimethyl-1 H-indole-5-
Example 71 carboxylic acid (1 -hydroxy- b A 0.74 301 .13 cyclohexylmethyl)-amide
4-Chloro-7-ethyl-1 H-indole-5-
Example 72 carboxylic acid (1 -hydroxy- b A 0.80 335.02 cyclohexylmethyl)-amide
4-Chloro-7-ethyl-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 73 b A 0.80 370.94 hydroxy-cyclohexylmethyl)- amide
7-Chloro-4-methyl-1 H-indole-5-
Example 74 b A 0.77 321 .04 carboxylic acid (1 -hydroxy- cyclohexylmethyl)-amide
7-Chlorc-4-methyl-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 75 b A 0.78 356.95 hydroxy-cyclohexylmethyl)- amide
4-Chloro-7-methoxy-1 H-indole-
Example 76 5-carboxylic acid (1 -hydroxy- b A 0.76 336.98 cyclohexylmethyl)-amide
7-Methoxy-4-methyl-1 H-indole- 5-carboxylic acid (4,4-difluoro-1 -
Example 77 b-e A 0.74 353.14 hydroxy-cyclohexylmethyl)- amide
7-Methoxy-4-methyl-1 H-indole-
Example 78 5-carboxylic acid (1 -hydroxy- b-e A 0.73 317.09 cyclohexylmethyl)-amide
4-Chloro-7-ethoxy-1 H-indole-5-
Example 79 carboxylic acid (1 -hydroxy- b A 0.80 350.92 cyclohexylmethyl)-amide
4-Chloro-7-hydroxy-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 80 VIII A 0.71 359.03 hydroxy-cyclohexylmethyl)- amide
4-Chloro-7-ethoxy-1 H-indole-5- carboxylic acid (4,4-difluoro-1 - precipitate
Example 81 A 0.80 387.27 hydroxy-cyclohexylmethyl)- from DCM
amide
4-Chloro-7-propyl-1 H-indole-5-
Example 82 carboxylic acid (1 -hydroxy- b A 0.84 349.21 cyclohexylmethyl)-amide
4-Chloro-7-propyl-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 83 b A 0.84 385.19 hydroxy-cyclohexylmethyl)- amide
7- (2-te rt- B utoxy-eth oxy)-4-
Example 84 b A 0.86 423.07 chloro-1 H-indole-5-carboxylic acid (1 -hydroxy- cyclohexylmethyl)-amide
7- (2-te rt- B utoxy-eth oxy)-4- chloro-1 H-indole-5-carboxylic
Example 85 VII A 0.86 459.03 acid (4,4-difluoro-1 -hydroxy- cyclohexylmethyl)-amide
4-Chloro-7-(2-hydroxy-ethoxy)- 1 H-indole-5-carboxylic acid (1 -
Example 86 see below under section B
hydroxy-cyclohexylmethyl)- amide
4-Chloro-7-(2-hydroxy-ethoxy)- 1 H-indole-5-carboxylic acid (4,4-
Example 87 see below under section B
difluoro-1 -hydroxy- cyclohexylmethyl)-amide
7-Acetyl-4-chloro-1 H-indole-5-
Example 88 carboxylic acid (1 -hydroxy- d A 0.76 349.20 cyclohexylmethyl)-amide
4-Chloro-7-(1 -hydroxy-1 -methyl- ethyl)-1 H-indole-5-carboxylic
Example 89 see below under section B
acid (1 -hydroxy- cyclohexylmethyl)-amide
4,7-Difluoro-1 H-indole-5-
Example 90 carboxylic acid (1 -hydroxy- b A 0.76 309.21 cyclohexylmethyl)-amide
4,7-Difluoro-1 H-indole-5- carboxylic acid (4,4-difluoro-1 -
Example 91 b A 0.77 345.23 hydroxy-cyclohexylmethyl)- amide
4-Fluoro-7-methoxy-1 H-indole-
Example 92 5-carboxylic acid (1 -hydroxy- b A 0.76 321 .09 cyclohexylmethyl)-amide
4- Fluoro-7-methoxy-1 H-indole-
5- carboxylic acid (4,4-difluoro-1 -
Example 93 b A 0.77 357.04 hydroxy-cyclohexylmethyl)- amide 4-Chloro-7-(2-ethoxy-ethyl)-1 H- indole-5-carboxylic acid (4,4-
Example 94 g A 0.81 415.23 difluoro-1 -hydroxy- cyclohexylmethyl)-amide
4-Chloro-7-(1 -methoxy-1 - methyl-ethyl)- 1 H-indole-5-
Example 95 carboxylic acid (4,4-difluoro-1 - d A 0.82 415.21 hydroxy-cyclohexylmethyl)- amide
B. Post amide coupling steps
Example 21 4-Chloro-2-hydroxy-1 H-indole-5-carboxylic acid (1-hydroxy- cycloheptylmethyl)-amide
21. 1 3, 3-Dibromo-4-chloro-N-( ( 1-hydroxycycloheptyl)methyl)-2-oxoindoline-5- carboxamide
To a suspension of 4-chloro-1 H-indole-5-carboxylic acid (1-hydroxy-cycloheptylmethyl)- amide (Example 3) (0.143 mmol) in terf-butanol (0.3 mL) was added pyridinium tribromide (0.456 mmol). The mixture was stirred for 30 min at RT, concentrated in vacuo and partitioned between EtOAc and water. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was precipitated from CH3CN/DMF and the solid washed with EtOH to give the title compound as yellowish solid.
LC-MS (A): tR = 0.78 min; [M+H]+: 494.94
2 2 4-Chloro-2-hydroxy- 1 H-indole-5-carboxylic acid ( 1 -hydroxy-cycloheptyl methyl- amide
To a suspension of 3,3-dibromo-4-chloro-N-((1-hydroxycycloheptyl)methyl)-2-oxoindoline- 5-carboxamide (intermediate 21.1) (0.036 mmol) in AcOH (0.33 mL) was added portionwise zinc dust (0.364 mmol). The mixture was stirred for 15 min at RT, filtered over a pad of celite and the cake washed with EtOAc. The filtrate was concentrated in vacuo and the crude was purified by CC using EtOAc to give the title compound as white solid. LC-MS (A): ta = 0.65 min; [M+H]+: 337.04
Example 31 4-Chloro-1 H-indole-5-carboxylic acid (1-hydroxymethyl-cyclohexylmethyl)- amide
To a suspension of lithium aluminum hydride (0.172 mmol of a 1 M solution in THF) in THF (0.5 mL) was added dropwise at 0°C a solution of 1-{[(4-chloro-1 H-indole-5-carbonyl)- amino]-methyl}-cyclohexanecarboxylic acid methyl ester (Example 30) (0.086 mmol) in THF (0.2 mL). The mixture was stirred for 5 min at 0°C and 1 h at RT, cooled to 0°C and quenched by the consecutive addition of water (0.043 mL) and of a 1 M aqueous solution of NaOH (0.043 mL). It was extracted 3 times with EtOAc and washed with brine. The organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC using DCM/MeOH 95/5 to give the title compound as white solid.
LC-MS (A): tR = 0.79 min; [M+H]+: 321.17
Example 32 7-Amino-4-chloro-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexyl methyl)-amide
To a solution of 4-chloro-7-nitro-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexylmethyl)- amide (Example 29) (0.043 mmol) in DMF (0.085 mL) was added tin (II) chloride dihydrate (0.128 mmol). The mixture was stirred ON at RT and quenched with water. It was basified with a 1 M solution of NaOH and extracted with DCM. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by preparative LC-MS using method IV to give the title compound as white solid.
LC-MS (A): ta = 0.64 min; [M+H]+: 321.90
Example 34 4-Chloro-1 H-indole-5-carboxylic acid (1-carbamoyl-cyclohexylmethyl)- amide
34. 1 1 '-{[(4-Chloro- 1H-indole-5-carbonyl)-amino]-methyl}-cyclohexanecarboxylic acid This compound was prepared using a method analogous to that of 4-chloro-1 H-indole-5- carboxylic acid, 1-{[(4-chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexane carboxylic acid methyl ester (Example 30) replacing methyl 4-chloro-1 H-indole-5- carboxylate.
LC-MS (A): tR = 0.75 min; [M+H]+: 335.1 1
34. 1 4-Chloro- 1 H-indole-5-carboxylic acid ( 1-carbamoyl-cyclohexylmethyl)-amide This compound was prepared according to the general procedure V for amide coupling engaging 1-{[(4-chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexanecarboxylic acid as carboxylic acid and ammonium hydroxide as amine.
LC-MS (A): tR = 0.68 min; [M+H]+: 334.20
Example 35 4-Chloro-1 H-indole-5-carboxylic acid (1-methylcarbamoyl- cyclohexylmethyl)-amide
This compound was prepared according to the general procedure V for amide coupling engaging 1-{[(4-chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexanecarboxylic acid as carboxylic acid and methylamine (as a 2M solution in THF) as amine.
LC-MS (A): tR = 0.71 min; [M+H]+: 348.16 Example 36 4-Chloro-1 H-indole-5-carboxylic acid (l-cyano-cyclohexylmethyl)-amide
To a solution of 4-chloro-1 H-indole-5-carboxylic acid (1-carbamoyl-cyclohexylmethyl)- amide (Example 34) (0.090 mmol) in DCM (1 ml_) was added under argon Burgess reagent (0.180 mmol). The mixture was stirred for 1 h30 at RT and for 3h at 50°C and quenched with water. It was extracted 3 times with DCM and the combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC using DCM/MeOH from 100/0 to 97/3 to give the title compound as white solid.
LC-MS (A): tR = 0.80 min; [M+H]+: 316.19
Example 39 4-Chloro-1 H-indole-5-carboxylic acid (l-amino-cyclohexylmethyl)-amide hydrochloride
To a solution of (1-{[(4-chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexyl)-carbamic acid terf-butyl ester (Example 37) (1.42 mmol) in EtOAc (10 ml_) was added dropwise a 4M solution of HCI in dioxane (14.2 mmol). The mixture was stirred ON at RT and concentrated in vacuo. The residue was precipitated from Et20/CH3CN to give the title compound as light pink solid.
LC-MS (A): tR = 0.58 min; [M+H]+: 306.00
Example 46 4-Chloro-1 H-indole-5-carboxylic acid (1-acetylamino-cyclohexylmethyl)- amide
To a suspension of 4-chloro-1 H-indole-5-carboxylic acid (1-amino-cyclohexylmethyl)- amide hydrochloride (Example 39) (0.1 16 mmol) and Et3N (0.578 mmol) in DCM (1 ml_) was added at 0°C acetyl chloride (0.139 mmol). The mixture was stirred for 40 min at 0°C, quenched with a sat. solution of NaHC03 and extracted 3 times with EtOAc. The combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using H ept./EtOAc/M eO H from 100/0/0 to 20/76/4 to give the title compound as white solid.
LC-MS (A): tR = 0.73 min; [M+H]+: 348.08
Example 47 4-Chloro-1 H-indole-5-carboxylic acid (1-methanesulfonylamino- cyclohexylmethyl)-amide
To a suspension of 4-chloro-1 H-indole-5-carboxylic acid (1-amino-cyclohexylmethyl)- amide hydrochloride (Example 39) (0.1 16 mmol) and Et3N (0.578 mmol) in DCM (1 mL) was added at 0°C methanesulfonyl chloride (0.139 mmol). The mixture was stirred for 40 min at 0°C, quenched with a sat. solution of NaHC03 and extracted 3 times with EtOAc. The combined organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-SIL™ from Biotage) using Hept./EtOAc/MeOH from 100/0/0 to 20/76/4 to give the title compound as light beige solid.
LC-MS (A): ta = 0.75 min; [M+H]+: 383.93
Example 48 4-Chloro-1 H-indole-5-carboxylic acid (1-dimethylamino-cyclohexylmethyl)- amide
To a solution of 4-chloro-1 H-indole-5-carboxylic acid (l-amino-cyclohexylmethyl)-amide hydrochloride (Example 39) (0.433 mmol) in DCM (4 ml_) and MeOH (6 ml_) was added AcOH (0.520 mmol) followed by a 37% aqueous solution of formaldehyde (0.477 mmol) and by sodium triacetoxyborohydride (0.607 mmol). The mixture was stirred for 2h at RT and an additional amount of a 37% aqueous solution of formaldehyde (0.200 mmol) was added. It was stirred for 1 h at RT, quenched with a sat. solution of NaHC03 and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC (SNAP KP-NH™ from Biotage) using Hept./EtOAc/MeOH from 100/0/0 to 0/95/5 to give the title compound as white solid.
LC-MS (A): tR = 0.60 min; [M+H]+: 334.18
Example 49 4-Chloro-1 H-indole-5-carboxylic acid (1-benzylamino-cyclohexylmethyl)- amide
To a solution of 4-chloro-1 H-indole-5-carboxylic acid (l-amino-cyclohexylmethyl)-amide hydrochloride (Example 39) (0.144 mmol) in DCM (1 ml_) was added AcOH (0.159 mmol) followed by benzaldehyde (0.173 mmol) and by sodium triacetoxyborohydride (0.296 mmol). The mixture was stirred for 2h at RT and ON at 60°C. Additional amounts of sodium triacetoxyborohydride (2 x 0.471 mmol) was added and the mixture stirred for 5h at 60°C and ON at RT. It was quenched with a sat. solution of NaHC03 and extracted 3 times with EtOAc. The combined organic phases were dried over MgS04 and concentrated in vacuo. The crude was purified by preparative LC-MS using method VI and additionally by CC (Isolute™ NH2 from Biotage) using EtOAc to give the title compound as white solid.
LC-MS (A): ta = 0.73 min; [M+H]+: 396.05 Example 51 (1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexylsulfamoyl)- acetic acid methyl ester
This compound was prepared using a method analogous to that of Example 47, methyl chlorosulfonylacetate replacing methanesulfonyl chloride except that the mixture was stirred for 1.5h at 0°C.
LC-MS (A): tR = 0.80 min; [M+H]+: 441.90
Example 56 4-Chloro-1 H-indole-5-carboxylic acid [1-(2-hydroxy-ethanesulfonylamino)- cyclohexylmethyl]-amide
This compound was prepared using a method analogous to that of Example 31 , (1-{[(4- chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexylsulfamoyl)-acetic acid methyl ester (Example 51) replacing 1-{[(4-chloro-1 H-indole-5-carbonyl)-amino]-methyl}- cyclohexanecarboxylic acid methyl ester (Example 30).
LC-MS (A): tR = 0.70 min; [M+H]+: 413.97
Example 67 rac-4-Chloro-7-(1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro- 1-hydroxy-cyclohexylmethyl)-amide
To as suspension of 7-acetyl-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide (example 66) (0.08 mmol) in MeOH (1 ml_) was added sodium borohydride (0.18 mmol). The mixture was stirred for 5h at RT, quenched with water and extracted three times with EtOAc. The organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Isolute™ Silica II from Biotage) using DCM/MeOH from 95/5 to 93/7 to give the title compound as white solid.
LC-MS (A): tR = 0.71 min; [M+H]+: 387.23
Example 68 4-Chloro-7-(1-hydroxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (4,4- difluoro-1-hydroxy-cyclohexylmethyl)-amide
To a solution of 7-acetyl-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide (example 66) (0.08 mmol) in THF (1.5 mL) was added dropwise at -10°C a 3M solution of methylmagnesium bromide in diethyl ether (0.15 mmol). The mixture was stirred for 5h at RT and an additional amount of a 3M solution of methylmagnesium bromide in diethyl ether (0.60 mmol) was added at RT. The mixture was further stirred ON at RT and cooled to 0°C. It was quenched with a sat. solution of NH4CI and extracted three times with EtOAc. The organic phases were washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Isolute™ Silica II from Biotage) using DCM/MeOH 95/5 to 93/7 to give the title compound as light yellow solid.
LC-MS (A): tR = 0.74 min; [M+H]+: 401.18
Example 86 4-Chloro-7-(2-hydroxy-ethoxy)-1 H-indole-5-carboxylic acid (1-hydroxy- cyclohexylmethyl)-amide
A solution of 7-(2-tert-butoxy-ethoxy)-4-chloro-1 H-indole-5-carboxylic acid (1-hydroxy- cyclohexylmethyl)-amide (example 84) (0.08 mmol) in DCM (0.33 mL) was treated with TFA (4.14 mmol). The mixture was stirred for 2h 30 min at RT, concentrated in vacuo and coevaporated with toluene. The crude was purified by preparative LC-MS using method VIII to give the title compound as white solid.
LC-MS (A): tR = 0.69 min; [M+H]+: 367.03
Example 87 4-Chloro-7-(2-hydroxy-ethoxy)-1 H-indole-5-carboxylic acid (4,4-difluoro-1- hydroxy-cyclohexylmethyl)-amide
This compound was prepared using a method analogous to that of example 86, 7-(2-tert- butoxy-ethoxy)-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide (example 85) replacing 7-(2-tert-butoxy-ethoxy)-4-chloro-1 H- indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide (example 84).
LC-MS (A): tR = 0.70 min; [M+H]+: 403.02
Example 89 4-Chloro-7-(1-hydroxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (1- hydroxy-cyclohexylmethyl)-amide
This compound was prepared using a method analogous to that of example 68, 7-acetyl- 4-chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide (example 88) replacing 7-acetyl-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide (example 66).
LC-MS (A): tR = 0.73 min, [M+H]+: 365.27
II. BIOLOGICAL ASSAYS
A. In vitro assay
The P2X7 receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method. B. Experimental method:
Cell line generation and YO-PRO assay
Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole blood using the Qiagen RNeasy kit (Qiagen, CH) according to the manufacturer's instructions. Subsequently cDNA was made (Superscript II, Invitrogen AG, CH) and the human P2X7 gene (genbank ref. BC011913) was amplified with the following primers:
ATCGCGGCCGCTCAGTAAGGACTCTTGAAGCCACT and
CGCCGCTAGCACCACCATGCCGGCCTGCTGCAGCTGCA. The amplified sequence was subsequently ligated into a pcDNA3.1 (+) Notl, Nhel digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL - 1573, Manassas, VA, USA) were transfected with the pcDNA3.1 (+).hP2X7 plasmid using lipofectamine 2000 (Invitrogen AG, CH) according to the manufacturer's instructions. Following a 24h exposure to DNA, cells were trypsinized and re-seeded at low density in the presence of 250 μg Geneticin. Geneticin resistant cells were then selected during two consecutive rounds of cloning by serial limiting dilution with visual inspection. Individual clones were screened for P2X7 expression by applying ATP and recording the resultant uptake of YO-PR01. Specific cell clones were chosen based on RNA and protein expression. HEK cells stably expressing P2X7 were used to screen drugs using the YO-PR01 assay. Cells were grown to confluency in adherent culture at 37°C in a humidified 5% C02 incubator (split 1/5 every 3 - 4 days with DMEM, 10 % FCS, 1 % Penicillin/Streptomycin, 250 μg/vΓ^\ Geneticin). Adherent cells were detached by incubation with Trypsine (1 ml per 165 cm2 dish) for 2 minutes, then washed off with 10 ml PBS (without Mg2+ and Ca2+), and resuspended in DMEM, 10 % FCS, 1 % Penicillin/Streptomycin, no Geneticin. 10Ό00 cells per well (48 hours before the assay) or 25Ό00 cells per well (Vi-cell XR (Beckman Coulter) (24 hours before the assay) in 50 μΙ full medium were seeded on 384-well black-wall, clear bottom plates, that were coated before with 10 μΙ per well Poly-L-Lysine, incubated for 30 - 60 minutes at 37° C and washed once with PBS. Medium was removed from cells and 50 μΙ of assay buffer containing 0.5 μΜ YO-PRO-1 was added into the wells. Solutions of antagonist compounds were prepared by serial dilutions of a 10 mM DMSO solution of the antagonist into PBS using a BioMek (Beckman Coulter). Each concentration was performed in duplicate. For IC50 measurements 10 concentration points were measured (10 μΜ being the highest concentration followed by 9 serial dilution steps 1/3). The cells were incubated with the antagonists of the present invention together with ATP at a final concentration of 250 μΜ for 90 minutes. During this time period, four time points were taken. Each time point comprised the average of several measurements made within a few seconds. Fluorescence was measured in the FLIPR tetra (Molecular Devices) using the filters appropriate for YO-PRO-1 fluorescence (excitation485/20, emission 530/25). The FLIPR tetra was equipped with Molecular Devices Screen Works system control software to define and run experimental protocols. For antagonist activity measurements, the maximal intensity was expressed as a percentage of that induced by the EC50 value for agonist activation (0.25 mM ATP for HEK-293 cells expressing human recombinant P2X7 receptor). For IC50 measurements the maximum intensity is plotted against the concentration of compound to determine IC50 values.
Antagonistic activities with respect to the P2X7 receptor (IC50 values) of exemplified compounds are displayed in Table 1.
Table 1
ICso ICso ICso
Compound Compound Compound
[nM] [nM] [nM]
Example 1 13 Example 2 35 Example 3 12
Example 4 42 Example 5 77 Example 6 211
Example 7 50 Example 8 198 Example 9 1152
Example 10 57 Example 11 4.1 Example 12 3.2
Example 13 17 Example 14 4.5 Example 15 238
Example 16 442 Example 17 14 Example 18 178
Example 19 18 Example 20 6.1 Example 21 302
Example 22 1183 Example 23 1147 Example 24 4.7
Example 25 2.9 Example 26 11.4 Example 27 682
Example 28 151 Example 29 20 Example 30 221
Example 31 38 Example 32 11 Example 33 44
Example 34 130 Example 35 666 Example 36 27
Example 37 420 Example 38 1315 Example 39 1558 Example 40 1600 Example 41 264 Example 42 14
Example 43 218 Example 44 1427 Example 45 81
Example 46 209 Example 47 21 Example 48 1083
Example 49 497 Example 50 246 Example 51 24
Example 52 5.9 Example 53 4.4 Example 54 13
Example 55 6.7 Example 56 9.0 Example 57 68
Example 58 6.4 Example 59 5.4 Example 60 6.3
Example 61 4.0 Example 62 4.1 Example 63 4.0
Example 64 51 Example 65 79 Example 66 24
Example 67 4.7 Example 68 7.2 Example 69 10
Example 70 10 Example 71 12 Example 72 4.1
Example 73 4.2 Example 74 17 Example 75 9.5
Example 76 2.9 Example 77 21 Example 78 21
Example 79 6.1 Example 80 100 Example 81 5.4
Example 82 3.8 Example 83 3.3 Example 84 25
Example 85 30 Example 86 6.7 Example 87 7.3
Example 88 25 Example 89 8.3 Example 90 563
Example 91 701 Example 92 45 Example 93 70
Example 94 9.4 Example 95 9.3

Claims

Claims
1. A compound of the formula I),
Figure imgf000134_0001
(I)
wherein
n represents 1 , 2, 3 or 4;
R1 represents hydrogen and R2 represents hydroxy; hydroxy-(d-C3)alkyl; (Ci-C3)alkoxy; -NHR ; -N(CH3)2; -CN; -CONH2; (d-C4)alkoxy-carbonyl; (Ci-C4)alkylamino-carbonyl; aryl which is unsubstituted or mono- or di-substituted with (CrC3)fluoroalkyl or halogen; or heteroaryl which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl, (C C3)fluoroalkyl or halogen; or
R1 represents (Ci-C3)alkyl or hydroxy-(Ci-C3)alkyl and R2 represents hydrogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen, (Ci-C4)alkyl or halogen;
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkyl-carbonyl, hydroxy-(Ci-
C4)alkyl, hydroxy-(C2-C4)alkoxy, (C1-C2)alkoxy-(C1-C4)alkyl, (d-C4)alkoxy-(C2-
C4)alkoxy, hydroxy, amino, nitro or halogen;
R7 represents hydrogen or (Ci-C3)alkyl;
R8 represents hydrogen, (Ci-C4)alkyl or hydroxy;
R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkylthio, formyl or halogen;
R10 represents fluoro, chloro, methyl, ethyl, (Ci-C2)fluoroalkyl or methoxy; and
R11 represents hydrogen, benzyl, (Ci-C4)alkyl-carbonyl, (Ci-C4)alkoxy-carbonyl or (Ci-
C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci- C4)alkoxy-carbonyl;
or a salt of such a compound.
2. A compound of formula (I) according to claim 1 , wherein
n represents 2, 3 or 4;
R1 represents hydrogen; R2 represents hydroxy; hydroxy-(Ci-C3)alkyl; -NHR ; -CN; or a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with (Ci- C4)alkyl, (CrC3)fluoroalkyl or halogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R5 represents hydrogen;
R6 represents hydrogen, (Ci-C4)alkyl, (Ci-C4)alkoxy or (Ci-C2)alkoxy-(d-C4)alkyl;
R7 represents hydrogen;
R8 represents hydrogen;
R9 represents hydrogen, (Ci-C4)alkyl or halogen;
R10 represents chloro or methyl; and
R11 represents (Ci-C4)alkyl-sulfonyl which is unsubstituted or mono-substituted with hydroxy or (Ci-C4)alkoxy-carbonyl;
or a salt of such a compound.
3. A compound of formula (I) according to any one of claims 1 or 2, wherein
n represents 2 or 3;
or a salt of such a compound.
4. A compound of formula (I) according to any one of claims 1 to 3, wherein
R2 represents hydroxy; hydroxy-(Ci-C3)alkyl; -NHR11; or -CN; and
R11 represents methyl-sulfonyl which is unsubstituted or mono-substituted with methoxy- carbonyl; or ethyl-sulfonyl which is mono-substituted with hydroxy;
or a salt of such a compound.
5. A compound of formula (I) according to any one of claims 1 to 3, wherein
R2 represents a 5- or 6-membered monocyclic heteroaryl group which group is unsubstituted or mono-substituted with (Ci-C4)alkyl, (CrC3)fluoroalkyl or halogen;
or a salt of such a compound.
6. A compound of formula (I) according to any one of claims 1 to 5, wherein
R6 represents (Ci-C4)alkyl, (Ci-C4)alkoxy or (Ci-C2)alkoxy-(Ci-C4)alkyl;
or a salt of such a compound.
7. A compound of formula (I) according to any one of claims 1 to 6, wherein
R5, R7, R8 and R9 represent hydrogen;
or a salt of such a compound.
8. A compound of formula (I) according to any one of claims 1 to 7, wherein R10 represents chloro;
or a salt of such a compound.
9. A compound of formula (I) according to claim 1 , which is also a compound of formula
Figure imgf000136_0001
wherein
n represents 2 or 3;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro;
R6 represents (d-C4)alkyl, (Ci-C4)alkoxy, hydroxy-(Ci-C4)alkyl, hydroxy-(C2-C4)alkoxy, (Ci-C2)alkoxy-(Ci-C4)alkyl or halogen; and
R10 represents chloro, methyl or trifluoromethyl;
or a salt of such a compound.
10. A compound of formula (I) according to claim 1 , which is also a compound of formula
Figure imgf000136_0002
wherein
n represents 2 or 3;
X represents CH or N;
R2S represents hydrogen, (Ci-C4)alkyl, (CrC3)fluoroalkyl or halogen;
R3 represents hydrogen or fluoro;
R4 represents hydrogen or fluoro; and
R6 represents hydrogen or (Ci-C4)alkyl; or a salt of such a compound.
11. A compound of formula (I) according to claim 1 , selected from the group consisting of: 4-Chloro-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-1 H-indole-5-carboxylic acid [(S)-1-(4,4-difluoro-cyclohexyl)-2-hydroxy-ethyl]- amide;
4-Chloro-1-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-1-methyl-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;
4-Chloro-3-formyl-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-2-hydroxy-ethyl)-amide;
4-Chloro-3-formyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-cycloheptyl-2-hydroxy-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(2-trifluoromethyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(6-chloro-pyridin-3-yl)-cyclohexylmethyl]-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(6-trifluoromethyl-pyridin-3-yl)-cyclohexylmethyl]- amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(6-chloro-pyridin-3-yl)-4,4-difluoro- cyclohexylmethyl]-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(4-chloro-phenyl)-cyclohexylmethyl]-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(4-trifluoromethyl-phenyl)-cyclohexylmethyl]- amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-pyridin-3-yl-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-pyridin-3-yl-cyclopentylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (1-pyridin-3-yl-cycloheptylmethyl)-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-2-oxo-2,3-dihydro-1 H-indole-5-carboxylic acid (1-hydroxy-cycloheptylmethyl)- amide;
4-Chloro-2-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-7-iodo-3-methylsulfanyl-1 H-indole-5-carboxylic acid (1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-3-fluoro-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide;
4-Methoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide;
3,4-Dichloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-nitro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexanecarboxylic acid methyl ester;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxymethyl-cyclohexylmethyl)-amide;
7-Amino-4-chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-3-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-1 H-indole-5-carboxylic acid (l-carbamoyl-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-methylcarbamoyl-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-cyano-cyclohexylmethyl)-amide;
(1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexyl)-carbamic acid tert-butyl ester;
4,6-Dichloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-amino-cyclohexylmethyl)-amide;
4-Chloro-6-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclopentylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclooctylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-methoxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid ((S)-1-cyclohexyl-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid ((R)-1-cyclohexyl-ethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-acetylamino-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-methanesulfonylarnino-cyclohexylrnethyl)-arTiide; 4-Chloro-1 H-indole-5-carboxylic acid (l-dimethylamino-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid (l-benzylamino-cyclohexylmethyl)-amide;
3- Bromo-4-chloro-7-methyl-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexylmethyl)- amide;
(1-{[(4-Chloro-1 H-indole-5-carbonyl)-amino]-methyl}-cyclohexylsulfamoyl)-acetic acid methyl ester;
4- Chloro-7-isobutyl-1 H-indole-5-carboxylic acid (l-hydroxy-cycloheptylmethyl)-amide; 4-Chloro-7-(3-methoxy-propyl)-1 H-indole-5-carboxylic acid (1-hydroxy-cycloheptylmethyl)- amide;
4-Chloro-7-isobutyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide; 4-Chloro-7-(3-methoxy-propyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(2-hydroxy-ethanesulfonylamino)- cyclohexylmethyl]-amide;
4-Methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [1-(2-methyl-pyrimidin-5-yl)-cyclohexylmethyl]- amide;
4-Chloro-7-methoxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-1 H-indole-5-carboxylic acid [4,4-difluoro-1-(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid [4,4-difluoro-1-(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4-Chloro-7-methyl-1 H-indole-5-carboxylic acid [1-(2-methyl-pyrimidin-5-yl)- cyclohexylmethyl]-amide;
4,7-Dimethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide;
4-Methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide;
4-Ethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide;
7-Acetyl-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-(1-hydroxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-(1-hydroxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
7-Methyl-4-trifluoromethyl-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexylmethyl)- amide;
7-Methyl-4-trifluoromethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4,7-Dimethyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-ethyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-ethyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
7-Chloro-4-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
7-Chloro-4-methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide; 4-Chloro-7-methoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 7-Methoxy-4-methyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
7-Methoxy-4-methyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Chloro-7-ethoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-hydroxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-ethoxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-propyl-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-propyl-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)- amide;
7-(2-tert-Butoxy-ethoxy)-4-chloro-1 H-indole-5-carboxylic acid (1-hydroxy- cyclohexylmethyl)-amide;
7-(2-tert-Butoxy-ethoxy)-4-chloro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-(2-hydroxy-ethoxy)-1 H-indole-5-carboxylic acid (1-hydroxy-cyclohexylmethyl)- amide;
4-Chloro-7-(2-hydroxy-ethoxy)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
7-Acetyl-4-chloro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4-Chloro-7-(1-hydroxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (1-hydroxy- cyclohexylmethyl)-amide;
4,7-Difluoro-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide;
4,7-Difluoro-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide; 4-Fluoro-7-methoxy-1 H-indole-5-carboxylic acid (l-hydroxy-cyclohexylmethyl)-amide; 4-Fluoro-7-methoxy-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide;
4-Chloro-7-(2-ethoxy-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1-hydroxy- cyclohexylmethyl)-amide; and
4-Chloro-7-(1-methoxy-1-methyl-ethyl)-1 H-indole-5-carboxylic acid (4,4-difluoro-1- hydroxy-cyclohexylmethyl)-amide;
or a salt of such a compound.
12. A compound of formula (I) according to any one of claims 1 to 11 , or a pharmaceutically acceptable salt thereof, for use as a medicament.
13. A pharmaceutical composition containing, as active principle, a compound of formula (I) according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
14. Use of a compound of formula (I) according to any one of claims 1 to 1 1 , or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a disease selected from pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
15. A compound of formula (I) according to any one of claims 1 to 11 , or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a disease selected from pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
PCT/IB2013/061029 2012-12-18 2013-12-17 Indole carboxamide derivatives as p2x7 receptor antagonists WO2014097140A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP13826623.4A EP2935211B1 (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as p2x7 receptor antagonists
JP2015548833A JP6295270B2 (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as P2X7 receptor antagonists
CN201380065566.6A CN104854087B (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as P2X7 receptor antagonists
ES13826623.4T ES2614495T3 (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as P2X7 receptor antagonists
KR1020157019206A KR102232744B1 (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as p2x7 receptor antagonists
CA2891499A CA2891499C (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as p2x7 receptor antagonists
US14/653,363 US9556117B2 (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as P2X7 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197880 2012-12-18
EP12197880.3 2012-12-18

Publications (1)

Publication Number Publication Date
WO2014097140A1 true WO2014097140A1 (en) 2014-06-26

Family

ID=47358029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061029 WO2014097140A1 (en) 2012-12-18 2013-12-17 Indole carboxamide derivatives as p2x7 receptor antagonists

Country Status (10)

Country Link
US (1) US9556117B2 (en)
EP (1) EP2935211B1 (en)
JP (1) JP6295270B2 (en)
KR (1) KR102232744B1 (en)
CN (1) CN104854087B (en)
AR (1) AR094053A1 (en)
CA (1) CA2891499C (en)
ES (1) ES2614495T3 (en)
TW (1) TW201427945A (en)
WO (1) WO2014097140A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388197B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
WO2018168818A1 (en) * 2017-03-13 2018-09-20 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as p2x7 receptor antagonists
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2022189636A1 (en) * 2021-03-12 2022-09-15 Biomedcode Hellas Sa Anti-inflammatory carboxamide derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106187899B (en) * 2016-06-28 2019-07-16 绍兴文理学院 A kind of synthetic method of fluoro azepine aromatic hydrocarbons

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023623A1 (en) 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009118175A1 (en) 2008-03-25 2009-10-01 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012114268A1 (en) 2011-02-22 2012-08-30 Actelion Pharmaceuticals Ltd Benzamide derivatives as p2x7 receptor antagonists

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636341A1 (en) * 1988-09-12 1990-03-16 Air Liquide METHOD AND INSTALLATION FOR RECOVERING THE HEAVIEST HYDROCARBONS OF A GASEOUS MIXTURE
SE9704544D0 (en) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
BR0009651A (en) 1999-04-09 2002-01-08 Astrazeneca Ab Compound, process for preparing a compound, pharmaceutical composition, use of a compound, and method for treating rheumatoid arthritis and an obstructive airway disease
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (en) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
SE0200920D0 (en) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
EP1581507A1 (en) 2002-12-31 2005-10-05 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
SE0300480D0 (en) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
DE602004005033T2 (en) 2003-05-12 2007-08-09 Pfizer Products Inc., Groton BENZAMIDINHIBITORS OF THE P2X7 RECEPTOR
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (en) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (en) 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
JP2007535553A (en) 2004-04-29 2007-12-06 アボット・ラボラトリーズ Amino-tetrazole analogs and methods of use
SA05260265A (en) 2004-08-30 2005-12-03 استرازينيكا ايه بي Novel compounds
SE0402925D0 (en) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
GB0428232D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
JP2008528580A (en) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Novel bicyclic aromatic compounds that are inhibitors of P2X7 receptors
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US7745641B2 (en) * 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2007055374A1 (en) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for osteoporosis
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
CA2645551C (en) 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
DK2001474T3 (en) 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
CA2645652A1 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP2009539795A (en) 2006-06-06 2009-11-19 グラクソ グループ リミテッド N- (phenylmethyl) -2- (1H-pyrazol-4-yl) acetamide derivatives as P2X7 antagonists for the treatment of pain, inflammation and neurodegeneration
GB0611154D0 (en) 2006-06-06 2006-07-19 Glaxo Group Ltd Novel receptor antagonists and their methods of use
WO2008003697A1 (en) 2006-07-06 2008-01-10 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
MX2009005478A (en) 2006-11-27 2009-08-12 Lundbeck & Co As H Heteroaryl amide derivatives.
EP2124562B1 (en) 2007-03-09 2016-04-20 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP2010522227A (en) 2007-03-22 2010-07-01 アストラゼネカ・アクチエボラーグ Quinoline derivatives for the treatment of inflammatory diseases
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
US20100168171A1 (en) 2007-03-28 2010-07-01 Paul John Beswick Piperidinone Carboxamide Derivatives as P2X7 Modulators
US20100144727A1 (en) 2007-03-29 2010-06-10 Paul John Beswick Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators
WO2008119825A2 (en) 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
US20100056595A1 (en) 2007-04-11 2010-03-04 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
ATE502017T1 (en) 2007-05-10 2011-04-15 Glaxo Group Ltd PYRAZOLE DERIVATIVES AS P2X7 MODULATORS
ES2551095T3 (en) 2007-07-19 2015-11-16 Lundbeck, H., A/S 5-membered heterocyclic amides and related compounds
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
GB0724258D0 (en) 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
WO2009077559A2 (en) 2007-12-18 2009-06-25 Glaxo Group Limited 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
GB0724625D0 (en) 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
KR101598397B1 (en) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. Quinoline or isoquinoline substituted p2x7 antagonists
CA2724077C (en) * 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound
WO2010051085A1 (en) * 2008-10-30 2010-05-06 Oncotherapy Science, Inc. 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
EP2243772B1 (en) 2009-04-14 2012-01-18 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
WO2011123719A2 (en) * 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
US20120157494A1 (en) 2010-12-16 2012-06-21 Harris Iii Ralph New Isoindolyl compounds
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (en) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 As P2X7The heterocyclic amide derivative of receptor antagonist
KR102033190B1 (en) 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Heterocyclic amide derivatives as p2x7 receptor antagonists
TWI598325B (en) 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 Benzamides
TW201427947A (en) 2012-10-12 2014-07-16 Lundbeck & Co As H Cyclic amines
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023623A1 (en) 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009118175A1 (en) 2008-03-25 2009-10-01 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012114268A1 (en) 2011-02-22 2012-08-30 Actelion Pharmaceuticals Ltd Benzamide derivatives as p2x7 receptor antagonists

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Salt selection for basic drugs", INT. J. PHARM., vol. 33, 1986, pages 201 - 217
ANGEW. CHEM. INT. ED., vol. 44, 2005, pages 1549 - 1551
BIOORG. MED. CHEM. LETT., vol. 14, no. 1, 2004, pages 43 - 46
BROWN F J ET AL: "1,3,6-Trisubstituted Indoles as Peptidoleukotriene Antagonists: Benefits of a Second, Polar, Pyrrole Substituent", J. MED. CHEM, vol. 35, no. 13, 26 June 1992 (1992-06-26), pages 2419 - 2439, XP002017012 *
CHEMISTRY LETT., 1984, pages 937 - 940
CHESSELL, . P.; HATCHER, J. P. ET AL., PAIN, vol. 114, no. 3, 2005, pages 386 - 96
DEUCHARS, S. A.; ATKINSON, L. ET AL., J. NEUROSCI., vol. 21, no. 18, 2001, pages 7143 - 52
FERRARI, D.; CHIOZZI, P. ET AL., NEUROPHARMACOLOGY, vol. 36, no. 9, 1997, pages 1295 - 301
HELV. CHIM. ACTA, vol. 20, 1937, pages 1407 - 1412
J. AM. CHEM. SOC., vol. 133, 2011, pages 6948 - 6951
J. ORG. CHEM., vol. 72, 2007, pages 7455 - 7458
J. ORG. CHEM., vol. 73, no. 4, 2008, pages 1643 - 1645
NORTH, R. A., PHYSIOL. REV., vol. 82, no. 4, 2002, pages 1013 - 67
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing"
ROBERT T JACOBS ET AL: "Synthesis, structure-activity relationships, and pharmacological evaluation of a series of fluorinated 3-benzyl-5-indolecarboxamides: identification of 4-((5-(((2R)-2-methyl-4,4,4,-trifluorobutyl)carbamoyl)-1-methylindol-3-yl)methyl)-3-methoxy-N-((2-methylphenyl)sulfonyl)benzamide, a Potent, Orally", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 9, 1 January 1994 (1994-01-01), AMERICAN CHEMICAL SOCIETY, US, pages 1282 - 1297, XP002158917, ISSN: 0022-2623, DOI: 10.1021/JM00035A008 *
SOLLE, M.; LABASI, J. ET AL., J. BIOL. CHEM., vol. 276, no. 1, 2001, pages 125 - 32
SPERLAGH, B.; KOFALVI, A. ET AL., J. NEUROCHEM., vol. 81, no. 6, 2002, pages 1196 - 211
SURPRENANT, A.; RASSENDREN, F. ET AL., SCIENCE, vol. 272, no. 5262, 1996, pages 735 - 8
SYNTHESIS, vol. 4, 2008, pages 507 - 510
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE
VIRGINIO, C.; MACKENZIE, A. ET AL., J. PHYSIOL., vol. 519, 1999, pages 335 - 46
WILEY, J. S.; CHEN, J. R. ET AL., CIBA FOUND SYMP., vol. 198, 1996, pages 149 - 60,160-5
YU, Y.; UGAWA, S. ET AL., BRAIN. RES., vol. 1194, 2008, pages 45 - 55

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
US9388197B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
WO2018168818A1 (en) * 2017-03-13 2018-09-20 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as p2x7 receptor antagonists
RU2724350C1 (en) * 2017-03-13 2020-06-23 Раквалиа Фарма Инк. Tetrahydroquinoline derivatives as p2x7 receptor antagonists
US11077100B2 (en) 2017-03-13 2021-08-03 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as P2X7 receptor antagonists
US11439633B2 (en) 2017-03-13 2022-09-13 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as P2X7 receptor antagonists
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2022189636A1 (en) * 2021-03-12 2022-09-15 Biomedcode Hellas Sa Anti-inflammatory carboxamide derivatives

Also Published As

Publication number Publication date
CA2891499C (en) 2021-07-06
TW201427945A (en) 2014-07-16
US9556117B2 (en) 2017-01-31
JP6295270B2 (en) 2018-03-14
ES2614495T3 (en) 2017-05-31
CA2891499A1 (en) 2014-06-26
CN104854087A (en) 2015-08-19
US20150344425A1 (en) 2015-12-03
EP2935211B1 (en) 2016-11-09
KR20150095905A (en) 2015-08-21
CN104854087B (en) 2017-03-22
JP2016504995A (en) 2016-02-18
AR094053A1 (en) 2015-07-08
EP2935211A1 (en) 2015-10-28
KR102232744B1 (en) 2021-03-26

Similar Documents

Publication Publication Date Title
US9556117B2 (en) Indole carboxamide derivatives as P2X7 receptor antagonists
CA2890886C (en) Indole carboxamide derivatives as p2x7 receptor antagonists
CA2863228C (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
CA2896790C (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
CA2897459C (en) Heterocyclic amide derivatives as p2x7 receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13826623

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2013826623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013826623

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2891499

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015548833

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14653363

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20157019206

Country of ref document: KR

Kind code of ref document: A